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General introduction
Colorectal cancer
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in the western 
world and accounts for many cancer related deaths.[1] The life-time risk of developing 
CRC is around 5%.[2] Treatment of primary CRC is based on surgery, complemented 
either with neoadjuvant therapy mainly for rectal cancer, and – dependent on the 
stage of disease – adjuvant systemic treatment mainly for colon cancer. Metastatic 
disease is the leading factor in CRC mortality. Currently, approximately 20% of CRC 
patients have metastatic disease at time of first presentation[3, 4] and another 20-30% 
of patients will develop distant metastases during follow-up[5-7] despite intensive 
follow-up and increasing therapeutic options for CRC. Population screening for CRC 
has been implemented since 2014. This is supposed to increase early detection of 
colorectal cancer and thereby reduce mortality. 
Staging
Disease management is essentially based on tumor stage. Staging of surgical 
resection specimens by pathology is considered the most accurate determination 
of local extent of disease, and as such the most powerful and reliable predictor of 
prognosis of primary CRC[8, 9]. Therefore, staging plays an essential role in choosing 
the most appropriate therapy for CRC patients. 
 In 1932 Cuthbert Dukes proposed a classification for rectal cancer, based on the 
extent of disease evaluated by the degree of tumor infiltration through the bowel 
wall and the presence or absence of lymph node metastases.[10] (Figure 1) The Dukes 
classification underwent several modifications by Dukes and other investigators, but 
still forms the backbone of the current staging system for CRC; the TNM classification. 
This classification is based on the assessment of the anatomic extent of disease at the 
time of diagnosis with a key role for lymph node metastases.[11] 
Figure 1. Adapted from Dukes et al.[10]
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The three pillars of the TNM system are: T stage, based on the depth of tumor 
infiltration, N stage, based on the presence of lymph node metastases, M stage, 
based on the presence of distant metastases. The number of categories in the TNM 
classification is expanded compared to original Dukes staging, with more categories 
of tumor invasion depth, with separate categories based on the number of regional 
lymph node metastases (stage III) and the inclusion of distant metastases (stage IV). 
Adjuvant chemotherapy is recommended for all patients with stage III colon cancer 
and in selected high risk stage II patients: pT4, presentation with perforation or 
obstruction, less than 10 lymph nodes examined, and/or vascular invasion.[12] The 
2017 update of the Dutch guideline for medical oncology has restricted these factors 
to pT4 stage. 
Histology
In addition to staging, other important histological factors in CRC are tumor type, tumor 
grade, resection margins, venous invasion and lymphatic invasion. CRC can be subdivided 
into different tumor types. The majority of CRCs are conventional adenocarcinomas, 
other tumor types include mucinous adenocarcinoma, signet-ring cell, medullary, 
micropapillary, serrated, adenosquamous, spindle cell and undifferentiated carcinoma, 
some of which are extremely rare. Conventional adenocarcinomas are graded 
according to the degree of gland formation. Good differentiation shows more than 95% 
gland formation, moderate differentiation shows 50-95% gland formation and poor 
differentiation shows less than 50% gland formation. A 2-tiered grading system, which 
combines well and moderately differentiated versus poorly differentiated, reduces 
interobserver variation and improves prognostic significance.[13] Although controversial, 
tumor grade is generally considered as a stage-independent prognostic variable, and 
poorly differentiated histology is associated with poor patient survival. 
 Venous invasion is the presence of tumor cells within venous blood vessels (Figure 
2a). It can be subdivided into intramural venous invasion (IMVI) and extramural venous 
invasion (EMVI), according to the location of the vessels towards the muscle wall. EMVI is 
a well-established independent prognostic indicator, associated with hematogenous 
spread and mortality in CRC. The importance of EMVI is recognized by the UK Royal 
College of Pathologists, which has adjusted its minimum audit standard of EMVI 
detection to 30% in CRC resections.[14] Next to EMVI, there is now increasing evidence 
that IMVI may also be of prognostic importance, although to a lesser extent.[15-17] 
Lymphatic invasion is the presence of tumor cells within lymphatic vessels (Figure 2b). 
The evidence for lymphatic invasion as a prognostic factor in colorectal cancer 
resection specimens is limited and it is considered a non-core dataset item for 
resection specimens.[14] However for superficial tumors (T1), lymphatic invasion is 
regarded as a significant risk factor for lymph node metastases.[18] Perineural invasion 
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(PNI) is the growth of tumor cells along or within nerves (Figure 2c). PNI is observed 
in up to 33% of colorectal tumors and is associated with a worse prognosis in some 
studies.[19] It is included as an accessory feature in pathology reports, because its 
prognostic value in CRC is not validated. In many CRC resection specimens nodules or 
foci of cancer cells can be found in the pericolic or perirectal fat, without evidence of 
residual lymph node tissue. Those nodules are called tumor deposits (Figure 2d ). 
Tumor deposits first appeared in the fifth edition of the TNM staging system.[20, 21] In 
TNM5 tumor deposits are considered as lymph node metastases if they have a 
diameter greater than 3 mm, and tumor deposits smaller than 3 mm are classified in 
T category as discontinuous extension. In TNM6 the 3-mm rule is withdrawn and 
replaced by a definition of tumor deposits based on contour.[22, 23] Tumor deposits are 
classified as lymph node metastases when they have the form and smooth contour of 
lymph nodes; irregular tumor deposits are classified in the T category and as venous 
invasion. In TNM7 and TNM8, classification of tumor deposits is left to the opinion of 
the pathologist, and a new N category (N1c) has been designed to include patients 
with tumor deposits in stage III.[11, 24] There are different opinions about the origin of 
tumor deposits, such as being totally replaced lymph nodes, vascular invasion or a 
direct extension of the primary tumor. The prognostic role of tumor deposits in CRC 
has still to be elucidated. 
Figure 2. 
2a. venous invasion
2c. perineural invasion
2b. lymphatic invasion
2d. tumor deposit
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Metastases
A key feature of cancer cells is their ability to dissociate from the primary tumor 
and form metastatic deposits. Colorectal tumors can move to other parts of the 
body using different pre-existing pathways, which can be investigated under the 
microscope. As mentioned above, tumor cells can invade blood vessels (venous 
invasion), lymphatic vessels and lymph nodes (lymph node invasion), grow along 
nerves (perineural invasion) or directly grow through the bowel wall (Figure 3). This 
direct growth of the tumor through the bowel wall is considered the key element 
for dissemination within the peritoneal cavity (peritoneal carcinomatosis). Perineural 
invasion may be important in local spread, while vascular and lymphatic invasion 
may be more important in dissemination to distant organs. Although staging and 
treatment of CRC is primarily based on regional lymph node metastases, other factors 
like vascular invasion, may be more direct markers of dissemination to distant organs. 
Approximately 40% of patients who develop liver metastases after curative resection 
of the primary tumor do not have regional lymph node metastases upon diagnosis.[25] 
Therefore it is important to investigate the role of other factors, like vascular invasion 
and tumor deposits, in dissemination of CRC. Next to histological factors, the genetic 
background of colorectal tumors could explain different patterns of dissemination. 
Somatic mutations have been linked to prognosis as well as to patterns of dissemination 
of CRC.[26] (K)RAS and BRAFV600E mutations indicate a worse prognosis compared to 
RAS/BRAF wildtype tumors.[27] In metastatic disease, the worse prognosis of tumors 
with a deficient mismatch repair (dMMR) system is mainly driven by BRAF mutation 
Figure 3.
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status.[28] KRAS mutations are associated with metastases outside the liver, particularly 
in the lung, but also in the brain and bone[26, 29] and BRAF mutations are associated 
with decreased liver-limited metastasis and increased peritoneal and lymph node 
metastases.[26, 30] In 2015 four consensus molecular subtypes (CMS) have been 
described for CRC, each with distinguishing features (CMS1: microsatellite unstable, 
hypermutated, strong immune activation, CMS2: epithelial with marked WNT and 
MYC signaling activation, CMS3: epithelial with metabolic dysregulation and CMS4: 
mesenchymal, stromal invasion and angiogenesis).[31] Since, for instance, BRAFV600E 
mutations are not restricted to a single CMS, this shows that the prognosis depends 
on many factors and not just on a single molecular marker. Another promising area is 
the detection of circulating tumor DNA (ctDNA), which may early identify patients at 
high risk for the development of metastases.[32]
Treatment of metastatic disease
Approximately half of the CRC patients will develop distant metastases. A minority of 
patients are candidates for immediate surgery of (mostly liver) metastases, sometimes 
preceded by induction systemic treatment to achieve downsizing of metastases, 
with curative intent. Surgery of metastases is increasingly preformed in patients with 
colorectal liver metastases and in patients with lung metastases[33] due to improvements 
in systemic regimens, imaging, surgical techniques and perioperative care.[34, 35]
 The remainder of patients may be treated with palliative systemic treatment with 
prolongation of life and maintaining quality of life as major goals. Backbones of 
systemic treatment are cytotoxic agents such as the fluoropyrimidines, irinotecan and 
oxaliplatin. Another class of agents, the so-called “targeted therapy” has added further 
benefit.[36] Three monoclonal antibodies have been approved for clinical use in CRC: 
bevacizumab, an antibody against the vascular endothelial growth factor (VEGF), and 
cetuximab and panitumumab, antibodies against the epidermal growth factor receptor 
(EGFR). Response to anti-EGFR treatment is restricted to patients without mutations in 
the proto-oncogenes KRAS NRAS and BRAF.[37, 38] Mutations in RAS are observed in 53% of 
colorectal tumors.[38] These proteins are part of the RAS/RAF/MAPK signal transduction 
cascade, where an activating mutation leads to constitutive activation of this pathway. 
In case of these activating mutations, inhibition of the pathway proximal to RAS will 
have no effect. While colorectal cancer was considered in the past as a single entity, 
it now has become clear that it is a very heterogeneous disease with many different 
subgroups that require different treatment approaches.[39]
 The 5-year overall survival for patients who are diagnosed with distant metastases 
is currently around 20%[40] and is, amongst others, strongly correlated with the location 
of metastatic disease and the possibility for surgical resection of metastases with 
curative intent. 
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Metastatic patterns
The most common site of distant metastases from colorectal cancer is the liver, 
followed by metastases in lung and peritoneal cavity.[33, 41] Next to the liver, lung 
and peritoneum, various other metastatic sites such as bone, spleen, brain and 
distant lymph nodes have been described.[42-44] Although differences in metastatic 
locations of various types of cancers, but also within a type of cancer, have been 
noticed, the precise biological mechanisms by which individual tumors disseminate 
to secondary sites remain unknown. Two hypotheses attempt to explain differences 
in metastatic patterns; the mechanistical hypothesis[45] and the seed-and-soil 
hypothesis.[46] According to the mechanistical view of metastatic spread, tumor 
cells can disseminate to distant organs through two pathways: the vascular and 
the lymphatic pathway. In the vascular pathway blood vessels transport tumor cells 
directly to distant organs. Hematogenous routes of CRC metastases run via the portal 
vein (involved in liver metastases), the systemic veins (involved in lung metastases), 
arteries (leading to metastatic deposits in all organs) or the venous plexus of Batson 
(leading to bone metastases). In the lymphatic pathway tumor cells may disseminate 
from regional lymph nodes to distant lymph nodes, reach the systemic circulation 
and subsequently form organ metastases.[47] As mentioned before, both vascular 
invasion and lymphatic invasion can be evaluated under de microscope and are 
associated with poor prognosis. However, the presence of tumor cells within a 
blood or lymph vessels only demonstrates the capability of tumor cells to invade 
other structures. It does not necessarily demonstrate the ability of the tumor cells to 
survive in blood vessels and their capability to form metastasis at another site with 
a different microenvironment. The second hypothesis, the seed-and soil hypothesis, 
is partly based on this assumption. According to the seed-and-soil hypothesis the 
distribution of distant metastases from a primary tumor is compared with the seeding 
of a plant: its seeds are carried in all directions, but they can live and grow only if they 
fall on congenial soil. In this hypothesis each ‘host’ organ is supposed to have its own 
microenvironment and each metastasis its own preferences. 
Outline of the thesis
Liver metastases are the most common metastases in CRC. Therefore, the first part 
of the thesis is based on research on colorectal liver metastases. In the first part of 
this thesis, both histological and molecular factors in colorectal liver metastases 
are investigated. Compared to the extensive research that is already performed 
on histological factors in primary CRC, less is known about histological factors 
in colorectal liver metastases. In chapter 1 we review the literature regarding 
histological features in colorectal liver metastases and suggestions are made on 
factors that should be included in the pathology reports. In chapter 2 we describe 
18
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the impact of intrahepatic dissemination on outcome in patients with colorectal liver 
metastases. We investigate the role of perineural invasion, lymphatic invasion, and 
vascular invasion of tumor cells within the liver. 
 Identification of mutations in the proto-oncogenes KRAS and NRAS as predictive 
markers for response to anti-EGFR therapy has improved patient selection, however 
even in patients with RAS wild type tumors the response to anti-EGFR therapy is limited. 
We investigate whether this suboptimal response can be explained by differences in 
mutation status between the primary tumor and the metastases. Chapter 3 presents 
data on the concordance in KRAS mutation status between primary tumors and their 
corresponding liver metastases. In chapter 4 we describe our expanded molecular 
research of primary tumors with corresponding liver and lung metastases. Next to 
KRAS mutation status, mutation status of the proto-oncogenes BRAF, HRAS, NRAS 
and PIK3CA are investigated. Mutations in patients with liver metastases and lung 
metastases are compared, in order to investigate whether convergent evolution 
explains different patterns of dissemination. 
 The results on the association of tumor deposits, vascular invasion and lymph node 
invasion on metastatic patterns are described in chapter 5. The prognostic value 
of tumor deposits in CRC is investigated by systematically reviewing the literature. 
Moreover, the impact of tumor deposits on metastatic patterns is investigated in four 
large cohorts and compared with the impact of vascular invasion and lymph node 
metastases. In chapter 6 we describe the influence of lymph node metastases on 
metastatic patterns in CRC. We performed a large autopsy study in which we compare 
patterns of metastases according to lymph node status and validate our results with 
a population based study. Chapter 7 concerns a meta-analysis on the impact of 
perineural invasion on survival in patients with CRC. A meta-analysis on the impact 
of intramural vascular invasion on survival is described in chapter 8. In the appendix 
an item about optimal reporting of research results is included. We developed a 
guideline to improve the reporting of retrospective histopathology studies, with the 
intention to facilitate the comparison of results across different studies.
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Chapter 1
Histopathological evaluation of 
resected colorectal cancer liver 
metastases: what should be done?
N. Knijn, J.A.M. de Ridder, C.J.A. Punt, J.H.W. de Wilt, I.D. Nagtegaal
Histopathology, 2013; 63(2):149-156
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Chapter 1 – Histopathological evaluation of resected colorectal cancer liver metastases
Abstract
Histological reporting of hepatic resections of colorectal liver metastases (CRLMs) 
is limited to confirmation of diagnosis and evaluation of resection margins. More 
exhaustive diagnostic reporting might be warranted. 
Here, we critically and systematically review the potentially important histological 
prognostic factors in CRLM. Histological features such as intrahepatic spread, 
resection margins, and tumour response to neoadjuvant chemotherapy have been 
defined. Intrahepatic spread (venous, lymphatic, bile duct and perineural invasion) 
was evaluated in a number of studies. 
Meta-analysis demonstrated a clear correlation between 5-year overall survival and 
both portal vein invasion (RR 1.8, 95% CI 1.3–2.5) and lymphatic invasion (RR 1.7, 95% 
CI 1.4–2.0). The impact of hepatic vein invasion and bile duct invasion on outcome 
is not clear. Perineural invasion was linked to survival in one study. Resection margin 
is an important prognostic factor; however, the significance of the width of negative 
margins remains controversial. Various studies have evaluated tumour response to 
neoadjuvant chemotherapy, but different grading systems were used, and definite 
recommendations cannot be made.
In conclusion, with the high incidence of CRLM and the increase in the number of 
hepatic resections, we need well-defined prognostic factors, studied in homogeneous 
patient populations, to optimize diagnostic work-up. This review identifies several of 
these factors.
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Introduction
Liver metastases constitute the major cause of death in colorectal cancer patients, 
with an overall survival rate in untreated patients of <10 months.[1, 2] Surgery is the only 
way to achieve long-term survival, with 5-year survival rates ranging from 40% to 60%.
[3-6] These survival rates are almost the same as those of patients with TNM stage III 
colorectal cancer.
 Because of improvements in radiological imaging techniques, surgical techniques, and 
perioperative care, and the availability of effective systemic therapy, increasing numbers 
of patients are being selected for resection of their colorectal liver metastases (CRLMs).[1, 
7, 8] However, there is no clear consensus on the resectability of liver metastases.[9] Several 
clinical scoring systems have been developed for patient selection and to predict overall 
survival (OS) after liver resection, with size and number, and the interval between the 
treatment of the primary tumour and the development of CRLM, as important prognostic 
items.[4, 10, 11] In addition to the clinical scoring systems, it seems highly probable that 
molecular and histopathological features of resected CRLMs could have potential value 
in the selection of patients who may benefit from adjuvant systemic treatment. For 
primary colorectal carcinoma, many histological prognostic factors have been identified, 
and therapeutic decisions concerning adjuvant systemic therapy are made on the basis 
of these histopathological findings.[12] However, in reporting metastatic lesions, there is 
usually only confirmation of the malignancy, and the (lack of ) involvement of resection 
margins is mentioned. More exhaustive diagnostic reporting of the metastases might be 
warranted. In this article, we critically review potentially important prognostic factors for 
resected CRLM and focus specifically on histopathological features.
Resection margin
The surgical margin of liver metastases is an important prognostic factor. Patients 
with positive margins usually have a worse outcome.[3, 13-15] Although patients with a 
negative resection margin have an improved outcome, the significance of the width 
of the negative margins remains controversial. Traditionally, anatomical resection 
was proposed in liver surgery in order to achieve minimal margins of 10  mm.[16] Dhir 
et  al.[17] conducted a meta-analysis of 18 studies with 4821 patients, to determine 
whether negative resection margins of ≥10  mm confer a survival advantage over 
negative resection margins of <10 mm. The 5-year overall survival rate for the subgroup 
with margins of ≥10  mm was 46% (95% CI 44–48%), as compared with 38% in the 
subgroup with margins of <10  mm (95% CI 36–40%), suggesting that a margin of 
10 mm should be pursued. However, owing to anatomical restrictions, these margins 
cannot always be achieved, and they might not always be necessary, especially in 
the era of neoadjuvant chemotherapy.[9, 18] Ayez et al. described similar disease-free 
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and overall survival rates in patients with either R0 or R1 resection treated with 
neoadjuvant chemotherapy,[18] suggesting that microscopic tumour remnants after 
treatment are no longer of major importance, and that survival after neoadjuvant 
chemotherapy is more related to tumour biology than to resection margins. A 
molecular approach in a limited number of patients (n  =  12) showed that DNA of 
tumour cells could be detected 4  mm from the tumour;[19] biopsies of surrounding 
liver tissue at 8, 12 and 16  mm from the tumour border showed no tumour DNA, 
suggesting that a resection margin of >4 mm is adequate.
Intrahepatic invasion
Theoretically, metastatic tumour can spread within the liver by different pathways. 
Tumour cells might use pre-existing portal and hepatic veins, lymphatic vessels, bile 
ducts and nerves for dissemination within and outside the liver. Multiple studies have 
investigated the incidence of intrahepatic spread;[20-29] however, the exact definitions 
of intrahepatic spread and the methods used to detect it were not described in most 
articles. Only two studies defined the different forms of intrahepatic spread,[24, 28] and 
one of these also specified the methods used for detection.[28] The study by Sasaki et al. 
defined portal vein, hepatic vein and bile duct invasion as cancer cells growing in 
the lumen of a vessel or bile duct branches within the liver.[24] Intrahepatic lymphatic 
invasion was described as cancer cells in luminal structures in the portal area lined 
by endothelial cells. The study by Korita et  al. defined lymphatic invasion as single 
tumour cells or cell clusters visible within vessels that show immunoreactivity for D2-
40 monoclonal antibody.[28] Other forms of intrahepatic spread (portal vein, hepatic 
vein, and sinusoidal and bile duct invasion) were not defined in this study.[28] With 
standard H&E staining, lymphatic vessels cannot be distinguished from blood vessels 
(Figure  1A). D2-40 staining of the lymphatic vessels could be helpful in detecting 
tumour cells within lymphatic vessels (Figure  1B). This staining was used in one 
study,[28] and, because other studies did not mention the method used to visualize 
lymphatic invasion, it remains unclear how they differentiated between invasion of 
blood vessels and invasion of lymphatic vessels.
Portal vein invasion
Eight studies have investigated the incidence of portal vein invasion in CRLM 
(Figure 2).[20-24, 26, 28, 29] These studies included 607 patients in total. The mean incidence 
of portal vein invasion was 26.2% (range 10–49%). Four studies (n = 247) reported data 
on 5-year OS in patients with and without portal vein invasion.[20, 23, 24, 29] Although the 
sample sizes of these studies are relatively small, leading to significant heterogeneity, 
there seems to be better overall survival in patients without portal vein invasion (RR 
1.77, 95% CI 1.26–2.47) (Figure 3A).
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Figure 1. A, Haematoxylin and eosin staining at the border of a tumour. Small vessels are present, but 
differentiation between blood and lymphatic vessels is difficult. B, Immunohistochemical staining 
with the D2-40 monoclonal antibody reveals tumour cells within lymphatic vessels.
A
B
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Figure 2. Frequency of different types of intrahepatic spread.
Hepatic vein invasion
Seven studies investigated the incidence of hepatic vein invasion (Figure  2).[20-24, 26, 2] 
They included 523 patients, 62 of whom had hepatic vein invasion (11.9%, range 
5–24%). Three studies (n  =  192) investigated the impact of hepatic vein invasion on 
5-year OS.[20, 23, 24] Because of the small number of patients, the impact of hepatic vein 
invasion remains unclear (RR 1.53, 95% CI 0.81–2.89) (Figure 3B).
Lymphatic invasion
Two studies investigated the incidence of lymphatic invasion (Figure 2),[24, 28] with a 
total of 170 patients. Lymphatic invasion was found in 12% and 15% of CRLMs. Both 
studies showed a negative impact of lymphatic invasion on survival (RR 1.66, 95% 
CI 1.42–1.95) (Figure 3C).
Bile duct invasion
Nine studies investigated the incidence of bile duct invasion (Figure  2).[21-28] These 
studies included 781 patients, 30.2% of whom had bile duct invasion (range 13–42%). 
Five studies (n = 346) reported data on 5-year OS in patients with and without bile 
duct invasion of the CRLMs.[20, 23-26] There seems to be no correlation between bile 
duct invasion of the CRLMs and clinical outcome (1.22, 95% CI 0.94–1.58) (Figure 3D).
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Figure 3A
Figure 3B
Figure 3C
Figure 3D
Figure 3. Forest plots for the prognostic value of intrahepatic spread. A, Portal vein invasion (PVI). 
B, Hepatic vein invasion (HVI). C, Lymphatic invasion (LI). D, Bile duct invasion (BDI). CI, confidence 
interval; OS, overall survival.
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Perineural invasion
Three studies investigated the incidence of perineural growth in CRLM (Figure 2).[20, 21, 26] 
Perineural invasion was found in 40 of 285 patients (14.0%) (range 12–17%). One study, 
by Yamamato,[20] investigated the impact of perineural invasion on 5-year OS, and found 
that it was negative.
Presence of micrometastases
In analogy with primary colorectal tumours, micrometastases may occur in liver 
metastases. Micrometastases are defined as discrete microscopic cancerous lesions 
ranging from a single cell to clusters of cells within the liver parenchyma or portal 
tracts surrounding the dominant macroscopic hepatic tumour. Yokoyama et  al. 
detected micrometastases in 32 of 46 patients, by using CK20 staining.[30] Patients 
with micrometastases were reported to have a higher probability of intrahepatic 
recurrence and poorer survival. They had a 10-year survival rate of 21.9%, versus 
64.3% for patients without micrometastases. In the definition used by Yokoyama, 
there is an overlap between micrometastases and intrahepatic spread.
Presence of a fibrous capsule
The presence of a fibrous capsule has been recognized as a favourable prognostic factor 
in hepatocellular carcinomas.[31] A study by Okano et  al. investigated the prognostic 
value of a fibrous capsule in liver metastases of colorectal origin.32 Fibrotic tissue 
between the tumour and surrounding hepatic parenchyma was classified as thick (≥10 
layers of collagen bundles) or thin (several layers of collagen bundles). Fibrotic tissue 
was observed in 61% of patients, and was associated with improved survival. Patients 
with a thick pseudocapsule had 5-year survival rates of 88%, as compared with 64% 
in patients with a thin pseudocapsule and 31% in patients without a pseudocapsule. 
Yamamoto et  al. confirmed the prognostic value of a fibrous pseudocapsule after 
hepatectomy for colorectal metastases.[20] A thick pseudocapsule was associated with a 
5-year survival rate of 71%, a thin pseudocapsule with a 5-year survival rate of 63%, and 
the absence of a pseudocapsule with a 5-year survival rate of only 19%.
Response to neoadjuvant chemotherapy
Tumour regression grading
Five studies investigated the histological response of liver metastases to preoperative 
chemotherapy (Table 1).[33-37] All studies showed some effect on survival, but different 
grading systems were employed to assess pathological response to chemotherapy. 
Two studies used complete pathological response versus all other responses, 
including non-responses.[33, 37] In the study by Adam et al.,[33] each nodule was sampled 
for histological examination, one block for each centimetre of diameter of the nodule. 
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Complete pathological response was defined as the absence of any viable tumour 
cells irrespective of the proportions of necrosis and fibrosis. In the study by Tanaka 
et  al.,[37] complete pathological response was defined as the absence of any viable 
tumour cells, irrespective of the proportions of necrosis and fibrosis, in the largest 
cut surface of macroscopically confirmed metastatic tumours, or at sites in resected 
specimens corresponding to areas where metastases were initially detected in 
preoperative images. A limitation of those grading systems is the inability to identify 
partial responders who may also have better survival. In addition, even complete 
pathological response is sensitive to bias, because it depends on the number of 
lesions assessed and the interpretation of the pathologist. Other pathological response 
grading systems are based on a semi-quantitative analysis of the proportion of viable 
cancer cells remaining, and are therefore subject to variability in interpretation.[34, 35] It 
is impossible to determine the percentage of remaining cancer cells, because there 
are no data on the baseline percentage of tumour cells prior to chemotherapy. 
Moreover, liver metastases frequently show necrosis surrounded by adenocarcinoma 
cells, regardless of neoadjuvant therapy, and the value of necrosis has not been 
established. A large area of necrosis will decrease the percentage of remaining cancer 
cells in most grading systems, and does not represent the efficacy of chemotherapy.
 The grading system of Rubbia-Brandt et al. seems to be the most accurate, because 
it takes into account the necrotic areas, fibrotic areas, and residual cancer cells.[36] 
Moreover, for its establishment, chemotherapy-naïve tumours were used as a control. 
Although this seems essential, this is the only study to incorporate such controls. The 
system is a modified version of the tumour regression scheme of Mandard et al.[38] for 
oesophageal carcinomas. The score identifies five tumour regression grades (TRGs) 
on the basis of the presence of residual tumour cells and the extent of fibrosis. TRG1 
corresponds to the absence of tumour cells replaced by abundant fibrosis; TRG2 to 
rare residual tumour cells scattered throughout abundant fibrosis; TRG3 to a greater 
number of residual tumour cells with predominant fibrosis; TRG4 to a large number of 
tumour cells predominating over fibrosis; and TRG5 to tumour cells without fibrosis.
Tumour thickness at the tumour–normal interface
Maru et  al. measured the tumour thickness at the tumour–normal interface of 103 
patients with CRLMs resected after preoperative chemotherapy.[39] The recurrence-
free survival rates were 70% for patients with a tumour thickness of <0.5 mm, 51% for 
patients with a tumour thickness between 0.5 mm and 5 mm, and 35% for patients 
with a tumour thickness of ≥5 mm. A limitation of this study is that the role of tumour 
thickness in chemotherapy-naïve liver metastases was not investigated. Therefore, it 
could be that tumour thickness at the tumour–normal interface is a prognostic factor, 
rather than a predictive factor for response to chemotherapy.
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Number of lesions to be assessed for chemotherapy response
There is conflicting literature on the histological response to chemotherapy of 
different liver metastases within one patient. Rubbia-Brandt et  al. showed 89% 
concordance in histological response.[36] However, Tanaka et  al. found that, within 
the same patient, some liver metastases showed a complete response, whereas 
other metastases did not.[37] Better survival was demonstrated in patients with a 
pathologically complete response in at least one liver metastasis than in patients with 
no pathologically complete responses. The best overall survival rate was reached in 
patients with all lesions showing complete responses. Until there are more data on 
the variation in histological response of multiple liver metastases within a patient, 
histological sampling of each lesion is recommended to assess the pathological 
response to chemotherapy.
Table 1. Correlation of histological response of colorectal liver metastases after neoadjuvant 
chemotherapy with 5-year overall survival
author year no of 
pts
neo-adjuvant 
chemo-therapy
surgery 
alone
grading system histological response 
to chemotherapy
5y OS p-value
Adam 2008 767 767 - complete pathological response  
(n=29)
76%
no complete pathological response 
(n=738)
45% 0.004
Blazer 2008 271 271 - complete response
(no residual cancer cells) (n=25)
75% 0.037
major response  
(1%-49% residual cancer cells) (n=97)
56%
minor response  
(>50% residual cancer cells) (n=149)
33% 0.028
Chan 2010 50 50 - strong pathological response  
(<10% viable tumor cells) (n=17)
80% 0.019
weak pathological response 
(>10% viable tumor cells) (n=33)
51%
Rubbia-
Brandt
2007 181 112 69 major or complete histological tumor 
regression (TRG 1+2) (n=27)
41%
partial histological tumor regression (TRG 
3) (n=36)
38% 0.0003
no histological tumor regression  
(TRG 4+5) (n=49)
9% 0.0019
Tanaka 2009 63 63 - complete pathological response  
(n=23)
69%
no complete pathological response (n=40) 8% 0.001
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Discussion
The benefits of hepatic resection for survival in patients with CRLMs are well 
established; however, there is still a challenge in selecting the right patients and 
preventing recurrence. Macroscopic features of resected metastases, such as size, 
number, and synchronous or metachronous disease, are important prognostic factors 
in many studies. These, together with staging of the primary tumour, are factors in 
clinical risk scores (CRSs), such as that of Fong et al.[4] This CRS is widely used to stratify 
patients into high-risk and low-risk groups for overall survival.[40, 41]
 In analogy with primary tumours, histopathological factors, such as vascular 
or perineural invasion and response to chemotherapy, have been investigated in 
CRLMs. Whereas studies in primary colorectal cancer typically consist of large series 
of patients, in which well-defined histological factors are investigated, pathological 
research of liver metastases is still in its infancy. Potentially useful factors have been 
investigated in relatively small, sometimes heterogeneous, groups of patients, but 
the evaluation of promising features, such as intrahepatic invasion and tumour 
regression grade, will require study of larger series with, for investigation of tumour 
response to neoadjuvant chemotherapy, use of well-defined grading systems with 
chemotherapy-naive liver metastases as controls.
 With the high frequency of CRLMs and the increasing number of hepatic resections, 
there is a need for well-defined prognostic histopathological factors. Prospective 
studies of populations of patients with CRLMs are warranted to evaluate prognostic 
and/or predictive factors, such as histopathological features and (novel) biomarkers, 
in order to assist treatment decisions.
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Abstract
For a selection of patients with colorectal liver metastases (CRLM), liver resection is 
a curative option. In order to predict long-term survival, clinicopathologic risk scores 
have been developed, but little is known about histologic factors and their prognostic 
value for disease-free and overall survival. The objective of the present study was 
to assess possible prognostic histologic factors in patients with solitary CRLM treated 
with liver resection who did not receive neoadjuvant treatment.
Patients with solitary CRLM who underwent liver resection between 1992 and 
2011 were evaluated for clinical prognostic factors. Histologic analyses on tumor 
thickness at the tumor-normal interface, presence of a fibrotic capsule, intrahepatic 
vascular invasion, lymphatic invasion, or bile duct invasion and perineural growth 
were performed, using immunohistochemistry.
A total of 124 patients were analyzed with a median follow-up of 41 months (range 
1–232 months). There was no association between histologic factors and disease-
free survival in multivariate analysis. In multivariate analysis, intrahepatic lymphatic 
invasion was associated with a decreased overall survival (41.9 vs. 61.0 months; 
p = 0.041), especially in combination with vascular invasion (n = 15) (28.1 vs. 62.2 
months; p < 0.0001). In addition, size over 50 mm (29.2 vs. 65.9 months; p = 0.004) and 
interval less than 12 months between resection of the primary tumor and diagnosis 
of liver metastasis (49.0 vs. 91.5 months: p = 0.019) were also independent adverse 
prognostic factors.
Intrahepatic lymphatic invasion, especially in combination with vascular invasion, is 
an important adverse prognostic factor for overall survival in patients with solitary 
CRLM after liver resection.
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Introduction
Colorectal cancer is one of the leading causes of cancer death worldwide as a result 
of its considerable risk of development of metastases.[1] When metastatic disease is 
confined to the liver, partial liver resection is the only curative therapeutic option, 
with 5-year overall survival (OS) percentages between 20 and 60%, depending 
on patient and tumor characteristics.[2-4] In order to explain these varying survival 
rates, different clinicopathologic risk scores have been developed. In many of these 
risk scores, nodal status of the primary tumor, size and number of the colorectal 
liver metastases (CRLM), disease-free interval from treatment of the primary until 
detection of the CRLM, and preoperative level of carcinoembryonic antigen (CEA) are 
combined to predict long-term survival.[5-9] These scoring systems are relevant with 
respect to prediction of survival, but to our knowledge, they have not been used for 
risk stratification in controversial areas such as the administration of neoadjuvant or 
adjuvant systemic therapy or surveillance.
 In primary colorectal cancer histologic factors such as extramural venous 
invasion, perineural growth, lymphatic invasion, angioinvasion, and diffuse growth 
pattern have been associated with poorer survival outcomes.[10, 11] Extramural 
venous invasion in particular is considered a poor prognostic factor, and as a result, 
patients with extramural venous invasion in stage II colon cancer are considered 
candidates for adjuvant systemic treatment.[12] Very little is known about the impact 
of histologic features of colorectal liver metastases on OS, as described in a recent 
review.[13] Vascular invasion, bile duct invasion, or lymphatic invasion by tumor cells 
in CRLM have all been suggested as prognostic factors for long-term survival.[5, 14-
23] Perineural growth, the presence of a fibrous capsule, and tumor thickness at the 
tumor–normal interface have also been linked to survival in patients with CRLM.[14, 
15, 19, 24-26] Variations in definitions and selection of patients have limited the impact of 
these studies. Furthermore, none of these previous studies has evaluated multiple 
histologic factors of the liver resection specimens, in combination with established 
risk scores in a homogenous group of patients. Most studies included patients who 
underwent neoadjuvant therapy as well as chemotherapy-naive patients, patients 
with multiple liver metastases, or patients with extrahepatic disease.[5, 14-21, 23, 24] The 
results of these previous studies might be biased because of the known changes 
in histologic features observed in liver metastases after systemic therapy, and the 
possible heterogeneous nature of multiple metastases.[27-30]
 The objective of the current study was to assess possible prognostic histologic 
factors for long-term survival in patients with solitary colorectal liver metastases who 
underwent a complete (R0) liver without neoadjuvant systemic therapy.
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Materials and methods
Patients
Patients were identified who underwent complete (R0) liver resection for a solitary 
CRLM between 1992 and 2011 in a tertiary referral hospital. R0 resections were 
defined as liver resections with clear resection margins in patients who did not have 
evidence of disease in any other locations.
 Demographics and clinicopathologic factors with regard to the primary tumor, 
as well as the liver metastasis, were collected per patient. Special attention was 
given to the four different items from the clinical risk score according to Fong 
et al.: nodal status of the primary tumor; preoperative CEA level and size of the 
metastasis, and interval between resection of the primary tumor and diagnosis of 
CRLM.[9] It is unknown whether systemic treatment influences the presence of certain 
histopathology factors and therefore patients who were treated with neoadjuvant 
systemic therapy were excluded from the current study. Patients who died from 
postoperative complications, defined as within 30 days after liver resection, were also 
excluded. Patients underwent follow-up according to our current Dutch follow-up 
guidelines, with regular outpatient visits, CEA testing and computed tomographic 
scans of chest and abdomen.
Histopathology
R0 liver resection specimens with a solitary CRLM were selected from the archive. 
Routine workup consisted of sampling of macroscopically normal liver tissue, 
invasive front of the metastasis, and additional tumor blocks, depending on the size 
of metastasis. Slide revision was performed independently by two investigators (JdR, 
NK). Discrepancies were resolved by simultaneous re-examination of the slides by 
both investigators using a two-headed microscope. In case of discrepancy, the senior 
pathologist (IN) made the final call.
 Tumor thickness at the tumor–normal interface was determined in routine slides. 
Tumor–normal interface was defined as the interface between tumor and normal liver 
tissue, as described by Maru et al. and validated by others.[26, 31, 32] In all tumors, tumor 
thickness was measured with a ruler at multiple foci, and maximum tumor thickness 
was used and defined as uninterrupted layers of tumor cells without admixed fibrotic 
stroma, acellular mucin, or nonneoplastic liver parenchyma. The median tumor 
thickness at tumor–normal interface was used to divide the patient group in a group 
with a larger and a smaller layer of vital tumor cells (Figure 1).
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Figure 1. Tumor thickness at tumor–normal interface; arrow indicates correct measurement with 
uninterrupted layer of tumor cells. Original magnification, x10
The presence of a fibrotic capsule around the metastasis was evaluated in routine 
slides. The fibrous tissue between tumors and liver parenchyma was classified as 
absent (no fibrous tissue observed) or present: tumor was separated from the liver 
parenchyma by several layers of collagen bundles in histologic sections (Figure 2).
Immunohistochemistry and scoring methods
Immunohistochemistry was performed as previously described.[33] Perineural growth 
was defined as a nerve, identified by S-100 staining, being surrounded by tumor 
cells for at least three quarters of the circumference and was scored as being present 
or absent (Figure 3A). Lymphatic invasion was defined as single tumor cells or cell 
clusters visible within vessels that showed immunoreactivity for D2-40 but not for 
CD31. Lymphatic invasion was scored as being present or absent (Figure 3B).Vascular 
invasion was defined as single tumor cells or cell clusters visible within vessels that 
showed immunoreactivity for CD31 but not for D2-40. It was scored as being present 
or absent (Figure 3C). Bile duct invasion was defined as single tumor cells or cell 
clusters (CK7 negative) visible within bile ducts that showed immunoreactivity for 
CK7. It was also scored as being present or absent (Figure 3D).
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Figure 2. a Colorectal liver metastasis without fibrous capsule. Original magnification, x20. 
b Colorectal liver metastasis with fibrous capsule (arrow). Original magnification, x20
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Figure 3. Different forms of intrahepatic invasion by tumor cells. 
a Perineural growth showing S-100 reactivity. 
b Lymphatic invasion showing D2-40 reactivity. 
c Vascular invasion showing CD-31 reactivity. 
d Bile duct invasion showing CK-7 reactivity. Original magnification, x20
Outcome
Primary outcomes were disease-free survival (DFS) and OS. DFS was defined as the 
interval in months between liver resection and disease recurrence, death, or last 
follow-up. OS was defined as the interval in months between liver resection and 
death or date of last followup.
Statistical analysis
Pearson’s Chi square test was used to calculate correlations between the various 
histologic features. Survival curves were estimated by the Kaplan–Meier method 
and compared by log rank testing. Multivariate analysis was performed using Cox 
proportional hazard model, and variables were included that were associated with 
survival in univariate analysis with a p value of <0.10. SPSS statistical software, version 
18.0 (IBM, Armonk, NY, USA) was used for all statistical analysis. A p value of <0.05 was 
considered statistically significant.
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Results
Patients
Between January 1992 and March 2011, a total of 383 patients underwent liver 
resection for metastatic disease. After excluding patients with multiple metastases, 
135 patients remained who were surgically treated (R0) for solitary CRLM. Eleven 
patients were excluded because they received neoadjuvant chemotherapy (n = 5), 
were lost to follow-up (n = 2), or died within 30 days after liver resection (n = 4). 
A total of 124 patients were eligible to be included in the current study, 76 men 
(61.3%) and 48 women (38.7%). Median age at time of resection was 64 years (range 
40–80 years). Liver metastasis were detected at a median of 8.8 months (range 0–82 
months) after resection of the primary tumor. Median size of the metastasis was 35 
mm (range 10–130 mm). Median follow-up was 41 months (range 1–232 months). In 
the complete study population, median DFS was 28 months (range 1–228 months) 
with a median OS of 57 months (range 1–232 months) and a 5-year survival of 48.1%.
Histopathologic tumor features
Fibrous capsule and tumor thickness 
In 34.4% of patients (n = 43), the liver metastasis was surrounded by a fibrous capsule. 
Presence of a fibrous capsule was not associated with DFS, but it was associated with 
an improved OS of 109.3 months, versus 56.7 months in patients without a fibrous 
capsule (p = 0.037). In multivariate analysis, presence of a fibrous capsule was not an 
independent risk factor for OS (Tables 1, 2). Tumor thickness at tumor–normal interface 
varied between 0.1 and 7.2 mm, with a median of 3 mm, and was not correlated with the 
size of the liver metastases (p = 0.213). Although there was a significant association of 
increased thickness with decreased outcome (both DFS and OS) in univariate analysis, 
it was no longer significant in multivariate analysis (Tables 1, 2).
Intrahepatic spread 
Frequency of different forms of intrahepatic invasion varied; perineural growth (n 
= 11; 8.9%) and bile duct invasion (n = 11; 8.8%) were both relatively uncommon, 
whereas vascular and lymphatic invasion were seen more frequently (n = 46; 37.1%, 
respectively n = 33; 26.6%). In univariate analysis, presence of bile duct invasion was 
associated with improved OS (76.7 vs. 55.9 months; p = 0.048), but this was not the 
case in multivariate analysis (p = 0.094). Presence of intrahepatic lymphatic invasion 
was correlated with a decreased median OS (41.9 vs. 62.2 months, p = 0.013), which 
remained significant in multivariate analysis (p = 0.041).
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Table 1. Relation of clinical and histologic factors with DFS after liver resection in patients with 
solitary CRLM
n % Median DFS UV p value MV p value
Size (mm)
≤50 93 75 50.1 0.002* 0.020*
>50 31 25 14.5
CEA (ng/ml)
≤200 121 97.6 27.5 0.508 –
>200 3 2.4 40.6
DFI (months)
≤12 72 58.1 27.8 0.232 –
>12 52 41.9 25.4
Nodal state primary
N0 54 43.5 35.7 0.446
N+ 70 56.5 27.5 –
Adjuvant therapy
No 106 85.5 20.2 0.013* 0.025*
Yes 18 14.5 >50
Tumor thickness at TNI (mm)
≤3 60 48.4 >51 0.023* 0.118
>3 64 51.6 19.4
Fibrous capsule
Present 43 34.4 27.8 0.468 –
Absent 81 65.6 25.8
Perineural growth
Present 11 8.9 50.2 0.539 –
Absent 113 91.1 27.5
Vascular invasion
Present 46 37.1 18.0 0.055 0.287
Absent 78 62.9 40.8
Lymphatic invasion
Present 33 26.6 19.4 0.280 –
Absent 91 73.4 29.2
Bile duct invasion
Present 11 8.8 27.8 0.624 –
Absent 113 91.2 27.5
DFS disease-free survival, CRLM colorectal liver metastases, UV univariate, MV multivariate, CEA 
carcinoembryonic antigen, DFI disease-free interval between treatment of primary tumor and 
detection of the CRLM, TNI tumor–normal interface
* p< 0.05 was considered statistically significant
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Table 2. Relation of clinical and histologic factors with OS after liver resection in patients with 
solitary CRLM
 n % Median OS UV p value MV p value
Size (mm) 
≤50 93 75 65.9 0.050* 0.004*
>50 31 25 29.2
CEA (ng/ml)
≤200 121 97.6 57.3 0.912 –
>200 3 2.4 28.9
DFI
≤12 72 58.1 49.0 0.059 0.019*
>12 52 41.9 91.5
Nodal state primary
N0 54 43.5 61.0 0.231 –
N+ 70 56.5 44.6
Adjuvant therapy
No 106 85.5 57.2 0.955 –
Yes 18 14.5 29.2
Tumor thickness at TNI (mm)
≤3 60 48.4 95.3 0.043* 0.068
>3 64 51.6 48.8
Fibrous capsule
Present 43 34.4 109.3 0.037* 0.240
Absent 81 65.6 56.7
Perineural growth
Present 11 8.9 109.3 0.652 –
Absent 113 91.1 55.9
Vascular invasion
Present 46 37.1 48.8 0.483 –
Absent 78 62.9 58.2
Lymphatic invasion
Present 33 26.6 41.9 0.013* 0.041*
Absent 91 73.4 62.2
Bile duct invasion
Present 11 8.8 76.7 0.048* 0.094
Absent 113 91.2 55.9
OS overall survival, CRLM colorectal liver metastases, UV univariate, MV multivariate, CEA 
carcinoembryonic antigen, DFI disease-free interval between treatment of primary tumor and 
detection of the CRLM, TNI tumor–normal interface
* p< 0.05 was considered statistically significant
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In the current study, no correlation between different forms of intrahepatic spread or 
between any of the histologic features and the various items of the clinical risk score 
was observed. However, there was a correlation between presence of a fibrous capsule 
and absence of intrahepatic vascular invasion (p = 0.014) and between presence of a 
fibrous capsule and presence of intrahepatic bile duct invasion (p = 0.013).
 In 15 patients, a combination of intrahepatic lymphatic invasion and intrahepatic 
vascular invasion was present, and this combination was associated with a decreased 
OS (median 28.1 vs. 62.2 months) in univariate and multivariate analysis (p<0.0001).
Discussion
The current study describes the association between multiple histologic features 
in combination with clinical factors and survival in 124 patients who underwent 
liver resection for CRLM. A homogenous group of patients was evaluated because 
all patients underwent a complete resection (R0), for a solitary metastasis without 
neoadjuvant systemic treatment. The only significant histologic factor associated with 
decreased survival in multivariate analysis was presence of intrahepatic lymphatic 
invasion, especially in combination with intrahepatic vascular invasion. 
 Other authors also described lymphatic invasion as a negative predictor for survival.
[13, 18, 20] In the current study, we observed a relative high frequency of lymphatic 
invasion (26.6%) compared to earlier studies (12–15%).[18, 20] This might be due to 
the use of immunohistochemistry, which is supported by a recently published study 
with the same methodology and a similar frequency of lymphatic invasion (29%).
[18, 20, 34-36] Presence of lymphatic invasion has been associated with spread to hepatic 
lymph nodes, which often leads to incurable disease.[20, 37] In the current study, the 
worse prognosis was demonstrated in patients with a combination of vascular and 
lymphatic invasion. This unfavorable combination has been observed before and 
might reflect a tumor with aggressive behavior.[23]
 Another interesting finding from the current study was that the median tumor 
thickness at tumor–normal interface in patients who were not treated with 
neoadjuvant systemic therapy was 3.0 mm. This was only slightly higher than the tumor 
thickness of 2.8 mm described in patients treated with neoadjuvant chemotherapy.[26] 
This raises the question whether tumor thickness at tumor–normal interface reflects 
chemotherapy response or tumor biology; this would be an interesting subject for 
further research.
 A major strength of the present study is the inclusion of patients with solitary 
CRLM only, who were operated with complete margins (R0) to create an homogenous 
group of patients. Previous studies on histologic prognostic factors included patients 
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with multiple CRLM and R1 resections as well, which might lead to significant bias 
of the results.[18, 20, 36] First, heterogeneity of histologic features between the different 
liver metastases might exist and could lead to bias studying prognostic factors for 
survival. Second, patients who undergo R1 resection usually have a higher risk of 
local recurrences and have an impaired survival.[38, 39] Third, patients with multiple 
metastases have a significantly decreased survival, and number of metastases is the 
most important factor in the Fong classification for survival.[9] By excluding these 
potential biases in the present study, the assessment of the prognostic histologic 
factors are more reliable.
 Another strength is that this homogenous group of patients with solitary metastasis 
were not treated with neoadjuvant systemic therapy. In recent studies, patients 
with and without neoadjuvant systemic therapy were mixed, and conclusions were 
drawn from a population highly susceptible to bias.[25, 36, 40] Neoadjuvant systemic 
therapy has a significant impact on tumor histology, and even prognostic factors 
such as resection margins might be less important.[27, 28, 41] Because the detection 
of histologic prognostic factors in metastatic disease is still in its infancy and the 
effects of neoadjuvant systemic therapy on lymphatic invasion are unknown, a study 
with an homogeneous population should be a first step. However, there seems 
to be an increasing preference to utilize neoadjuvant systemic therapy for high 
risk patients, despite a lack of convincing evidence on survival benefit in patients 
with limited metastases.[42-44] Therefore, a limitation of the present study is that the 
impact of lymphatic invasion on survival has to be confirmed in patients treated with 
neoadjuvant systemic therapy. In the total group of patients treated in our institution 
only 5 patients (3.8%) with solitary metastasis were treated with neoadjuvant 
chemotherapy, which made it impossible to compare, but this should be the goal for 
future research.
 In conclusion, intrahepatic lymphatic invasion, based on immunohistochemical 
detection of lymphatic vessels, is an adverse prognostic factor for OS in patients with 
a solitary CRLM. Therefore, we recommend evaluating the presence or absence of 
intrahepatic lymphatic and vascular invasion in the histologic assessment of CRLM. 
Future research is needed to determine whether adjuvant treatment strategies 
should be based on these adverse prognostic histologic factors.
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Abstract
KRAS mutation is a negative predictive factor for treatment with anti-epidermal 
growth factor receptor antibody in metastatic colorectal cancer (CRC). KRAS mutation 
analysis is usually performed on primary tumour tissue because metastatic tissue is 
often not available. However, controversial data are available on the concordance of 
test results between primary tumours and corresponding metastases. We assessed 
the concordance of KRAS mutation status in a study of 305 primary colorectal tumours 
and their corresponding liver metastases.
Patients with histologically confirmed CRC who underwent surgical resection of the 
primary tumour and biopsy or surgical resection of the corresponding liver metastasis 
were included. KRAS mutation analysis was performed for codons 12 and 13.
 
KRAS mutation was detected in 108 out of 305 primary tumours (35.4%). In 11 cases 
(3.6%), we found a discordance between primary tumour and metastasis: 5 primary 
tumours had a KRAS mutation with a wild-type metastasis, 1 primary tumour was wild 
type with a KRAS mutation in the metastasis, and in 5 cases the primary tumour and 
the metastasis had a different KRAS mutation.
We observed a high concordance of KRAS mutation status of 96.4% (95% CI 93.6–
98.2%) between primary colorectal tumours and their corresponding liver metastases. 
In only six patients (2.0%; 95% CI 0.7–4.2%), the discordance was clinically relevant. 
In this largest and most homogenous study to date, we conclude that both primary 
tumours and liver metastases can be used for KRAS mutation analysis.
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Introduction
Recent advances in specific signalling pathways of cancer cells have introduced 
targeted therapy into treatment regimes for patients with metastatic colorectal 
cancer (CRC).[1] Cetuximab and panitumumab are monoclonal antibodies that bind to 
the extracellular domain of the epidermal growth factor receptor (EGFR). They inhibit 
ligand-induced stimulation of several intracellular signalling pathways, such as RAS/
RAF/MAPK and phosphoinositide-3 pathway, which results in decreased stimulation 
of cell cycle progression, proliferation, angiogenesis, and stimulation of apoptosis.[2] 
The KRAS oncogene is currently the most relevant molecular biomarker that predicts 
the response to EGFR-targeted therapy in CRC. An oncogenic mutation in KRAS leads 
to constitutive activation of the RAS/RAF signalling pathway independent from EGFR 
activation by binding of the ligand.[3]
 KRAS mutations occur in approximately 38% of colorectal tumours and involve 
codon 12 and 13 in 496% of cases.[4] Metastatic CRC patients with tumours harbouring 
a KRAS mutation are resistant to treatment with anti-EGFR antibodies, showing 
lower response rates, decreased progression- free survival, and overall 
survival compared with patients with KRAS wild-type tumours.[5-7] Therefore, 
the European Medicines Agency and the Food and Drug Administration have 
restricted the use of anti-EGFR antibodies in metastatic CRC to patients with 
KRAS wild-type tumours.
 Cetuximab and panitumumab have shown efficacy both as monotherapy[5, 8] and 
in combination with chemotherapy[6, 7] in patients with KRAS wild-type metastatic 
CRC. Nevertheless, even among patients with KRAS wild-type tumours, the majority 
of patients do not respond to anti-EGFR therapy. Efficacy of anti-EGFR therapy was 
suggested to be further restricted to patients with BRAF wild-type tumours.[9] An 
additional explanation for the suboptimal response rates to anti-EGFR antibodies in 
patients with KRAS wild-type tumours is discordance of KRAS mutation status between 
primary colorectal tumours and corresponding metastases. In the early dissemination 
model, tumour cells depart the primary lesion before the acquisition of a fully 
malignant phenotype to undergo new mutations and metastatic growth at a distant 
site.[10] According to this model, a discordance in mutation status between primary 
tumours and metastases may occur, and as a consequence the mutation status of the 
primary tumour might not be adequate to predict the response of metastases to anti-
EGFR treatment. Current data on the concordance in KRAS mutation status between 
primary colorectal tumours and metastases are conflicting.
 Five studies showed a 100% concordance of KRAS mutation status in primary CRC 
and corresponding metastases.[11-15] In contrast to these data, others have reported a 
discordance of KRAS mutation status in primary tumours and metastatic sites, with 
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an overall discordance observed in 4–32% of the patients.[16-28] These controversial 
results are probably due to the fact that these studies were underpowered with a 
small number of patients, and included a wide variety of metastatic sites. Therefore, 
it is still uncertain whether the evaluation of KRAS mutation status in the most 
commonly available primary tumour correctly reflects the KRAS mutation status of 
corresponding metastasis. This is highly relevant given the large number of CRC 
patients as well as the potential toxicity and costs of anti-EGFR therapy. We assessed 
the concordance in KRAS mutation status in primary tumours and their corresponding 
liver metastases in an adequately powered study of 305 CRC patients.
Material and methods
Patient selection
Patients with histologically confirmed CRC who underwent surgical resection 
of the primary tumour and biopsy or surgical resection of the corresponding 
liver metastasis were included in this analysis. Results were obtained from 
archived material of three large pathology laboratories and from material 
collected from the CAIRO2 study, a large multicentre trial of the Dutch 
Colorectal Cancer Group.[6] 
 In patients with a discordance of KRAS mutation status between the primary 
tumour and metastasis, additional blocks of the primary tumour were obtained 
to exclude heterogeneity within the tumour. Lymph node metastases present 
at the time of diagnosis were also acquired in these patients.
Tumour DNA preparation
Formalin-fixed paraffin-embedded tissue blocks were cut at 4 mm thickness 
and stained with haematoxylin and eosin (HE). The presence of tumour tissue 
was marked by a pathologist. Subsequently the blocks were cut at 20 – 40 mm 
thickness and micro dissected for DNA extraction. Tumour tissue was dissolved in 
200 ml lysis buffer (QIAamp DNA Micro Kit, Qiagen, Venlo, The Netherlands) and 
incubated with proteinase K overnight at 56 1C for two nights. DNA was extracted 
according to the manufacturer’s protocol (QIAamp DNA Micro Kit, Qiagen), and 
DNA concentration was determined at 260 nm using the Nanodrop 26 ND-1000 
spectro- photometer (Nanodrop Technologies Inc., Wilmington, NC, USA).
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For KRAS mutation analysis, exon 2 (codon 12 and 13) was amplified using a 50 ml reaction 
mixture containing 0.2 mm forward (5’-TGTAAAACGACGGCCAGTAGGCCTGCTGAAAATG 
ACTG-3’) and reverse (5’-CAGGAAACAGCTATGACCTGGATCATATTCGTCCACAAAA-3’) 
primers (Invitrogen, Breda, The Netherlands); dATP, dCTP, dGTP and dTTP (GE Healthcare, 
Zeist, The Netherlands) at 0.2 mM each; 50 mM KCl; 10 mM Tris-HCl (pH 8.3); 2.5 mM 
MgCl2; 1 U AmpliTaq Gold polymerase (Applied Biosystems, Nieuwkerk a/d IJsel, The 
Netherlands) and 50 ng of template DNA. The PCR conditions were as follows: 94 1C for 
10 min; 92 1C for 1 min, 60 1C for 1 min, 72 1C for 1 min (40 cycles); and 72 1C for 10 min.
 All PCR products were purified with the MultiScreen HTS, 96 well Filtration 
System (Millipore, Carrigtwohill, Ireland). Subsequently, the purified products 
were sequenced using fluorescently labelled terminators (BigDye Terminators 
(v 1.1); Applied Biosystems, Foster City, CA, USA) with both M13-forward and M13-
reverse sequencing primers. The sequencing products were analysed on an ABI 
3730 DNA Analyser (Applied Biosystems) and the data analysis was performed 
using Sequencing Analysis Software Sequencing Analysis Software v5.3.1 with 
KBTM Base- caller. Sequence results were scored by visual inspection of the 
chromatograms (Applied Biosystems).
Statistical analysis
We considered a discordance level of 5% or more to be clinically relevant, that is, leading 
to substantial change in routine clinical practice. To exclude such level of discordance 
under the assumption that the true discordance was 2.5% or less, we set the sample 
size at 304 paired samples. With this sample size, the precision in the estimated 
percentage of discordance was 2.5% (i.e., s.e. 1.25, half- width of the 95% confidence 
interval equal to 2.5%).
 The comparison of patient and primary tumour characteristics between patients 
with KRAS wild-type and KRAS mutant primary tumours was done using Wilcoxon’s 
rank sum test or χ2 for numerical or categorical variables, respectively. Differences in 
KRAS mutation status between the primary tumour and corre- sponding metastasis 
were analysed by calculating the percentage of concordance, and (clinically relevant) 
discordance, together with the corresponding Clopper– Pearson 95% confidence 
intervals. Differences were considered to be statistically significant when the P-value 
was below 0.05. All statistical tests were two-sided.
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Results
Patient characteristics
We analysed KRAS codon 12 and 13 mutations in 320 matched primary 
colorectal tumours and liver metastases. The tumour cell percentages in 
all primary tumours and metastases were above 30%. We failed to obtain 
a KRAS mutation status in 15 patients; therefore our further analyses were 
performed in 305 paired samples. Patient characteristics are shown in Table 1.
KRAS mutation and histopathological parameters
A total of 108 patients (35.4%) had a KRAS mutation in the primary 
tumour; of which 37 patients had a Gly12Asp mutation, 28 patients a Gly12Val 
mutation, 14 patients a Gly13Asp mutation, 10 patients a Gly12Cys mutation, 
7 patients a Gly12Ser mutation, 7 patients a Gly12Ala mutation, 3 patients 
a Gly12Arg mutation, 1 patient a Gly12Asp and Gly12Ala mutation and 1 
patient a Gly12Phe mutation (Table 2). Histopathological characteristics of 
the primary tumour were comparable between patients with and without a 
KRAS mutation (Table 1).
Concordance of KRAS status in primary tumours and 
corresponding liver metastases
In 294 patients (96.4%; 95% CI 93.6 – 98.2%), the same KRAS mutation status 
was obtained from the primary tumour and the corresponding liver metastasis. 
In 11 patients (3.6%; 95% CI 1.8 – 6.4%), of which 7 had synchronous metastases 
at diagnosis and 4 developed metachronous metastases, we found a discordance 
between primary tumours and metastases. Five patients had a KRAS 
mutation in the primary tumour and not in the liver metastasis. Only one 
patient had a wild-type status of the primary tumour, while the metastasis 
showed a KRAS mutation. In five patients, the primary tumours had different 
KRAS mutations compared with the metastases. One of these patients had 
two primary tumours. Both primary tumours had the same KRAS mutation 
(Gly13Asp), while the liver metastasis had a different KRAS mutation 
(Gly12Ser). In another patient, the primary tumour had a double mutation 
(Gly12Asp/Gly12Val) and the metastasis had a Gly12Asp mutation (Figure 1, 
Table 3). Taken together, the observed discordance was clinically relevant in 
only six patients (2.0%; 95% CI 0.7 – 4.2%).
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Table 1. Distribution of tumour characteristics according to KRAS status of the primary tumour
Overall,
n =305
KRAS mutation,
n =108
KRAS wild type,
n = 197
P-value
Age
Median (IQR) 64 (57 – 70) 65 (58 – 71) 64 (57 – 70)
0.20
Gender 0.37
Male 191 (62.6%) 64 (59.3%) 127 (64.5%)
Female 114 (37.4%) 44 (40.7%) 70 (35.5%)
Metastases presentation
Synchronous 169 (55.4%) 63 (58.3%) 106 (53.8%)
0.45
Metachronous 136 (44.6%) 45 (41.7%) 91 (46.2%)
Tumour location
Colon 167 (54.8%) 59 (54.6%) 108 (54.8%)
0.63
Rectum 54 (17.7%) 16 (14.8%) 38 (19.3%)
Rectosigmoid 80 (26.2%) 32 (29.6%) 48 (24.4%)
Unknown 4 (1.3%) 1 (0.9%) 3 (1.5%)
Histopathological subtype
Adenocarcinoma 271 (88.9%) 90 (83.3%) 181 (91.9%)
0.12
Adenocarcinoma with muc. component 21 (6.9%) 10 (9.3%) 11 (5.6%)
Mucinous adenocarcinoma 8 (2.6%) 5 (4.6%) 3 (1.5%)
Unknown 5 (1.6%) 3 (2.8%) 2 (1.0%)
Differentiation grade
Good 33 (10.8%) 13 (12.0%) 20 (10.2%)
0.21
Moderate 196 (64.3%) 65 (60.2%) 131 (66.5%)
Poor 52 (17.0%) 17 (15.7%) 35 (17.8%)
Unknown 24 (7.9%) 13 (12.0%) 11 (5.6%)
T stage 0.62
T1 4 (1.3%) 2 (1.9%) 2 (1.0%)
T2 20 (6.6%) 9 (8.3%) 11 (5.6%)
T3 231 (75.7%) 81 (75.0%) 150 (76.1%)
T4 36 (11.8%) 11 (10.2%) 25 (12.7%)
Unknown 14 (4.6%) 5 (4.6%) 9 (4.6%)
N stage
N0 114 (37.4%) 46 (42.6%) 68 (34.5%)
0.10
N1 87 (28.5%) 31 (28.7%) 56 (28.4%)
N2 86 (28.2%) 26 (24.1%) 60 (30.5%)
Unknown 18 (5.9%) 5 (4.6%) 13 (6.6%)
Number of lymph nodes examined
Median (IQR) 10 (6 – 15) 10 (6 – 13) 10 (6 – 16)
0.28
Number of lymph node metastases 0.15
Median (IQR) 1 (0 – 4) 1 (0 – 3) 1 (0 – 4)
Abbreviation: IQR = interquartile range
60
Chapter 3 – KRAS mutation analysis
Subsequent analyses in patients with a discordance of 
KRAS status
Several tests were performed to exclude bias of the test results. First, the 
HE coupes of all patients with a discordant KRAS mutation status between 
the primary tumour and liver metastasis were revised. The primary tumours 
and liver metastases had a mean tumour cell percentage of 65 and 60%, 
respectively. Subsequent independent reanalysis of the KRAS mutation 
status resulted in the same discordances.
 Second, several mutation analyses were performed on different areas of 
the tumour and from different tumour blocks in order to establish possible 
tumour heterogeneity. Two patients showed heterogeneity of KRAS status 
within the primary tumour. One of these patients demonstrated two areas 
with a Gly12Asp mutation and one area with wild-type status, of which the 
latter resembled the liver metastasis. The other patient showed two different 
KRAS mutations within the same tumour, of which one is concordant with 
the liver metastasis (Table 3).
 Third, 6 of the 11 patients with discordant results did have lymph nodes 
metastases at the time of diagnosis. KRAS mutation testing of all lymph nodes 
separately revealed overall concordant KRAS status between lymph node 
metastases and the primary tumour in three patients. The KRAS status of 
the lymph nodes in the other three patients showed heterogeneity, of which 
at least one lymph node metastases showed a different KRAS status compared 
with the primary tumour. However, this explains the discordance between 
the primary tumour and liver metastasis only in one patient (Table 3).
Discussion
This is the first adequately powered study in CRC that compares KRAS mutation 
status between primary tumours and their corresponding liver metastases. 
We showed that tissue from the primary tumour can reliably be used for KRAS 
mutation testing in order to select patients for anti-EGFR therapy.
 We observed a concordant KRAS mutation status in 96.4% of 305 paired 
samples of colorectal tumours and liver metastases. However, the difference 
in KRAS status was not clinically relevant in 5 of the 11 patients with 
discordant results, because both primary tumour and metastasis had a 
different KRAS mutation. Given the high statistical power of our analysis, we 
were able to obtain a highly accurate estimate of the level of discordance 
that enabled us to conclude that the level of discordance was 2.0%. The high 
3Table 2. Distribution of KRAS mutation types 
Codon 12/13 Patients with KRAS mutation (n, %)
Gly12Asp 37 (34%)
Gly12Val 28 (26%)
Gly13Asp 14 (13%)
Gly12Cys 10 (9%)
Gly12Ser 7 (6%)
Gly12Ala 7 (6%)
Gly12Arg 3 (3%)
Gly12Phe 1 (1%)
Gly12Asp + Gly12Val 1 (1%)
Table 3. Patients with a discordant KRAS status between primary tumour and liver metastasis. Multiple 
blocks of primary tumour tissue and lymph node metastases were tested when available.
KRAS status primary tumour KRAS status 2nd tumour KRAS status LN metastasis KRAS status liver metastasis
1 Gly12Ala - LN 1: Gly12Ala
LN 2: Gly12Ala
LN 3: Gly12Ala
WT
2 Gly12Asp
Gly12Asp
WT
- - WT
3 Gly12Cys - - WT
4 Gly12Asp
Gly12Asp
Gly12Asp
Gly12Asp
- LN 1: Gly12Asp
LN 2: Gly12Asp
LN 3: Gly12Asp
LN 4: Gly12Asp
LN 5: WT
WT
5 Gly12Ser - - WT
6 WT - - Gly12Cys
7 Gly12Asp - LN 1: WT
LN 2: WT
LN 3: WT
Gly12Ala
8 Gly13Asp Gly13Asp LN 1: Gly13Asp Gly12Ser
9 Gly12Ser - - Gly12Ala
10 Gly12Cys
Gly12Asp
- LN 1: Gly12Asp
LN 2: Gly12Asp
LN 3: Gly12Asp
LN 4: Gly12Asp
LN 5: Gly12Asp
LN 6: WT
Gly12Asp
11 Gly12Asp/Gly12Val - LN 1: Gly12Val
LN 2: Gly12Val
LN 3: Gly12Val
LN 4: Gly12Asp
LN 5: Gly12Asp
LN 6: Gly12Asp
LN 7: Gly12Asp
Gly12Asp
Abbreviation: WT = wild type
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rate of concordance is in agreement with the notion that KRAS mutations 
are considered as early driving events in CRC progression, and associated 
with the growth of small adenoma to clinically significant size.[29] Therefore, 
KRAS mutation status is expected to be equal in both primary tumours and 
metastases.[10]
 The previously reported lower concordance levels between primary tumours 
and metastases are most likely due to bias caused by false-negative results in 
underpowered studies. We calculated that 304 paired cases were needed to 
reliably exclude a rate of discordance of 45%, 110 patients (Table 4). Moreover, 
in these studies metastases of different sites were compared with the primary 
tumour. As the molecular patterns may differ between metastatic sites[10], more 
reliable results are obtained when KRAS mutation status is tested more rigorously 
for each metastatic site. The liver is the predominant site of metastases in the 
majority of metastatic CRC patients; therefore the results of our large series of 
305 liver metastases provide a solid reference for clinical decision making as to 
anti-EGFR therapy. Another issue is the fact that KRAS testing is technically not as 
straightforward as is often assumed. Several quality assurance systems are now in 
place, and the first ‘round robin’ test indicates that at least 30% of the experienced 
pathology laboratories fail to pass the threshold level of the quality assurance 
programs.[30] Other important facts about KRAS testing are the correct evaluation of 
the amount of tumour tissue in the sample and the sensitivity of testing methods. 
In a previous study, we demonstrated in 4500 samples that both sequencing and 
real-time PCR are reliable methods.[31]
 A discordant KRAS status between the primary tumour and metastasis 
was observed in a small number of patients (3.6%). In these cases, tumour 
cells may have departed the primary lesions before the acquisition of a 
fully malignant phenotype to undergo somatic mutations or deletions at 
a distant site.[10] Another explanation for the discordant results may be 
hetero- geneity of KRAS status within the primary tumour, although this was 
the case in only a small number of patients. Finally, a discordance may in 
theory be explained by metastases from a non- detected second primary.
 Previously published data showed that a considerable fraction (25%, 
Table 4) of colorectal lymph node metastases does not resemble the 
primary tumour in terms of KRAS mutation status. In 5 of the 25 lymph node 
metastases that we tested the KRAS status was not concordant with the 
primary tumour, which is consistent with the literature (Table 4). Therefore, 
lymph node metastases do not seem suitable for determination of the KRAS 
mutation status of colorectal carcinomas. Discordance in KRAS mutation 
status might be due to clonal selection during the process of metastasis, 
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however, heterogeneity in lymph node metastases could explain this 
discordance in only one patient.
 Eight different KRAS mutation types were observed in our study, of which 
Gly12Asp showed the highest frequency. Five patients (1.6%) harboured 
different KRAS mutation types in the primary tumour compared with the 
metastases. This confirms the findings of Cejas et al[17] and Albanese et al[19], 
who reported a small number of patients (4 and 7%, respectively) with 
different mutation types between primary tumours and metastases. A 
different KRAS mutation type between primary lung adenocarcinomas and 
corresponding lymph node metastases was also observed in only 1% of the 
patients.[32] Currently, all patients with a KRAS mutation are excluded from 
treatment with anti-EGFR antibodies, independently of the mutation type. 
However, a recent paper indicated that codon 13 mutated tumours may be 
sensitive to cetuximab treatment.[33] As we observed a low frequency in KRAS 
mutation type discrepancies between primaries and metastases, this is not 
of clinical importance in selecting patients for anti-EGFR therapy.
 In conclusion, we demonstrated a high level of concordance of 96.4% 
between primary tumours and liver metastases, which for clinical purposes 
to select CRC patients for anti-EGFR therapy was even higher with 98%. The 
implication of these results for general oncology practice is that both tissue 
of primary tumour or liver metastasis may be used for KRAS mutation testing. 
The results of our study are only valid for liver metastases and cannot be 
extrapolated to other metastatic locations. Furthermore, we demonstrated 
that discordance of test results between primary tumour and metastases 
cannot account for the failure rate of anti-EGFR therapy in patients with KRAS 
wild-type tumours. Therefore, novel predictive markers in addition to KRAS 
and BRAF mutation status are warranted.
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Figure 1. Overall concordance of the KRAS mutation status between primary tumour and liver 
metastasis (A), discordance without clinical impact (B), and discordance with clinical impact (C). 
Abbreviations: WT, wild type, MT, mutation. 
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Chapter 4 – Sequencing of RAS/RAF pathway genes in primary colorectal cancer
Abstract
Mutations in the RAS/RAF pathway predict resistance to anti-epidermal growth 
factor receptor antibodies in colorectal cancer (CRC), and may be targets for future 
therapies. This study investigates concordance of BRAF, HRAS, KRAS, NRAS and PIK3CA 
mutation status in primary CRC with matched liver (n=274), lung (n=114) or combined 
liver and lung metastases (n=14). 
Next generation sequencing was performed on DNA from formalin-fixed paraffin 
embedded CRC and matched liver and/or lung metastases, for recurrent mutations 
in BRAF, HRAS, KRAS, NRAS and PIK3CA and using the single-molecule molecular 
inversion probe method.
Paired sequencing results on all five genes were reached in 249 of the 402 cases (62%). 
The obtained number of unique reads was not always sufficient to confidently call 
the absence or presence of mutations for all regions of interest. The mutational status 
of matched pairs was highly concordant; 91.1% concordance for all five genes, 95.5% 
for KRAS, 99.1% for NRAS. Lung metastases more often harboured RAS mutations 
compared to liver metastases (71% vs. 48%, p<0.001).
In this large series of CRC we show that both primary tumors and corresponding 
metastases can be used to determine the mutational status for targeted therapy, 
given the high concordance rates. Next generation sequencing including single 
molecule tags is feasible, however in combination with archival formalin-fixed 
paraffin embedded material is limited by coverage depth.
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Introduction
Monoclonal antibodies against the Epidermal Growth Factor receptor (EGFR) are nowadays 
firmly established within treatment regimens for patients with metastatic colorectal 
cancer (CRC). These antibodies inhibit ligand induced stimulation of several intracellular 
signalling pathways such as RAS/RAF/MAPK and phosphoinositide-3 (PI3K) pathway, which 
results in decreased stimulation of cell cycle progression, proliferation, angiogenesis and 
stimulation of apoptosis. The presence of activating mutations in the RAS/RAF signalling 
pathway limits the effects of this treatment.[1-3] It is therefore standard procedure to 
perform molecular testing in order to determine the indication for these types of therapy. 
However, whether to test the primary tumor or the metastasis remains a matter of debate.[4-6] 
In previous work we have shown that for a limited number of KRAS mutations there 
is minimal discordance between primary CRC and liver metastases[7] However, we 
performed conventional Sanger sequencing and did not test all relevant RAS genes, nor 
BRAF and PIK3CA genes. 
 Next generation sequencing is increasingly performed in daily clinical practice. 
One advantage over Sanger sequencing is that low-frequency mutations can be 
detected. However, application of enrichment methods to gain sufficient quantities of 
DNA may result in amplification bias. To overcome this issue single molecule tags can 
be used.[8, 9] Consequently, in the current study we applied a single-molecule molecular 
inversion probe (smMIP)-based next generation sequencing approach to investigate 
concordance rates for all relevant BRAF, HRAS, KRAS, NRAS and PIK3CA mutations in CRC 
with matched lung and liver metastases.
Material and methods
Patient selection
All patients with histologically confirmed CRC who underwent surgical resection of 
the primary tumor and a sufficient biopsy or surgical resection of the corresponding 
liver or lung metastasis between 1984 and 2011 were included in this analysis. 
In case of multiple primary tumors or metastases, all material was used for 
sequencing. Formalin-fixed-parafin-embedded (FFPE) material from three large 
pathology laboratories; Radboud university medical center, Nijmegen, Rijnstate 
hospital, Arnhem and Laboratory of Pathology East Netherlands, Hengelo, was used. 
The Institutional Review Board of the Radboud university medical center, Nijmegen, 
ruled that the current study does not require informed consent according to Dutch 
law, but based on national guidelines for the use of archival material, the Institutional 
Review Board agrees with the study proposal (CMO 2013/048, date 23/4/2013).
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DNA extraction and mismatch repair status analysis
FFPE tissue blocks were cut at 4 µm thickness and stained with haematoxylin 
and eosin (HE). The slide with highest tumor cell percentage was selected and the 
presence of tumor was marked by an expert pathologist (IN). Samples with tumor 
cell percentages above 30% were included. Subsequently the blocks were cut at 20 
– 40 mm thickness and macrodissected for DNA extraction. DNA was extracted 
according to the manufacturer’s protocol (QIAamp DNA Micro Kit, Qiagen, 
Hilden, Germany), and DNA concentration was determined with Qubit (2.0, 
Life Technologies, Foster city, CA, USA). For each sample approximately 250 
nanogram of DNA was included.
 Mismatch repair status analysis was assessed by immunohistochemistry. 
Microsatellite instability (MSI) analysis was performed in all cases with absence or 
unequivocal protein expression, using five microsatellite markers (NR21, NR24, NR27, 
BAT 25 and BAT 26, pentaplex PCR system). A tumor was defined as MSI if at least two 
of the five markers showed instability.[10]
Mutational analysis smMIP sequencing
smMIP based sequencing was used to detect mutations in BRAF (exon 15, targeted 
codons D594-K601), HRAS (exon 2, targeted codons G12, G13, exon 3, targeted codons, 
A59, Q61), KRAS (exon 2, targeted codons G12, G13, exon 3, targeted codons A59, 
Q61, exon 4 targeted codons K117, A146), NRAS (exon 2, targeted codons G12, G13, 
exon 3, targeted codons A59, Q61, exon 4 targeted codons K117, A146), and PIK3CA 
(exon 10, targeted codons E542-Q546, exon 21, targeted codons M1043-G1049). 
This technique is clinically validated and implemented in the routine diagnostics 
workflow of our hospital and is extensively described elsewhere.[9] In short, smMIPs 
are long oligonucleotides consisting of two targeting arms, the extension probe and 
the ligation probe, joined by a backbone including a single molecule tag. The probe 
sequences are complementary to the sequences surrounding the target region. 
During the capture reaction, the smMIP mixture is hybridized to the DNA, followed by 
gapfilling through extension and ligation, resulting in a circular smMIP. Exonuclease 
treatment removes all linear DNA. The circular smMIP are amplified by PCR using 
barcoded primers recognizing sequences in the backbone of the smMIP. After target 
enrichment, products were pooled with comparable amounts of the smMIP enriched 
products (based on an agarose gel) and sequenced on a NextSeq500 instrument 
(Illumina, San Diego, CA, USA). The commercial analysis software Sequence Pilot (JSI 
medical systems, Ettenheim, Germany) was used for variant identification. Sequencing 
reads are aligned and reads sharing the same unique single molecule tag are merged 
into a consensus read sequence. This reduces the number of sequencing artifacts, 
mutations present in the genomic template are maintained. The settings as described 
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by Eijkelenboom et al[9] were used for generating the consensus reads and for variant 
calling. The transcripts for variant annotation were: BRAF ENST00000288602; KRAS 
ENST00000311936; PIK3CA ENST00000263967; HRAS ENST00000451590; NRAS 
ENST00000369535. After variant calling using the commercial software, all variants 
were manually inspected and curated based on Cosmic (Cosmic v.81 (May 2017), 
Sanger Institute) and Alamut (AlamutVisual 2.9.0 (Dec. 2016), Interactive Biosoftware). 
Furthermore, in the downstream analysis the minimum mutant allele frequency was 
set at 5%. In fact, 96% of the variants selected had an allele frequency greater than 
or equal to 10%. Therefore, the minimum absolute coverage to reliably exclude the 
presence of mutations was set at 125 combined. This threshold excludes, with an 
approximate certainty of >90%, the presence of a mutation at minimally 10% mutant 
allele frequency within the covered regions.
Statistical analysis
To compare patient and primary tumor characteristics between patients with wild-
type and mutant sequencing results Wilcoxon’s rank sum test or χ2 for numerical or 
categorical variables, respectively was used. Differences in mutation status between 
the primary tumor and corresponding metastasis were analyzed by calculating the 
percentage of concordance and discordance. Concordance was defined as both 
primary tumor and metastasis having no mutations (wildtype-wildtype) or exactly 
the same mutation (mutation-mutation, same variant). Discordance was defined as 
a mutation in either tumor or metastasis which was not found in the corresponding 
counterpart (wildtype-mutant, mutant-wildtype) or as two different mutations in 
tumor and metastasis (mutant-mutant, different variants). Statistical analyzes were 
performed using the statistical software package SPSS 20.0 (SPSS Inc, Chicago, 
Illinois, USA). Differences were considered to be statistically significant with a P-value 
below 0.05. All statistical tests were two-sided.
Results
A total of 402 patients with CRC were included, 274 with liver metastases, 114 with 
lung metastases and 14 with both liver and lung metastases. The majority of patients 
presented with a solitary liver metastasis (253 patients), 10 patients had multiple liver 
metastases (range 2-5), nine patients had two primary tumors together with one liver 
metastasis and two patients had two primaries and two liver metastases sequenced. 
In most patients with lung metastases (n=103) one metastasis was available for 
testing, nine patients had two lung metastases and two patients presented with two 
primaries and one lung metastasis. 
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Concordant cases
We observed an overall concordance rate of 91.1% (216 concordant/237 total) in 
mutation status for all five genes in paired samples. The individual concordance rates 
for BRAF, HRAS, KRAS, NRAS and PIK3CA were 99.6% (246 concordant/247 total), 100% 
(364 total), 95.5% (193 concordant/202 total), 99.1% (228 concordant/230 total), 
94.7% (213 concordant/225 total), respectively. All discordant cases for BRAF and NRAS 
were based on mutations present in the primary tumor, as were the majority of the 
KRAS (6/7) and PIK3CA discordant cases (9/13) (Figure 1). The observed discordance 
in RAS was clinically relevant (i.e. would result in a different treatment approach) in 9 
patients (3.9%). 
Figure 1. Overview of specific mutation and MMR status in primary tumors and matched single 
metastases. A: primary tumors with liver metastases; B: primary tumors with lung metastases.
Grey bars: insufficient unique reads to confidently classify the paired sample as wildtype or mutant 
(this could be due to insufficient reads of either the primary tumor, the metastasis or both).
The last two rows of the Figure depict the exact number of samples and the percentage of samples. A 
percentage less than 1% is depicted with a “·”. 
Abbreviations: MMR: mismatch repair; MSI: microsatellite instable; MSS: microsatellite stable.
A
B
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Differences between liver and lung metastases
The overall mutation frequency in patients with lung metastases was higher 
than the mutation frequency in patients with liver metastases (Figure 2). 
The concordance rate in mutational status for all five genes was not statistically 
different for tumors with liver metastases and tumors with lung metastases (91.2% 
(166 concordant/182 total) vs. 89.1% (49 concordant/55 total), p=0.64). The rate of 
MSI was relatively low (2.2%), all patients with lung metastases were MSS and only 
eight patients with liver metastases showed MSI (3.2%).
Figure 2. Overview of specific mutations found in patients with liver and lung metastases. 
Mutations detected in liver metastases are shown in the grey panel, mutations detected in lung 
metastases are shown in white. An overall mutation frequency in percentages is given for different 
genes in the table. For specific mutations, the actual number of mutations is depicted. 
*Patients with both liver and lung metastases are excluded.
Multiple metastases
In 10 of the 14 patients with liver and lung metastases we obtained sequencing 
results of all tumor samples. In four patients we did not retrieve sufficient 
unique sequence reads (in three due to the  primary tumor, in one due to 
failure of all samples). Identical results in mutation status of primary tumor, 
liver and lung metastases were observed in 9 of the 10 patients, (Figure 3A). 
In 10 of the 21 patients with multiple liver or lung metastases, sequencing results were 
obtained for both primary tumor and metastases. Insufficient sequence coverage 
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was due to failure of all samples (two patients), failure of primary tumor (six patients) 
or failure of metastases (three patients) 7 of the 10 patients showed concordance of 
primary tumor and metastases (Figure 3B, 3C). Discordance was due to mutations 
limited to the primary tumor (one case) and to the metastases (two cases).
Figure 3. Overview of mutations in primary tumors with multiple metastases. Data of samples with 
sufficient coverage on nearly all genes. 
A: 10 primary tumors with both liver and lung metastases; 1 discordant patient with a PIK3CA 
alteration limited to the primary tumor.
B: 5 primary tumors with multiple liver metastases; 1 discordant patient with two different KRAS 
mutations in the primary tumor, of which one mutation was also detected in both metastases. This 
patient also had a PIK3CA alteration limited to the primary tumor. 
C: 5 primary tumors with multiple lung metastases; 2 discordant patients; 1 patient with a KRAS 
alteration limited to both metastases, 1 patient with a NRAS mutation limited to one of the metastasis. 
Grey bars: insufficient unique reads to confidently classify the multiple paired sample as wildtype or 
mutant (due to insufficient reads of one of the metastases).
A
B
C
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Figure 4. Lowest coverage per tissue type. 4A. Primary tumor, 4B. Liver metastasis, 4C. Lung metastasis. 
y-axis: the lowest coverage of samples in unique reads. Dotted line: the minimum absolute coverage 
of 125 unique reads x-axis: the percentage of samples. 
In all samples HRAS mutation analysis performs better (coverage above 125 unique reads in the 
highest percentage of samples), followed by BRAF, PIK3CA, and NRAS/KRAS. Sequencing of liver 
metastases more often result in enough coverage (75% of samples), followed by lung metastases 
(70% of samples) and primary tumors (60% of samples).
A
B
C
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Coverage
With our settings, we obtained paired sequencing results in 62.0% (249 concordant/402 
total). The minimum coverage depth was reached for BRAF, HRAS, KRAS, NRAS and 
PIK3CA in 68%, 72%, 58%, 58% and 63% of the 415 primary tumors and in 80%, 83%, 
68%, 70% and 74% of the 443 metastases (Figure 4). According to the type of material 
analyzed, metastases are more often complete on all five genes (69% of metastases 
vs. 59% of primary tumors, p=0.003).
Comparison with Sanger sequencing
In all patients KRAS Sanger sequencing was performed for exon 2. Good quality results 
of both Sanger and smMIP sequencing were available for 292 patients. In 81 patients 
results were only obtained with Sanger sequencing; coverage for the smMIP analysis 
was too low. In 29 patients results were only obtained with smMIP sequencing. When 
results from both techniques were available (n=292), concordance was 100%.
Discussion
This is the first large study that compares mutation status between primary tumors and 
their corresponding liver and lung metastases using a single molecule tag approach. 
We observed an overall concordance rate of 91% in all five genes in paired samples. 
Concordance rates above 99% were reached for BRAF, HRAS and NRAS, concordance 
for KRAS and PIK3CA were 96% and 95%, respectively. Comparable concordance rates 
for KRAS and BRAF are described in three smaller series.[11-13] In contrast, a discordance 
rate of 23% for KRAS and 7% for BRAF was detected in a study of 43 primary tumors 
and matched liver metastases.[14] Although an increased KRAS discordance rate was 
previously reported in CRC with lung metastases[15], we did not observe a difference in 
concordance rate between liver and lung metastases. These high concordance rates 
implicate that, in the treatment-naïve setting, there is no need for additional biopsies 
from metastatic sites in order to obtain a molecular profile to decide on anti-EGFR 
therapy. This is an important message, given the impact of additional interventions 
on patients, like shown in the meta-analysis of CT guided lung biopsies with overall 
complication rates of 24% to 38%.[16] Next to the increased costs and complications, 
the delay due to additional biopsies and subsequent testing might be considerable. 
 Mutation analysis based on the primary tumor, would have incorrectly withhold 
anti-EGFR treatment to 8 patients (3.4%) and one patient (0.5%) would have 
incorrectly received anti-EGFR therapy. Nevertheless, acquired resistance after anti-
EGFR therapy, with novel KRAS or NRAS mutations in 38% to 60% of cases indicate the 
necessity of additional biopsies in that setting.[17, 18] [19] 
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 We observed mutations in the RAS/RAF pathway in 62% of the metastases, ranging 
from 73% in lung metastases and 56% in liver metastases. The difference between 
mutation frequency in liver and lung metastases is mainly caused by the higher 
incidence of RAS mutations in lung metastases (71% vs. 47%). This high occurrence 
of RAS mutations in colorectal cancer with lung metastases is in line with literature.
[15, 20, 21] KRAS mutations are also increased in colorectal bone and brain metastases.[22] 
Distinct metastatic patterns are observed for BRAF mutations as well, which are mainly 
associated with peritoneal and distant lymph node metastases.[23, 24] Furthermore, 
as expected,[25, 26] a low percentage of MSI was observed, and only in patients with 
liver metastases (3.2%). This confirms the inverse relation between MSI CRC and lung 
metastases.[24] MSI/BRAF mutated CRC seems to have a preference for widespread 
disease including peritoneal metastases, thus falling outside our current selection 
and explaining our relatively low incidence of MSI.
 Our study illustrates the main limitation of next generation sequencing using 
single molecule tags, which is coverage dependency. This is even more apparent in 
our study because we need good coverage for all five genes in two or more samples 
per patient. In clinical setting limited coverage for an exon of a gene that is not directly 
involved in resistance to therapy, is less often a problem. However, this is potentially 
important since a test is only as strong as its lowest coverage. Sufficient unique 
sequence reads are required to reliably identify the presence or absence of a mutation. 
Adjusting the settings would increase the number of false positive and false negative 
calls. We have chosen a certainty level of >90% to reliably identify or exclude the 
presence of a mutation. Currently, there are no guidelines on what level of certainty 
is acceptable in the molecular setting. Since this has potentially major impact on 
important treatment decisions, it is vital that oncologists become aware of this issue. 
In our study the insufficient coverage was most likely a result of fragmented DNA 
due to FFPE fixation. Additional sequencing of the same cases did not result in a 
large improvement of coverage, probably because of this fragmented DNA. All 
archived material was obtained from a wide timeframe, ranging from 1984 to 2011. 
Although subanalysis did not show any correlation between year of resection 
and completeness of sequencing, older samples are believed to have more 
fragmented DNA.[27, 28]
 In all cases with sufficient unique sequence reads, a high concordance 
of mutation status between primary tumors and metastases was observed. 
Therefore, we conclude that discordance in mutation status of anti-EGFR related 
genes is not an issue for molecular testing in treatment-naive CRC.
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Table 1. Distribution of patient and tumor characteristics per mutation. 
Patient/tumor characteristics RAS BRAF PIK3CA
mut wt mut wt mut wt
Age median (range) 64 (33-90) 63 (34-86) 63.5 (34-80) 63.5 (33-90) 63 (41-80) 63 (33-90)
Sex 
Male 
Female
 
106 (63) 
62 (37) 
 
113 (63) 
66 (37)
 
12 (55) 
10 (45)
 
198 (63) 
114 (37)
 
21 (51) 
20 (49)
 
183 (65) 
98 (35)
Location of tumor 
Colon 
Rectum 
Rectosigmoid 
Unknown
 
85 (51) 
39 (23) 
43 (26) 
1 (1)
 
95 (53) 
46 (26) 
37 (21) 
1 (1)
 
18 (82) 
3 (14) 
1 (5) 
-
 
158 (51) 
75 (24) 
77 (25) 
2 (1)
 
24 (59) 
6 (15)
9 (22) 
2 (5)
 
144 (51)
71 (25) 
66 (23) 
-
Histology 
Adenocarcinoma 
Adenocarcinoma with mucinous component 
Mucinous adenocarcinoma
Unknown
 
145 (86) 
14 (8) 
7 (4) 
2 (1)
 
165 (92) 
9 (5) 
3 (2) 
2 (1)
 
19 (86) 
1 (5) 
2 (9) 
-
 
281 (90) 
21 (7) 
6 (2) 
4 (1)
 
34 (83) 
2 (5) 
4 (10) 
1 (2)
 
258 (92) 
17 (6) 
3 (1) 
3 (1)
T stage 
T1 
T2 
T3 
T4 
Unknown
 
2 (1) 
15 (9) 
133 (79) 
16 (10) 
2 (1)
 
3 (2) 
13 (7) 
140 (78) 
19 (11) 
4 (2)
 
0 (0) 
0 (0) 
18 (82) 
4 (18) 
-
 
5 (2) 
26 (8) 
245 (79) 
31 (10) 
5 (2)
 
1 (2) 
6 (15) 
27 (66) 
6 (15)
1 (2)
 
4 (1) 
20 (7)
225 (80) 
28 (10) 
4 (1)
N stage 
N0 
N1 
N2 
Unknown
 
75 (45) 
56 (33) 
36 (21) 
1 (1)
 
66 (37) 
51 (28) 
54 (30) 
8 (4)
 
5 (23) 
7 (32) 
10 (45) 
-
 
132 (42) 
95 (30) 
77 (25) 
8 (3)
 
17 (41) 
19 (46) 
5 (12) 
1 (2)
 
116 (41) 
81 (29)
76 (27)
8 (3)
Location of metastases 
Liver 
Lung 
Both
101 (60) 
58 (35) 
9 (5)
 
142 (79) 
32 (18) 
5 (3)
 
18 (82) 
3 (14) 
1 (5)
 
218 (70) 
81 (26) 
13 (4)
 
26 (64) 
12 (29) 
3 (7)
 
199 (71) 
72 (26) 
10 (4)
Time to metastases 
Synchronous 
Metachronous
 
64 (38) 
104 (62)
 
84 (47) 
95 (53)
 
12 (55) 
10 (45)
 
130 (42) 
182 (58)
 
18 (44) 
23 (56)
 
116 (41) 
165 (59)
MMR status 
MSS 
MSI 
No result
 
163 (97) 
1 (1) 
4 (2)
 
168 (94) 
8 (4) 
3 (2)
 
19 (86) 
3 (14) 
0 (0)
 
302 (97) 
3 (1) 
7 (2)
 
41 (98) 
1 (2) 
0 (0)
 
269 (96) 
5 (2)
7 (2)
Abbreviations: RAS: HRAS, NRAS and KRAS; mut: mutant; wt: wildtype; MMR: Mismatch repair; MSS: 
microsatellite stable; MSI: microsatellite instable. Only samples reaching the acquired coverage per 
gene of interest are included in this table. 
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Abstract
Colorectal cancer (CRC) treatment is largely determined by tumor stage. Despite 
improvements made in the treatment of various types of metastatic disease, staging 
has not been refined. The role of tumor deposits (TDs) in staging remains debated. 
We have assessed the relation of TDs with metastatic pattern to evaluate whether TDs 
might add significant new information to staging. 
We performed a systematic literature search that was focused on the role of TDs 
in CRC. Studies with neoadjuvant-treated patients were excluded. Data on stage, 
histological factors, and outcome were extracted. Data from four large cohorts were 
analyzed for the relevance of the presence of TDs, lymph node metastases (LNMs) 
and extramural vascular invasion (EMVI) on the pattern of metastases and outcomes. 
Of the 10,106 included patients with CRC, 22% presented with TDs. TDs are invariably 
associated with poor outcome. Presence of TDs was associated with the presence of 
LNMs and EMVI. In a pairwise comparison, effects of TDs were stronger than both 
LNMs and EMVI. In the logistic regression model, TDs in combination with LNMs is 
the strongest predictor for liver (odds ratio (OR) 5.5), lung (OR 4.3) and peritoneal 
metastases (OR 7.0). The presence of EMVI adds information for liver and lung 
metastases, but not for peritoneal metastases. 
We have shown that TDs are not equal to LNMs or EMVI with respect to biology and 
outcome. We lose valuable prognostic information by allocating TDs into nodal 
category N1c and only considering TDs in the absence of LNMs. Therefore, we 
propose that the number of TDs should be added to the number of LNMs to derive a 
final N stage. 
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Introduction
Staging of cancer is one of the cornerstones of cancer treatment. The TNM staging 
system is an anatomically based classification that is applied worldwide for many 
tumor types. Originally, this system was used to determine prognostic outcomes 
and to enable the international comparison of different cohorts. With increasing 
treatment possibilities, tumor stage has become one of the main selection criteria for 
(adjuvant) therapy. In colorectal cancer (CRC), stage III patients are generally treated 
with systemic adjuvant therapy, as are patients with high risk stage II disease.[1,2] 
 However, for many patients with metastatic disease, cytotoxic therapy is no longer 
their only treatment option and more widespread multimodality treatment with 
curative intent has become possible. Patients with oligometastases in liver or lung 
can undergo curative treatment in ever increasing numbers,[3,4] and patients with 
peritoneal disease can undergo cytoreduction with hyperthermic intraperitoneal 
chemotherapy treatment.[5] Clinical trials that will investigate treatment with adjuvant 
hyperthermic intraperitoneal chemotherapy in high-risk patients are currently 
recruiting.[6] Therefore, we need more detailed staging systems that enable a better 
estimation for recurrence risk at different sites to guide new treatment choices.
 In recent editions of the TNM staging system, the inclusion of tumor deposits (TDs) 
within nodal staging has given rise to worldwide discussions.[7-12] Other important 
prognostic features, such as extramural vascular invasion (EMVI) are acknowledged, 
but not included in staging. One may wonder whether we lose useful information by 
ignoring the former and placing TDs with different etiologies into the nodal category, 
N1c, only in absence of lymph node metastases (LNMs). If TDs are equal to LNMs, 
both in prognostic and biological sense, this would simplify the staging systems as 
they can be placed in the N category without loss of information; however, if TDs add 
information to staging either alone or taking into account their etiology, we should 
apply specific sub-staging.
 We assessed the prognostic impact of TDs by performing a systematic review of 
existing data, investigated the association of TDs with other histologic prognostic 
factors and determined whether TD status influenced the metastatic pattern in CRC. 
On the basis of the results, we propose revisions to be considered for the modern 
anatomical staging of CRC.
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Material and methods
Strategy for search of articles and selection criteria
A comprehensive literature search for published studies was performed using 
Embase and Medline databases (OvidSP software) from inception to July 29th 2015, 
using the following keywords: “tumor deposits” or “microfoci” or “non-nodal” or 
“nodal independent” or “neoplastic foci” or “tumor aggregate” or “discontinuous” or 
“extranodal” or “staging” in combination with “Colorectal Neoplasms”[Mesh] “Cecal 
Neoplasms”[Mesh] or “colorectal” or “colon” or “rectum” or “rectal” and “cancer” or 
“carcinoma” or “tumor”, limited by “Survival Analysis”[Mesh]. Additional searches were 
performed by manual cross-referencing. 
 Only original studies that were published in English with at least 100 patients were 
selected. In case of overlapping patient data, results of the largest study or of the 
study with longest follow-up were included in this meta-analysis. Studies in which 
histology was not reviewed for whole cohorts were excluded, since reporting on 
TDs without histological review is unreliable and incomplete. Studies that included 
patients who were treated with neoadjuvant therapy were excluded. Test and 
validation cohorts that have been described in the individual studies are separately 
analyzed.
Data extraction
For each study the number of patients in both the TD-positive and the TD-negative 
group were obtained. Data on tumor stage, histological factors, 5-year disease free 
survival (DFS), 5-year disease specific survival (DSS) and 5-year overall survival (OS) 
were extracted from all studies. Data were entered in SPSS (SPSS for Windows, IBM 
SPSS Statistics 20, 2011) and Review Manager (RevMan). Version 5.3. Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2012). Data were retrieved 
by two independent investigators (IN, NK).
Quality assessment and risk of bias
A scale to assess the quality of study reporting was developed on basis of the REMARK 
guidelines and focused on TDs.[13,14] All studies were subjected to quality assessment; 
studies that were only used for correlation of TDs with other factors were subjected 
to quality assessment in which outcome-specific items were left out. The association 
between the quality of reporting and the Hazard Ratio (HR) was analyzed with 
scatter plots and nonparametric correlation testing. Publication bias was assessed by 
symmetry in funnel plots. 
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Cohort description
Data from four cohorts was further explored to determine the association between 
TDs and metastatic patterns. These cohorts have been extensively described 
elsewhere.[9,15] In brief, the first cohort is the test cohort from the Japanese Society 
for Cancer of the Colon and Rectum, which included 1,716 stage I-III CRC patients 
who underwent curative surgery between 1994 and 1998, with an average follow-up 
of 93 months.[15] The validation cohort from the Japanese Society for Cancer of the 
Colon and Rectum included 2,242 stage I-III CRC patients who underwent curative 
surgery between 1999 and 2003, with an average follow-up of 68 months.[15] The 
UK cohort consists of 455 stage I-IV CRC patients that were included in the Medical 
Research Council CLASICC trial between July 1996 and July 2002, with an average 
follow-up of 63 months.[9] The Swedish cohort represents a consecutive case series 
from Falu Lasarett of 505 stage I-IV CRC patients, who underwent surgery between 
1998 and 2000, with an average follow-up of 63 months.[9] Histology from all cases 
was reviewed with special attention for TDs, as has been described before.[9,15] 
Statistical analysis
A meta-analysis was performed with all available studies on correlation in terms of risk 
ratios (RRs) with 95% CI. Data of univariate and multivariate analyses were entered in 
terms of HR with 95% CI. If no HR was reported, it was calculated from the published 
data,[16] but only in studies with data on minimum and maximum follow-up times. A 
random effects model with inverse variance weighting of studies was used. In this 
model each study was given a weight that was equal to the inverse of the variance of 
the effect estimate and served to minimize the variance of the combined effect. Forest 
plots are used to demonstrate consistency of the results. For effect size, Z-statistic 
was used (standardized mean difference). Heterogeneity was assessed using a χ2 
test for heterogeneity with a P value of <.10 to show the presence of significant 
heterogeneity. Furthermore, we applied I2 statistic - percentage of variation across 
studies that is a result of heterogeneity rather than chance- in combination with Tau-
squared - estimate of between-study variance in a random effect meta-analysis.  In 
case of heterogeneity, subanalyses for sample size, timeframe and TNM stage were 
performed to identify the potential source of the heterogeneity. Logistic regression 
analysis was used to investigate the multivariate relationship of pathologic factors 
that predicted liver, lung and peritoneal metastases in the four cohorts. In the logistic 
regression analyses, the reference group used was the negative/ negative group, that 
is N0/TD negative. In the model, all first order interactions were included, adjusting 
for cohort, LNMs, TDs, EMVI and the combination of LNMs*TDs, LNMs*EMVI and 
TDs*EMVI. The model was simplified by leaving out non-statistical interactions with a 
p-value of >.10. Results were reported as odds ratios (ORs) with 95%CI. A p-value ≤ .05 
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was considered statistically significant. Hosmer and Lemeshow test for goodness of 
fit was used to evaluate the logistic regression models. We applied the Holm method 
for stepdown Bonferoni correction of multiple testing for each factor. 
Results 
Search results
A total of 574 studies were retrieved by the Medline database search, and 605 we 
found using Embase. Duplicates were excluded (n=283). A further 862 studies were 
excluded because they did not meet general inclusion criteria (Figure 1). We added 
two additional papers that fulfilled the eligibility criteria.[17,18] The remaining 36 
papers concerned TDs in CRC. We excluded six studies because of insufficient patient 
numbers,[19-24] one gave insufficient data for analysis,[25] two studies did not perform 
histologic revision of all historic cases,[18,26] and seven studies had overlapping data.
[12,27-32] Three studies included neoadjuvant-treated patients.[33-35]
  The remaining 17 studies, which comprised 10,106 patients, were included in the 
meta-analysis. The main characteristics of the studies are listed in table 1. 
Quality of the reporting of the included studies
Studies were subjected to quality assessment. Thirteen studies were used for meta-
analysis with outcome,[15,17,36-45] of which nine studies could also be used for correlation 
of TDs with other factors.[15,17, 38-41, 43-45] Two additional studies had no data on outcome 
and were only used for correlation of TDs with other factors.[9,46] Moreover, three 
studies that were identified in our systematic review provided insufficient data for 
meta-analysis.[47-49] The mean percentage of items that were reported in studies with 
outcome data was 66.6% (range 39% to 84%). The mean percentage of items reported 
in studies with data for correlation was 71.6% (range 50% to 82%). 
Frequency and impact of TDs
The average frequency of TDs for all studies was 22.0% (range 4.9% to 41.8%). Data on 
the impact of TDs on DFS in univariate analysis was available from five studies, which 
included, in total, 1,246 patients. In the presence of TDs the DFS was significantly 
decreased (HR 2.2, 95%CI 1.6-3.0) (Figure 2A). Considerable heterogeneity was 
observed among the studies (I2=78%). With respect to the quality assessment of the 
studies, the percentage of items reported ranged from 50% to 84%, and this did not 
correlate with the magnitude of HR (Spearman r=0.56, p=0.35). Multivariate DFS 
analysis was available in five studies that comprised 1,536 patients and that confirmed 
a decreased DFS in the presence of TDs (HR 2.0, 95%CI 1.4-2.8) (Figure 2B). Substantial 
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heterogeneity was observed among the studies (I2=66%). With respect to the quality 
assessment of the studies, the percentage of items reported ranged from 65% to 
84%, and this did not correlate with the magnitude of HR (Spearman r=0.82, p=0.13).
Figure 1. Flow chart of search strategy for the systematic review.
ca: cancer, TD: tumor deposit.
The effect of TDs on DSS in univariate analysis was determined in five cohorts that 
comprised 4,446 patients (Figure 2C) and that confirmed a decreased DSS in the 
presence of TDs (HR 3.3, 95%CI 2.2-4.7). Considerable heterogeneity was observed 
among the studies (I2=83%). With respect to the quality assessment of the studies, 
the percentage of items reported ranged from 50% to 79%, and this did not correlate 
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Figure 2. The impact of TD on outcome. 
A-B: Disease free survival (A: univariate, B: multivariate), 
C-D: Disease specific survival (C: univariate, D: multivariate), 
E-F: Overall survival (E: univariate, F: multivariate). 
TD-: tumor deposit negative, TD+: tumor deposit positive, HR: Hazard Ratio, SE: standard error.
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with the magnitude of HR (Spearman r=-0.16, p=0.78). Multivariate DSS analysis was 
available in four studies that comprised 1,185 patients and confirmed a decreased 
DSS in the presence of TDs (HR 1.7, 95%CI 1.4-2.1) (Figure 2D). No heterogeneity was 
observed among the studies (I2=0%). The percentage of items reported ranged from 
50% to 79%, and this quality indicator did not correlate with the magnitude of HR 
(Spearman r=-0.80, p=0.33).
 The impact of TDs on overall survival was available from three univariate and five 
multivariate cohorts, with respectively 814 and 1,699 patients (Figure 2E-F). Overall 
survival was decreased in the presence of TDs (univariate HR 2.9 (95%CI 2.2-3.8) and 
multivariate HR 2.2 (95%CI 1.7-2.8)). No heterogeneity was observed in the univariate 
analysis (I2=0%) nor the multivariate analysis (I2=0%). For the univariate studies, the 
percentage of items reported ranged from 56% to 84%, which did not correlate with 
the magnitude of HR (Spearman r=-0.50, p=1.00). For the multivariate studies, the 
percentage ranged between 65% and 84%, not correlating with the magnitude of HR 
(Spearman r=0.60, p=0.35).
Table 2. Logistic regression model for the various metastatic locations. 
Factor Liver metastases
Adjusted OR (95%CI)*
Lung metastases
Adjusted OR (95%CI)*
Peritoneal metastases
Adjusted OR (95%CI)*
N0/TD- 1.00 1.00 1.00
N0/TD+ 3.57 (2.38-5.35) 2.86 (1.71-4.78) 6.44 (3.04-13.65)
N+/TD- 2.60 (1.96-3.44)1 2.49 (1.81-3.44)2 3.21 (1.75-5.90)3
N+/TD+ 5.54 (4.23-7.25)1 4.29 (3.11-5.93)2 6.97 (3.96-12.25)3
EMVI 1.38 (1.08-1.77) 2.01 (1.48-2.72) 1.25 (0.76-2.05)
Hosmer & Lemeshow  
Goodness of fit
p=0.476 p=0.688 p=0.498
*  Data are corrected for cohort and all other listed variables. P-values using the Holm method for 
stepdown Bonferoni correction of multiple testing: 1p<0.001, 2p=0.004, 3p=0.018. OR: odds ratio, 
CI: confidence interval. N0: no lymph node metastases, N+: lymph node metastases positive, TD-: 
tumor deposit negative, TD+: tumor deposit positive, EMVI: extramural vascular invasion
None of the analyses showed evidence of publication bias. Observed heterogeneity in 
DFS and DSS analyses could not be explained by differences in sample size, timeframe 
and TNM stage. Despite the observed heterogeneity, the direction of the effect in the 
forest plots is rather consistent. HR as a result of TDs is smaller in the multivariate models, 
as would be expected because additional variance is accounted for, however, inclusion 
of these additional covariates does not diminish the significance of the HR due to TDs.
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Subdivisions of TD: does it matter?
The size of TDs influence prognosis; larger TDs (>12 mm in diameter) have a 
significantly poorer DSS (HR 2.5 and 3.2, respectively) compared to small TDs (<3 
mm).[15] Between 3 mm and 12 mm there was a nonsignificant increase in HR as a 
function of TD size. In another study[41] small TDs, defined as less than 2 mm, showed 
a very good DFS, compared to larger TDs.
 The contour of TDs can be described as smooth or irregular. Two studies[11,41] of 
respectively 214 and 3958 patients demonstrated a trend towards poorer outcome in 
the irregular groups, however, no direct comparison was performed.
 Increasing numbers of TDs are associated with poor outcome. In the absence 
of LNMs, four or more TDs are associated with a significantly shorter survival in a 
very small group of patients (n=17) (16.5 months versus 32.5 months, p=0.025).[48] 
Goldstein and Turner[38] showed that, irrespective of nodal status, the 5-year survival 
of patients with three or more TDs was significantly worse compared with  patients 
with only one or two TDs (2% versus 24%, p<0.01).
Associations between TDs and histological risk factors
In 13 cohorts with a total number of 7,583 patients the relation between nodal status 
and the presence of TDs was studied. TDs were present in 8.7% of patients without 
LNMs compared with 41.6% of patients with LNMs. There were six cohorts in which 
the number of involved lymph nodes was studied, there was a significant increase of 
TDs with increasing N-stage in all studies (p=0.002, Friedman test). The risk ratio for 
TDs in the presence of LNMs was 4.2 (95%CI 3.2-5.6). 
 The relationship between TDs and EMVI (as determined by examination of 
hematoxylin-eosin-stained slides) was studied in nine cohorts with a total number of 
2,805 patients. TDs were present in 20.9% of patients without EMVI, compared with 
31.6% of patients with EMVI. RR for TDs in the presence of EMVI was 2.6 (95%CI 1.8-3.7).
Comparison of LNM, TD and EMVI
Two studies investigated the prognostic power of TDs in combination with LNMs.[41,46] 
Whereas absence en presence of both TDs and LNMs was associated with the best 
and worst outcomes, respectively, both studies suggest that the presence of only TDs 
is associated with a worse outcome than the presence of only LNMs. 
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In order to establish the value of TDs, LNMs and EMVI in modern staging, we 
analyzed original data from four large cohorts of studies[9,15] that were selected 
in this systematic review in correlation with metastatic patterns, including both 
synchronous and metachronous metastases. Three different metastatic patterns 
were distinguished: liver metastases, lung metastases, and peritoneal metastases. In 
the four cohorts, which had a total of 4,918 patients, there were 397 liver metastases, 
268 lung metastases, and 92 peritoneal metastases. The distribution of metastases 
was different between the cohorts, with higher percentages of liver and peritoneal 
metastases in the Sweden cohort (Figure 3A).
 For RR at different metastatic locations (Figure 3B), the effect of LNMs was similar 
to that of TDs; however, the combination of TDs and LNMs was associated with a 
significantly higher risk of liver metastases than LNMs alone. When TDs and EMVI were 
compared (Figure 3C), it was clear that the presence of TDs significantly increased RR of 
liver metastases (RR 3.6 (95%CI 2.6-5.0) versus RR 1.7 (95%CI 1.3-2.3)). RR of TDs was not 
different from RR of TDs and EMVI combined. For lung metastases, the combination of 
TDs and EMVI significantly increased RR compared with EMVI alone. When the impact of 
EMVI in combination with LNMs was compared, it was clear that addition of LNMs caused 
a higher RR for both lung and liver metastases (Figure 3D).
 We subsequently evaluated the different factors by using a logistic regression model 
(table 2). For liver metastases, TDs, LNMs and EMVI were significant, with OR of 3.6, 2.6 and 
1.4 respectively. For lung metastases, the effects of TDs, LNMs and EMVI were comparable 
(OR 2.9, 2.5 and 2.0, respectively). For the development of peritoneal metastases, only TDs 
and LNMs contributed significantly (OR 6.4 and 3.2), but not EMVI. Combination of TDs 
and LNMs did not increase the risk of peritoneal metastases compared with TDs alone. 
3
Figure 3A
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Discussion 
In the current systematic review, we identified 17 large-scale studies that investigated 
the role of TDs in CRC. In a collection of 10,106  patients with CRC, the incidence of 
TDs was 22%, which illustrates its potential value. The presence of TDs was invariably 
associated with a poorer outcome as illustrated by decreased DFS (HR 1.7-2.0), DSS (HR 
1.7-3.9) and OS (HR 2.2-2.9). Some unexplained heterogeneity was present in the DFS 
and DSS analyses, however, the OS analyses did not show heterogeneity.
 Recent editions of TNM have acknowledged the importance of TDs by incorporating 
it in nodal staging. In the 5th edition of TNM,[50] the size of TDs was considered important, 
but this was replaced by contour in the 6th edition[51] and local interpretation in the 7th 
edition.[52] Despite the clinical impact of these definitions, limited data are available 
to study both size and contour. Two studies[15,41] have confirmed that size matters by 
demonstrating that larger TDs are associated with worse prognosis. Data on the impact 
of contour is less convincing. 
 The correlation between TDs and other types of regional spread might be part 
of the explanation of the poor prognosis. TDs occur more frequently in cases with 
perineural invasion[21,38,40] and lymphatic invasion.[17,39-41,45,46] We summarized the most 
relevant correlations and demonstrated increased TDs in patients with LNMs and 
EMVI; however, data from multivariate studies still demonstrated an independent 
prognostic effect of TDs.
 It is important to realize that TDs are not LNMs: the origin of TDs is diverse. By 
serial sectioning in a series of 30 irregular TDs[37], almost 40% showed a combined 
perineural, perivascular and intravascular origin. A perineural origin was present 
in 77% of cases and an intravascular origin in 83% of cases. A similar setup with 
69 TDs[53] showed similar diversity. Presence of vessels and nerves in the majority of the 
TDs explains the worse prognosis of patients with TDs compared with that of patients 
with LNMs alone. Tumor access to more than one anatomic highway to metastatic 
locations creates more extensive tumor spread; therefore, we decided to evaluate 
the metastatic patterns that occur in the presence of TDs. The early study of Goldstein 
and Turner[37] suggested a significant impact of TDs in the development of intra-
abdominal metastases. In their cohort, only 12% of patients without TDs developed 
peritoneal metastases compared with 44% of patients with TDs. In the current study, 
we examined original data from four different patient cohorts and the impact of TDs 
on the pattern of metastases. Presence of TDs and LNMs more than doubled the RR 
(5.3 versus 2.5) for liver metastases compared with LNMs alone. Similar trends are 
observed for other metastatic patterns. A first explanation would be that TDs indeed 
reflect EMVI, and thus explain the high risk on liver metastases;[54] however, when we 
compared TDs and EMVI the difference was even more pronounced. Whether there 
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is an unequivocal alternative biological explanation[55] remains to be investigated. 
From these results, it is clear that TDs do not equate to LNMs, nor recognizable EMVI, 
both in a prognostic and in a biological sense. This study shows that by allocating all 
TDs into a nodal category, pN1c, and subsequently ignoring them in the presence of 
LNMs, valuable prognostic information is lost. The same argument can be made for 
EMVI; we also lose potential information on the likely sites for recurrence.  
 This study confirms that sufficient consistent evidence exists to now justify TD 
assessment in the management of CRC. However, there are a number of significant 
issues. The lack of definition in the current edition of TNM is not acceptable as it leads 
to poor inter-observer agreement.[56] True effects of the total number of TDs have not 
been determined, nor has this aspect been considered against the number of LNMs 
present. We do not know the optimal way to classify TDs after neoadjuvant treatment. 
Size of TDs seems to matter and further characterization is required. It is not clear 
how we should integrate these prognostic markers into the debate over when to use 
adjuvant therapy.[57] Despite all of these issues, TDs and their number should be fully 
included in TNM staging. Inclusion of TDs only in the absence of LNMs is not justified by 
the evidence. TDs and their actual number should be considered equal to the number 
of LNMs in making treatment decisions; therefore, the number of TDs should be added 
to the number of LNMs in nodal staging to derive a final N stage.
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Abstract
Regional lymph node metastases in colorectal cancer (CRC) decrease outcome. 
Whether nodal metastases function as a biomarker, i.e. as a sign of advanced disease, 
or are in fact involved in the metastatic process is unclear. We evaluated metastatic 
patterns of CRC according to the lymph node status of the primary tumor.
A retrospective review of 1393 patients with metastatic CRC who underwent autopsy 
in the Netherlands was performed. Metastatic patterns of regional lymph node 
positive and negative CRC were compared and validated by population-based data 
from the Eindhoven Cancer Registry (ECR).
Patients with regional lymph node positive CRC more often developed peritoneal 
metastases (28% vs. 21%, p=0.003) and distant lymph node metastases (25% vs. 15%, 
p<0.001). Incidences of liver and lung metastases were comparable. Data from the 
ECR confirmed our findings regarding peritoneal (22.4% vs. 17.0%, p=0.003) and 
distant lymph node metastases (15.8% vs. 9.7%, p<0.001).
Regional lymph node positive CRC show a slightly different dissemination pattern, 
with higher rates of peritoneal and distant lymph nodes metastases. Comparable 
incidences of liver and lung metastases support the hypothesis that dissemination to 
distant organs occurs independently of lymphatic spread.
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Introduction
Despite intensive follow-up and increasing therapeutic options for colorectal cancer 
(CRC), metastatic disease remains the leading factor in CRC mortality. CRC most 
frequently metastasizes to the liver, lung and peritoneum, but other metastatic sites 
such as bone, spleen, brain and distant lymph nodes have been described.[1-3] 
 According to the mechanistical view of metastatic spread, tumor cells can 
disseminate to distant organs through two pathways: the vascular and the lymphatic 
pathway. The vascular hypothesis suggest that blood vessels transport tumor cells 
directly to distant organs. In the lymphatic pathway tumor cells may disseminate 
from regional lymph nodes to distant lymph nodes, reach the systemic circulation 
and subsequently form organ metastases.[4] The distinction between these pathways 
and their role in dissemination remains matter of debate. 
 Post-mortem studies offer a possibility to register both the extent and location 
of metastatic disease. Findings during autopsy may be considered the ultimate 
endpoint of disease. Autopsy studies are therefore usefull for getting insight in the 
relevance of lymphatic spread in the dissemination of cancer. Most autopsy studies, 
have focused on metastatic patterns in one or more types of cancer, but have failed 
to address differentiating aspects such as lymph node involvement. A large autopsy 
study by Budczies et al. across major cancer types, showed  higher rates of metastases 
in distant lymph nodes, peritoneal cavity, pleura, pericardial and adrenal glands in 
lymph node positive tumors.[5] Although this study has given insight into metastatic 
patterns, this was done by grouping various cancers together. 
 To gain insight in the relevance of lymphatic spread in the dissemination of CRC, we 
evaluated patterns of metastases according to the lymph node status of the primary 
tumor in 1393 autopsies. To confirm the clinical relevance, we analyzed population-
based data from the Eindhoven Cancer Registry.
Material and methods
Study design
An autopsy cohort was selected to compare patterns of metastases according to the 
regional lymph node status of the primary tumor. Findings at autopsy are the ultimate 
endpoint of disease, making autopsy reports suitable for analyzing the extend of disease. 
Autopsy data are derived from a restricted patient population, therefore a prospectively 
collected cohort of the Eindhoven Cancer Registry (ECR) was chosen for validation. 
First, differences in metastatic pattern according to the lymph node status of the 
primary tumor were analysed. Due to the close relationship between lymphatic spread, 
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regional and distant lymph node metastases, separate analyses were performed in 
tumors with and without distant lymph node metastases in the autopsy cohort. 
Autopsy cohort
A total of 1679 patients with metastatic colorectal cancer was identified in an autopsy 
study by Hugen et al.[6] Data from this study was used for the present analyses. Patients 
were selected from a retrospective review of pathological and autopsy records from 
the nationwide network and registry of histo- and cytopathology in the Netherlands 
(Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief; PALGA)[7] 
 Patients who were diagnosed with metastatic CRC and autopsied between 1991 
and 2010 were selected. In the Netherlands post-mortem examination is performed 
at the request of the family or treating doctor and is carried out by a pathologist. 
All autopsies included in this study were performed in order to obtain information 
on the medical status of the deceased or to determine the exact cause of death. 
No forensic autopsies were included. Tumor histology was assessed by different 
pathologists. Local staging of the primary tumor was reconstructed according to the 
TNM classification (5th edition).[8] Allocation to the lymph node category was based 
on pathological examination of the original resection specimen or on the autopsy 
specimen. For regional lymph nodes metastasis only positive lymph nodes along 
the colon or rectum, plus the nodes along the major arteries that supply blood to 
the colon or rectum were considered. Metastasis in all other nodes were considered 
distant lymph nodes metastases. Patients of whom the primary N-stage could not 
be retrieved were excluded (n=286). Colon tumors were classified as proximal if 
they were found in cecum, ascending colon or transverse colon, and classified as 
distal if they were found in the descending or sigmoid colon. Data on gender and 
age were available for all cases, but further clinical information (e.g. treatment or 
disease course) was lacking in this database and could not be retrieved. Metastatic 
disease was determined during pathological assessments of resected or biopsied 
specimens during follow-up or during autopsy. All metastases found at autopsy were 
histologically confirmed. Metastases that were detected more than six months after 
surgery of the primary tumor were considered metachronous.[9]
Clinical cohort
Data were retrieved from the Eindhoven Cancer Registry (ECR) which collects data of 
all patients with newly diagnosed cancer in the southeastern part of the Netherlands.
[10] All patients who were diagnosed with CRC between 2003 and 2008 were included 
if they had synchronous metastases or developed metastases during follow-up untill 
2010-2011 (n=3092). End of follow-up was defined as the date of death or end of data 
collection in 2010-2011.
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 Patients who underwent an autopsy were excluded to prevent overlap with 
the initial cohort (n=37). Moreover, patients with missing N-stage (n=673) were 
excluded. Tumor staging, classification of primary tumor location and onset of 
metastatic disease were performed as described for the autopsy cohort. Allocation 
to the lymph node category was based on pathological examination of the original 
resection specimen. Anatomical sites of metastases were registered according to the 
International Classification of Diseases for Oncology (ICD-O).[11] Patterns of metastatic 
disease were determined based on the first site of metastasis. 
Statistical analysis
The χ² test was used to compare baseline characteristics between regional lymph 
node positive and negative CRC. Logistic regression analysis was used to analyze 
patient and tumor characteristics associated with location specific metastases. 
This analysis was performed in the clinical cohort, because of potential bias in the 
autopsy cohort. Odds ratio’s (ORs) were provided with their 95% confidence interval 
(CI). In multivariate (MV) analyses adjustments were made for age, gender, primary 
T-stage, primary N-stage, differentiation grade of primary tumor, localization of 
primary tumor, primary tumor histology and onset of metastases. Statistical analyses 
were performed using SAS/STAT1 statistical software (SAS system 9.3, SAS Institute, 
Cary, North Carolina, USA) and the statistical software package SPSS 20.0 (SPSS Inc, 
Chicago, Illinois, USA). All tests of significance were two sided and differences at 
P-values of ≤0.05 were considered to be significant.
Results
In the autopsy cohort, there were 1393 patients with metastatic disease; 879 
patients (63%) with regional lymph node metastases (N+) and 514 patients (37%) 
without regional lymph node involvement (N-). The distribution of patient and tumor 
characteristics according to regional lymph node status is presented in Table 1. N+ 
patients more often had a higher T-stage (T3/T4: 90.8% vs. 85.4%, p<0.001), a tumor 
located in the proximal part of the colon (38.3% vs. 31.5%, p=0.01), mucinous or 
signet ring cell histology (20.9% vs. 14.2%, p=0.002), multiple metastases (56.5% vs. 
43.2%, p<0.001) and synchronous onset of metastases (61.2% vs. 36.2%, p<0.001).
Distribution of metastases
The liver was the most frequent site of metastasis irrespective of regional lymph 
node status (68% in N+ and 67% in N-, p=0.53). Lung metastases occurred in 33% 
of N- patients and in 35% of N+ patients (p=0.42; Figure 1A). There was a higher rate 
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of peritoneal metastases in N+ patients (28% vs. 21%, p=0.003) and distant lymph 
node metastases were more often found in N+ patients (25% vs. 15%, p<0.001). Other 
significant differences were found for metastases in omentum, spleen and pancreas 
(N+ vs. N-; 9.2 vs. 3.3%, p<0.001, 2.8 vs. 1.0%, p=0.02, and 2.6 vs. 1.0%, p=0.04, 
respectively). 
Table 1. Distribution of tumor and patient characteristics according to regional lymph node status of 
the primary tumor in the autopsy cohort.
 
Features N+ N- P-value
  879 (%) 514 (%)  
Gender 0.375
Male 514 58.5 313 60.9
Female 365 41.5 201 39.1
Age at diagnosis 0.681
<60 188 21.4 96 18.7
60-74 408 46.4 247 48.1
≥75 283 32.2 171 33.3
Location of primary 0.032
Proximal colon 337 38.3 162 31.5
Distal colon 271 30.8 162 31.5
Rectum 203 23.1 135 26.3
Colon, not specified 68 7.7 55 10.7
T Stage <0.001
T1 0 0 7 1.4
T2 37 4.2 53 10.3
T3 605 68.8 338 65.8
T4 193 22.0 101 19.6
Not specified 43 4.9 15 2.9
Histology 0.002
Non-mucinous adenocarcinoma 695 79.1 441 85.8
Mucinous adenocarcinoma 156 17.7 68 13.2
Signet ring cell 28 3.2 5 1.0
Onset of metastases <0.001
Synchronous 538 61.2 186 36.2
Metachronous 341 38.8 328 63.8
Number of distant metastases <0.001
1 382 43.5 292 56.8
>1 497 56.5 222 43.2
N+: primary tumor with regional lymph node metastases;
N-: primary tumor without regional lymph node metastases.
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When patients were subdivided according to the location of the primary tumor, a 
higher percentage of lung metastases in N+ rectal cancer as compared to N+ colon 
cancer (43.8% vs. 32.1%, p=0.001) and higher percentage of peritoneal metastases 
in N+ colon cancer as compared to N+ rectal cancer (30.8% vs. 19.2%, p=0.002) was 
found. This could be related to the higher overall percentage of lung metastases 
in rectal cancer compared with colon cancer (42.6% vs. 31.3%, p<0.001) and of 
peritoneal metastases in colon cancer compared with rectal cancer (28.1% vs. 17.2%, 
p<0.001). N+ colon cancers more often had peritoneal metastases and distant lymph 
node metastases compared with N- colon cancers (24.0% vs. 14.0%, p<0.001, and 
30.8% vs. 23.2%, p=0.009, respectively). In rectal cancer only distant lymph node 
metastases were more often seen in N+ than in N- patients (28.1% vs. 18.5%, p=0.05).
Validation of findings
A total of 2382 patients with metastatic colorectal cancer from the Eindhoven Cancer 
Registry (ECR) was included, of which 1711 patients (71.8%) had regional lymph node 
metastases and 671 patients (28.2%) did not. Median follow-up was 5.0 years (range 
1.2–8.8 years). The distribution of patient and tumor characteristics according to 
lymph node status is presented in Table 2. 
 N+ patients more often developed peritoneal metastases and distant lymph 
node metastases (22.4% vs. 17.0%, p=0.003, and 15.8% vs. 9.7%, p<0.001). Moreover, 
there was a higher percentage of liver metastases and a lower percentage of lung 
metastases in N+ patients compared with N- patients (71.6% vs. 66.3%, p=0.01 and 
23.7% vs. 27.7%, p=0.04, respectively).
 Logistic regression analyses identified several clinicopathological factors that 
were associated with location specific metastases (Table 3). Rectal tumors were 
associated with a higher risk of developing liver and lung metastases (OR for liver: 
1.33 (1.05-1.67), p<0.05, OR for lung: 2.25 (1.74-2.89), p<0.001), and with a lower risk 
of developing peritoneal carcinomatosis (OR: 0.24 (0.18-0.32), p<0.001). T4 tumors 
less often led to liver metastases (OR: 0.48 (0.38-0.61), p<0.001) and were associated 
with a higher risk of developing peritoneal carcinomatosis (OR: 2.18 (1.72-2.77), 
p<0.001). Lymph node positive tumors were associated with an increased risk of 
developing distant lymph node metastases, especially N2 tumors (OR: 3.03 (2.14-
4.29), p<0.001). N2 tumors were also associated with peritoneal carcinomatosis (OR: 
1.40 (1.05-1.87), p<0.05). Mucinous tumors less often led to liver metastases (OR: 0.46 
(0.34-0.62), p<0.001) and were associated with a higher risk of developing peritoneal 
carcinomatosis (OR: 2.53 (1.84-3.47), p<0.001). 
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Figure 1A. Distribution of CRC metastases according to regional lymph node status in the autopsy 
cohort. Left figure shows the distribution of metastases for regional lymph node negative primary 
tumors, right figure shows the distribution of metastases for regional lymph node positive primary 
tumors. * p=0.003, ** p<0.001
Figure 1B. Distribution of CRC metastases according to distant lymph node positivity in the autopsy 
cohort. Left figure shows the distribution of metastases for primary tumors without distant lymph 
node metastases, right figure shows the distribution of metastases for primary tumors with distant 
lymph node metastases. * p<0.001
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Table 2. Distribution of tumor and patient characteristics according to regional lymph node status of 
the primary tumor in the clinical cohort.
Features N+ N- P-value
  1711 (%) 671 (%)  
Gender 0.583
Male 952 55.6 365 54.4
Female 759 44.4 306 45.6
Age at diagnosis 0.008
<60 448 26.2 135 20.1
60-74 814 47.6 342 51.0
≥75 449 26.2 194 28.9
Location of primary 0.014
Proximal colon 609 35.6 192 28.6
Distal colon 504 29.5 216 32.2
Rectum 572 33.4 252 37.6
Colon, unknown 26 1.5 11 1.6
T Stage <0.001
T1 7 0.4 12 1.8
T2 83 4.8 89 13.3
T3 1101 64.4 411 61.2
T4 397 23.2 106 15.8
Unknown 123 7.2 53 7.9
Histology 0.230
Non-mucinous adenocarcinoma 1562 91.3 621 92.5
Mucinous adenocarcinoma 121 7.1 45 6.7
Signet ring cell 28 1.6 5 0.8
Onset of metastases <0.001
Synchronous 1155 67.5 318 47.4
Metachronous 556 32.5 353 52.6
Number of distant metastases <0.001
1 1067 62.4 460 68.6
>1 644 37.6 211 31.4
N-: primary tumor without regional lymph node metastases; 
N+: primary tumor with regional lymph node metastases
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Distant lymph node metastases
To provide further insight into the relevance of regional lymph node metastases for 
distant lymph node metastases, data was analyzed from 1024 cases with at least 
ten lymph nodes retrieved with the primary tumor. We found an increasing rate of 
distant lymph node metastases according to the number of positive lymph nodes 
detected in the primary tumor (Figure 2). Data from the ECR showed an increase from 
9.1% in patients without positive lymph nodes to 27.1% in patients with more than 
twelve positive lymph nodes detected in the primary tumor (p<0.001). Data from the 
autopsy study showed an increase from 8.2% to 48.4% (p<0.001).
 Compared with patients without distant lymph node metastases, patients with 
distant lymph node metastases more often had metastases in lung (57% vs. 29%, 
p<0.001), pleura (11% vs. 3%, p<0.001), bone (16% vs. 4%, p<0.001), adrenal gland 
(16% vs. 5%, p<0.001) and kidney (7% vs. 2%, p<0.001) (Figure 1B).
Figure 2. Percentage of patients with distant lymph node metastases according to the number 
of positive lymph nodes in primary tumor. Selection of patients with more than ten lymph nodes 
examined (N=1024 pts; autopsy cohort=258 pts; clinical cohort=766 pts), p<0.001
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Table 3: Risk of developing distant metastases in the clinical cohort
Clinicopathological 
factors
Risk of developing 
liver metastases
Risk of developing 
lung metastases
Risk of developing 
peritoneal 
carcinomatosis
Risk of developing 
distant lymph node 
metastases
MV analyses 
OR (95% CI)
MV analyses 
OR (95% CI)
MV analyses 
OR (95% CI)
MV analyses 
OR (95% CI)
Age 
<59 
60-74 
≥75
 
1.00 
0.99 (0.78-1.25) 
0.96 (0.74-1.25)
 
1.00 
1.26 (0.98-1.61) 
1.13 (0.85-1.50)
 
1.00 
0.85 (0.65-1.11) 
0.98 (0.73-1.31)
 
1.00 
0.87 (0.65-1.16) 
0.67 (0.48-0.94)*
Gender 
Male
Female
 
1.00 
0.60 (0.50-0.72)***
 
1.00
1.02 (0.83-1.24)
 
1.00 
1.19 (0.96-1.47)
 
1.00 
1.15 (0.90-1.46)
Location of tumor
Proximal colon
Distal colon
Rectum
not specified
 
1.00 
1.64 (1.30-2.08)***
1.33 (1.05-1.67)* 
0.76 (0.37-1.54)
 
1.00 
1.39 (1.06-1.81)*
2.25 (1.74-2.89)*** 
1.43 (0.63-3.23)
 
1.00 
0.60 (0.47-0.76)*** 
0.24 (0.18-0.32)*** 
1.20 (0.59-2.46)
 
1.00 
0.88 (0.65-1.20)
0.78 (0.58-1.06) 
0.88 (0.35-2.23)
T-stage
T1-2 
T3 
T4
not specified
 
1.23 (0.86-1.76) 
1.00 
0.48 (0.38-0.61)*** 
1.14 (0.74-1.75)
 
1.00 (0.71-1.42) 
1.00
1.10 (0.84-1.43) 
1.32 (0.87-2.01)
 
0.42 (0.23-0.77)**
1.00 
2.18 (1.72-2.77)*** 
1.26 (0.82-1.95)
 
1.17 (0.75-1.84)
1.00 
1.28 (0.94-1.74) 
3.76 (2.38-5.95)***
N-stage 
N0 
N1 
N2
 
1.00 
1.13 (0.90-1.41)
1.23 (0.95-1.58)
 
1.00 
1.25 (0.99-1.59)
0.92 (0.70-1.22)
 
1.00 
1.14 (0.87-1.49)
1.40 (1.05-1.87)*
 
1.00 
1.97 (1.43-2.72)***
3.03 (2.14-4.29)***
Histology
Non-mucinous adenoca
Mucinous adenoca
 
1.00
0.46 (0.34-0.62)***
 
1.00 
0.74 (0.52-1.05)
 
1.00 
2.53 (1.84-3.47)***
 
1.00 
1.20 (0.82-1.77)
Onset of metastases
Synchronous 
Metachronous
 
1.00 
0.38 (0.31-0.47)***
 
1.00 
4.10 (3.31-5.09)***
 
1.00 
1.09 (0.86-1.37)
 
1.00 
4.35 (3.31-5.71)***
In multivariate analyses adjustments were made for age, gender, location of the primary tumor, 
primary tumor stage, primary lymph node stage, tumor histology and onset of metastases. *p<0.05, 
**p<0.01, ***p<0.001. Abbreviations: MV: multivariate; OR: Odds Ratio; adenoca: adenocarcinoma.
Discussion
This is the first large study comparing metastatic patterns according to lymph node 
status of CRC. The most common site of distant metastasis was liver followed by lung, 
peritoneum and distant lymph nodes, with percentages comparable to literature.[2, 12] 
Peritoneal and distant lymph node metastases occurred more often in regional lymph 
node positive CRC, while liver and lung metastases occurred in a similar percentage. 
Our multivariate analysis shows that next to established risk factors for peritoneal 
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carcinomatosis, like T-stage, proximal location and mucinous carcinoma, regional 
lymph node metastases are an important risk factor. This is in line with other studies[13-16] 
making it likely that lymph node metastases are involved in the etiology of peritoneal 
carcinomatosis. The omentum is a preferential site of peritoneal metastases and the 
lymphoid milky spots in the omentum are a homing site for metastatic cancer cells.[17] 
Tumor cells in the omentum can reach the peritoneal cavity by direct growth. The milky 
spots and the anti-inflammatory function of the omentum suggest a relation between 
the peritoneum and the lymphatic system. Moreover, chylous ascites can occur after 
obstruction or resection of extra-peritoneal located lymphatic vessels, providing more 
evidence for direct communications between lymphatic vessels and the peritoneal 
cavity.[18]    
 The finding that regional lymph node positive CRC spread more often to distant 
lymph nodes is in line with others[5] and in support of the first part of the lymphatic 
hypothesis. However, since no difference was observed in liver metastases, the vascular 
hypothesis seems more important for liver metastases.[4] Based on the lymphatic 
hypothesis we expected that lymphatic drainage of the thoracic duct into the venous 
system would lead to a higher incidence of lung metastases in regional lymph node 
positive CRC. However, we found comparable  incidences of lung metastases in 
the whole group of patients with regional lymph node positive CRC (n = 1590). In a 
subgroup of patients with distant lymph node metastases analysed in the autopsy 
cohort (n = 297), we did find increased lung and pleural metastases, suggesting that for 
this small subgroup the lymphatic pathway is important for the metastatic pattern.
 Our unique setup, where we validated findings from autopsy studies in a registry 
based cohort with prospectively collected data, illustrated only a limited influence 
of lymph node metastases on metastatic patterns in CRC. Autopsy studies contain 
selected populations, in which patients are included who have died postoperatively, 
had an unexpected clinical course, or died of other causes than CRC. Nevertheless, 
autopsy studies offer a unique opportunity to study the final distribution of metastases. 
During autopsy all intra-abdominal and intra-thoracic organs are extensively explored, 
revealing more metastases than would have been detected with imaging. This explains 
the high rate of distant lymph node metastases found in the autopsy cohort compared 
to the clinical cohort. 
 17% of cases (286/1679) in the autopsy cohort and 22% of cases (673/3092) in our 
clinical cohort had to be excluded because of non-documentation of the regional 
lymph node status, since there was no resection of the primary tumor. This might have 
caused bias in our patient selection. Moreover, there could have been variations in the 
quality of the autopsy examination and in the pathological examination of resected 
primary tumor specimens, which will have occurred in both groups. Therefore we do 
not expect a significant bias.
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 We cannot exclude the possibility that changes in the management of colorectal 
cancer between 1991-2010, would have had an influence on the metastatic patterns 
established at autopsy. The introduction of radiotherapy, chemotherapy, targeted 
therapy and surgery of metastatic lesions, might have shifted the presence of 
metastases to more uncommon sites. However, our main findings were validated in the 
population study with a narrower time frame.
 This study shows that regional lymph node involvement in CRC is associated with a 
higher rate of peritoneal metastases and distant lymph node metastases. Our findings 
support the hypothesis that metastases to the liver and lung occur independently of 
lymphatic spread. Regional lymph node metastases function as a biomarker, i.e. as 
a sign of advanced disease, and seem only mechanisticly involved in the process of 
metastases in a small subgroup of patients with spread via the distant lymph nodes. 
Unfortunately, the presence of vascular invasion is grossly underreported in pathology 
reports, making a separate analysis for vascular invasion not possible. Therefore, 
our findings can only indirectly support the vascular pathway as a mechanism for 
development of common distant metastases, such as liver and lung metastases. 
However, the current recognition of extramural vascular invasion in the staging and 
treatment of colorectal cancer[19-21] seems justified.
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Abstract 
Perineural invasion (PNI) is a possible route for metastatic spread in various cancer 
types, including colorectal cancer. PNI is linked to poor prognosis, but systematic 
analyses are lacking. This study systematically reviews the frequency and impact of 
PNI in colorectal cancer. 
A literature search was performed using PubMed database from inception to 1 
January 2014. Data were analyzed using Review Manager 5.3. A quality assessment 
was performed based on modified REMARK criteria. Endpoints were local recurrence 
(LR), five year disease free survival (5yDFS), five year cancer specific survival (5yCSS) 
and five year overall survival (5yOS). Meta-analysis was performed in terms of risk 
ratios (RR) and hazard ratios (HR) with 95% confidence interval (95%CI). 
In this meta-analysis 58 articles with 22900 patients were included. PNI was present 
in 18.2% of tumors. PNI is correlated with increased LR (RR 3.22, 95%CI 2.33-4.44), 
decreased 5yDFS (RR 2.35, 95%CI 1.66-3.31), 5yCSS (RR 3.61, 95%CI 2.76-4.72) and 
5yOS (RR 2.09, 95%CI 1.68-2.61). In multivariate analysis PNI remains an independent 
prognostic factor for 5yDFS, 5yCSS and 5yOS (HR 2.35, 95%CI 1.97-3.08, HR 1.91, 
95%CI 1.50-2.42, and HR 1.85, 95%CI 1.63-2.12, respectively).
We confirmed the strong impact of PNI for local recurrence and survival in colorectal 
cancer. The prognostic value of PNI is similar to that of well-established prognostic 
factors as depth of invasion, differentiation grade, lymph node metastases, lymphatic 
and extramural vascular invasion. Therefore, PNI should be one of the factors in the 
standardised reporting of colorectal cancer and might be considered a high-risk feature. 
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Introduction
The study of metastases formation is of utmost importance to find strategies to 
prevent future cancer deaths. There are several routes that allow the spread of tumor 
cells: in addition to direct growth, the cells can disseminate via the blood and lymph 
channels or grow along the nerves.[1] The latter is called perineural invasion (PNI). 
The tumor cells can grow within, around and through any of the three nerve layers. 
Tumor cells should by definition surround more than 33% of the nerve circumference 
for PNI.[1] PNI has been gaining increased recognition, however, its true value has not 
been established yet. There is a wide difference in the used definitions, in reported 
frequencies and impact on prognosis. High incidences of PNI are especially reported 
in pancreatic adenocarcinomas (98%), cholangiocarcinomas (75-85%), prostate (75%) 
and gastric adenocarcinomas (60%). In colorectal cancer (CRC) the incidence of PNI 
seems to be much lower.[1]
 In CRC, well-established predictors of prognosis are depth of invasion, 
differentiation grade, presence of lymph node metastases, lymphangio-invasion 
and extramural vascular invasion. In the TNM 7th edition PNI was introduced as an 
accessory factor.[2] To establish the impact of PNI in CRC, we systematically reviewed 
the frequency and impact of PNI in CRC. The prognostic endpoints are local recurrence 
(LR), five year disease free survival (5yDFS), five year cancer specific survival (5yCSS) 
and five year overall survival (5yOS).
Materials and methods
Strategy for search of articles and selection criteria
A comprehensive literature search was performed using the PubMed database 
from inception to 1 January 2014, using the following keywords: “perineural” 
or “peri-neural” or “neural” or “nerve” or “nerves” and “invasion” or “Neoplasm 
Invasiveness”[Mesh] and “Peripheral Nerves”[Mesh] or “Peripheral Nervous System 
Neoplasms/secondary”[Mesh] or “Nervous System Neoplasms/secondary”[Mesh] 
and “Colorectal Neoplasms”[Mesh] or “colorectal” or “colon” or “rectum” or “rectal” 
and “cancer” or “carcinoma”. Additional searches were performed by manual cross-
referencing and an expert in the field (IN) was consulted for additional articles that 
met the inclusion criteria. 
 Two independent investigators (SM, NK) reviewed each report for eligibility. Articles 
published in English and studies with at least 100 patients were selected. Studies 
with and without (neo)adjuvant treatment were included. In case of overlapping 
patient data, the study with most outcome data or longest follow-up was included 
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in this meta-analysis. In order to select for studies in which PNI was studied more 
systematically, studies with missing values of PNI of more than 10% were excluded.
Data extraction
For each study the number of patients in the PNI+ and the PNI- group were obtained, 
only extramural PNI was included in the PNI+ group. Data on tumor stage, neo-
adjuvant therapy, LR, 5yDFS, 5yCSS and 5yOS were extracted. Data were entered in 
SPSS (SPSS for Windows, IBM SPSS Statistics 20, 2011) and Review Manager (RevMan) 
[Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2012).
Quality assessment and risk of bias
A scale to assess the quality of the reporting of the studies was developed based on 
the REMARK guidelines, specifically looking at the reporting of PNI (Supplemental 
Digital Content, table 1: Quality of reporting scoring criteria used).[3, 4] Only studies 
with data on outcome were subjected to quality assessment. Scoring was performed 
by two independent investigators (NK, FS). In case of disagreement, a consensus score 
was achieved after discussion. The association between the quality of reporting and 
the RR/HR was analyzed with scatter plots and non-parametric correlation testing. 
Publication bias was assessed by looking at symmetry in funnel plots. 
Statistical analysis
A meta-analysis was performed with all available studies on each endpoint in 
terms of risk ratios (RR) with 95%CI. Data of multivariate analyses were entered 
in terms of hazard ratios (HR) with 95%CI. A random effects model with inverse 
variance weighting of studies was used. Heterogeneity was assessed using a χ2 
test for heterogeneity with a p-value of <0.10 to show the presence of significant 
heterogeneity. In case of heterogeneity, sub-analyses were performed to identify 
the potential source of heterogeneity.
Results 
Search results
A total of 439 potentially relevant studies were retrieved by the database search. 382 
studies were excluded because they did not meet inclusion criteria (Figure 1). Cross-
referencing and consulting an expert in the field resulted in one additional article 
that fulfilled the eligibility criteria. The remaining 58 articles, comprising 22900 
patients, were included in the meta-analysis.[5-62] 
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19 studies investigated PNI in rectal cancer, ten studies in colon cancer and in 29 
studies rectal and colon carcinomas were grouped together. Of the latter one study 
subdivided incidences of PNI in rectal and colon cancer. The 20 studies with data 
on PNI in rectal cancer contained 6942 patients; 11 colon cancer studies contained 
4637 patients, and 28 studies with colorectal cancer incorporated 11321 cases. The 
main characteristics of the studies are shown in table 1. The mean number of patients 
included in the studies was 388 (range 100-2492).
Figure 1. Flow chart of search strategy. Abbrevations: PNI:perineural invasion
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Table 1A: Main characteristics of the articles on CRC
author country time-frame study design stage neoadjuvant RT n %PNI
Allard MA France 1998-2008 RSCS II-III no 117 21.4%
Bamias A Greece 1989-1997 RMCS II-III nm 499 7.8%
Barresi V Italy Nm RSCS I-IV no 152 21.7%
Bellis D Italy 1988-1989 RSCS nm nm 160 31.3%
Bouassida M Tunesia 2000-2010 RCCS I-IV yes, ns 280 32.9%
Chang DT USA 2000-2010 RCCS I-IV nm 128 18.8%
Choi PW Korea 1989-2004 RSCS I no 168 0.6%
Cohn KH USA 1988-1992 RSCS I-IV nm 104 8.7%
da Fonseca LM Brazil 2001-2010 RSCS I-IV nm 653 23.4%
Dogan L Turkey 1999-2006 RSCS II-III no 116 5.2%
Galindo Gallego M Spain 1982-1991 RSCS I-III no 126 10.3%
Gray KD USA 1990-1999 RMCS I-IV nm 213 12.7%
Guerra A Spain Nm RSCS I-IV nm 108 11.1%
Huang CW Taiwan 2002-2008 RSCS I-IV nm 1197 37.3%
Huh JW Korea 1997-2009 RSCS I-III no 1732 22.7%
Ianoşi G Romenia Nm RSCS I-IV nm 273 8.1%
Kang H Korea 1996-1999 RMCS I-IV nm 301 26.3%
Kim JY Korea 1998-2003 RSCS I-IV no 292 23.6%
Liebig C USA 1995-2000 RSCS I-IV nm 249 22.1%
Lin M China 2005-2008 RSCS I-IV nm 123 20.3%
Oñate-Ocaña LF Mexico 1983-1998 RSCS I-II no 124 41.9%
Pagès F France 1986-2004 RSCS I-IV nm 959 10.3%
Shiozawa J Japan 1996-1998 RSCS I-IV nm 115 19.1%
Ting WC China 2001-2007 RSCS I-IV nm 282 17.0%
Ueno H Japan 1999-2004 RMCS I-III no 2492 12.6%
Viana Lde S Brazil 2006-2009 RSCS I-IV no 114 7.0%
Yun HR Korea 1994-2004 RSCS IV no 127 12.6%
11321 18.5%
Abbrevations: RSCS: retrospective single center study; RMCS: retrospective multi center study; RCCS: 
retrospective case control study; RT: radiotherapy; nm: not mentioned; ns: not specified; n: number of 
patients; PNI: perineural invasion.
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Table 1B. Main characteristics of articles on rectal cancer
author country time-frame study 
design
stage neoadjuvant RT n %PNI
Bentzen SM Denmark 1979-1985 RMCS II-III no 494 26.1%
Ceyhan GO Germany 1990-2002 RSCS II-III yes, 53.0% CRT 45Gy/5FU 275 18.9%
Chandrasinghe PC Sri Lanka 1996-2010 RSCS I-IV yes, 33.6% CRT (ns) 226 11.1%
Dresen RC Netherlands 1994-2006 RCCS I-III yes, 53.4% RT (5x5Gy/50Gy) 277   7.2%
Guillem JG USA 1988-2002 RSCS 0-IV yes, 100% CRT 50Gy/5FU 297 9.1%
Horn A Norway Nm RS I-III yes, 49.6% RT (ns) 254 35.4%
Kim JS Korea 2001-2007 RSCS nm yes, 65.2% CRT 50Gy/5FU 797 26.0%
Knudsen JB Denmark 1968-1980 RSCS I-IV no 673 34.9%
Krebs B Slovenia 1998-2003 RSCS 0-IV nm 247 12.6%
Law WL Hong Kong 2000-2006 RSCS II-III yes, 12.8% CRT (ns) 421 13.5%
Lim JW Singapore 1999-2007 RSCS I-III no 261 18.4%
Peng J China 1996-2004 RSCS II no 173 24.3%
Peng J China 1992-2005 RSCS I, III no 124   9.7%
Poeschl EM* Austria Nm RSCS I-IV no 149 18.1%
Rullier A France Nm RSCS II-III yes, 100% RT 45Gy, 77% CRT 5FU 200 15.5%
Seefeld PH USA 1935-1936 RSCS I-IV no 100 30.0%
Shirouzu K Japan 1982-1992 RSCS I-IV nm 501 20.0%
Silberfein EJ USA 1993-2003 RSCS I-III yes, 88.8% CRT 45Gy/5FU 304   6.3%
Sitzler PJ Singapore 1989-1996 RSCS nm no 805 24.6%
Ueno H Japan 1981-1995 RSCS II-III no 364 14.3%
Total 6942 20.6%
Abbrevations: RSCS: retrospective single center study; RS: randomized study; RCCS: retrospective case 
control study; RMCS: retrospective multi center study; RT: radiotherapy; CRT: chemoradiotherapy; nm: 
not mentioned; ns: not specified; n: number of patients; PNI: perineural invasion; n.p: not performed; 
*seperate data on colon and rectal cancer
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Table 1C. Main characteristics of articles on colon cancer 
author country time-frame study design stage n %PNI
Desolneux G USA 1976-1989 RSCS I-II 362 4.4%
Jee SH Korea 1993-2006 RSCS II 363 14.3%
Lennon AM Ireland 1992-1997 RSCS II 118 11.0%
Liebl F Germany 1990-2005 RSCS I-IV 673 31.2%
Oh Korea 1998-2003 RSCS II-III 340 13.2%
Peng SL Australia 1999-2007 RMCS II 458 3.7%
Poeschl EM* Austria Nm RSCS I-IV 232 13.4%
Stor Z Slovenia 1994-2000 RSCS II 191 2.1%
Tanaka M Japan 1981-1993 RSCS II 138 9.4%
Weiser MR USA 1990-2000 RSCS I-III 1320 6.0%
Wied U Denmark 1970-1980 RSCS I-IV 442 39.1%
4637 14.1%
Abbrevations: nm: not mentioned; RMCS: retrospective multi center study; RSCS: retrospective single 
center study; n: number of patients; PNI: perineural invasion; *seperate data on colon and rectal 
cancer
Quality of reporting of the included studies
Studies with outcome data (n=31) were subjected to quality assessment, focussed 
on the quality of reporting of PNI (Supplemental Digital Content, table 2: Reporting 
scores per article, 0:no; 1:yes; na:not applicable). The mean percentage of items 
reported was 61.8% (range 17.7-84.2%). Only 4 studies reported less than 50% of 
required items, 22 studies reported 50-75% of required items and 5 studies reported 
>75% of items (Supplemental Digital Content, Figure 1: Overview of the percentage 
of items reported).
Frequency of PNI
The incidence of PNI was 18.2% in the overall cohort, 20.6% in rectal cancer and 14.1% 
in colon cancer studies (table 1). The percentage of PNI was not significantly different 
between studies that re-examined pathologic slides (25 studies; 8483 patients) and 
studies that extracted PNI from pathology reports (33 studies; 14417 patients) (19.0% 
vs. 18.1%, p=0.10).
 The frequency of PNI was stage dependent, with very low incidence in stage 
I (0.2%, total 412 cases). Tumors without lymph node metastases (stage I and II 
together) showed PNI in 9.5% (total 5353 cases), compared to 26.3% in stage III 
tumors (total 1840 cases) and 36.6% in tumors with distant metastases at the time 
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of presentation (total 287 cases)(Figure 2A). These differences could be explained by 
both an increased risk of PNI with increasing T-stage (total 4818 cases)(Figure 2B)
[11, 47, 51, 53, 57, 58] and N-stage (total 3512 cases)(Figure 2C).[11, 47, 57, 58] PNI occurred more 
often in tumors with poor differentiation (23.8%, total 416 cases) compared to well 
differentiated (6.9%, total 1441 cases) and moderately differentiated tumors (17.8%, 
total 1849 cases) (Figure 2D).[11, 36, 47, 57, 58]
Association between PNI and lymphatic and venous invasion 
The association between PNI, lymphatic and venous invasion was investigated in four 
studies.[45, 47, 51, 58] One study[45] did not differentiate between vascular and lymphatic 
invasion and detected PNI in 19.6% of the tumors without lymphovascular invasion 
(LVI) compared to PNI in 52% of the tumors with LVI (p<0.001). When combining 
the other three studies, PNI was observed in 4.6% of the tumors without (total 1408 
cases) and in 17.6% of the tumors with lymphatic invasion (total 2319 cases). PNI 
occurred in 4.4% of the tumors without venous invasion (total 1565 cases), compared 
to 18.7% in tumors with venous invasion (total 2160 cases). Thus, PNI positive tumors 
more often have lymphatic invasion compared to PNI negative tumors (RR 1.92, 95% 
CI 1.36-2.72, p<0.001 (Supplemental Digital Content, Figure 2A: Association between 
PNI and lymphatic invasion)), and more often have venous invasion (RR 1.92, 95% CI 
1.46-2.51, p<0.001 (Supplemental Digital Content, Figure 2B: Association between 
PNI and venous invasion)). In both analyses significant heterogeneity was observed 
(χ2=50.05, df 2 (p<0.001), I2=96% and χ2=55.21, df 2 (p<0.001), I2=96%), respectively), 
but sub-analyses were not possible due to the limited number of studies. 
Effect of neo-adjuvant treatment on PNI
Approximately half of the patients with rectal cancer received some form of neo-
adjuvant treatment.[11, 12, 19, 23, 24, 30, 34, 48, 52] In two studies all patients received neo-
adjuvant (chemo-)radiation (497 cases).[23, 48] In seven studies some patients received 
neo-adjuvant treatment (percentages of treated patients varying between 12.8% 
and 88.8%), which varied between short schedule radiotherapy, long schedule 
radiotherapy or combined chemo- and radiotherapy (total 2575 cases, 1224 with and 
1351 without radiotherapy). Two studies did not mention neo-adjuvant treatment 
(748 cases).[33, 51] In eight studies no neo-adjuvant treatment was given (2994 cases).
[9, 32, 38, 44, 45, 49, 53, 57] In the neo-adjuvant treatment group 528 of 3072 patients (17.2%) 
showed PNI. Of the 2994 patients who did not receive neo-adjuvant therapy, 746 
showed PNI (24.9%)(p<0.001).
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Effect of PNI on local recurrence
The influence of PNI on LR could be extracted from five studies comprising 1700 
patients.[30, 45, 49, 52, 57] The presence of PNI is associated with increased risk of LR with 
a RR of 3.22 (95%CI 2.33-4.44, p<0.001) (Figure 3A). No heterogeneity was observed 
(χ2=5.10, df=4 (p=0.28); I2=22%), and there was no indication of publication bias. The 
percentage of items reported ranged from 50% to 83.3%, and this quality indicator 
did not correlate with the magnitude of RR (Spearman r=0.53, p=0.35). Furthermore, 
studies in which PNI was extracted from pathology reports showed similar RR 
compared to studies with specific review of PNI (6.05 vs. 3.00, p=0.31). 
Figure 2. The frequency of PNI is stage dependent. A) Percentage of PNI in different TNM-stages, 
subdivided into rectal and colorectal cancer, 15 studies with 4954 patients included.[9, 11, 14, 28, 35, 
36, 45-47, 51, 54, 55, 57, 58, 62] B) Percentage of PNI according to T-stage extracted from six studies 
with 4818 patients. C) Percentage of PNI according to N-stage extracted from four studies with 3512 
patients. D) Percentage PNI according to differentiation grade extracted from five studies with 3706 
patients. Abbrevations: PNI:perineural invasion
A
C
B
D
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Figure 3. The impact of PNI on outcome in univariate analysis. A) Impact of PNI on LR. B) Impact of 
PNI on 5yDFS. C) Impact of PNI on 5yCSS. D) Impact of PNI on 5yOS. Abbrevations: PNI:perineural 
invasion; IV:inverse variance; CI:confidence interval; LR:local recurrence; 5yDFS:5-year disease free 
survival; 5yCSS:5year cancer specific survival; 5yOS:5year overall survival
3A
3B
3C
3D
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Two studies provided data on multivariate analysis, in both PNI is an independent 
prognostic factor for LR.[45, 57] A study by Ueno et al. shows that PNI is an independent 
risk factor for LR with an OR of 5.4 (95%CI 2.3-12.8).[57], which is comparable to lymph 
node involvement (OR 3.4, 95%CI 1.3-8.8). Patients with positive resection margins 
were excluded. Peng et al. found that PNI-positivity was the only independent risk 
factor for LR (HR 2.70, 95%CI 1.03-7.06, p=0.04).[45] Tumor grade, circumferential 
resection margin, LVI and number of sampled lymph nodes were not associated with 
local recurrence in multivariate analysis. One other study performed a multivariate 
analysis, but did not provide separate data.[30]
Effect of PNI on disease free survival
Data on the impact of PNI on the 5yDFS were available from nine studies with in total 
4832 patients.[5, 26, 30, 36, 43, 45, 47, 48, 58] The 5yDFS decreased in the presence of PNI (RR 
2.35, 95%CI 1.66-3.31, p<0.001) (Figure 3B). Significant heterogeneity was observed 
between the studies (χ2=183.25, df=8 (p<0.001); I2=96%). Sample size, time-frame, 
neo-adjuvant therapy, location of the primary tumor and TNM stage did not explain 
the heterogeneity. There was no indication of publication bias. The percentage of 
items reported in the articles ranged from 47.4% to 84.2%, and this quality indicator 
did not correlate with the magnitude of RR (Spearman r=-0.28, p=0.46). No difference 
was observed between studies with PNI from pathology reports and studies with 
specific review of PNI (2.35 vs. 2.58, p=0.76).  
 Multivariate analysis was available in 7 studies comprising 5951 patients, confirming 
a decreased 5yDFS in the presence of PNI (HR 2.35, 95%CI 1.79-3.08, p<0.001) 
(Figure 4A). Significant heterogeneity was observed between the studies (χ2=13.01, 
df=6 (p=0.04); I2=54%). We investigated study size, time-frame, neo-adjuvant therapy, 
location of the primary tumor and TNM stage, but these factors did not explain the 
heterogeneity. There was no indication of publication bias. The percentage of items 
reported varied from 38.9% to 84.2%, and did not correlate with the magnitude of 
HR (Spearman r=-0.05, p=0.91). Studies in which PNI was extracted from pathology 
reports showed similar HR compared to studies with specific review of PNI (2.30 vs. 
2.36, p=0.93). Other independent prognostic factors for 5yDFS in multivariate analysis 
were T-stage, N-stage and LVI. The HR of these factors were comparable with that of 
PNI (T-stage: combined HR of 3.13 (95%CI 2.05-4.79)[26, 47], N-stage: combined HR of 
2.22 (95%CI 1.72-2.87)[26, 58, 62], LVI: combined HR of 1.81 (95%CI 1.44-2.27)[26, 47, 58]). 
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Figure 4. The impact of PNI on outcome in multivariate analysis. A) Impact of PNI on 5yDFS. B) Impact 
of PNI on 5yCSS. C) Impact of PNI on 5yOS. Abbrevations: PNI:perineural invasion; SE:standard error; 
IV:inverse variance; CI:confidence interval; 5yDFS:5-year disease free survival; 5yCSS:5year cancer 
specific survival; 5yOS:5year overall survival
4A
4B
4C
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Effect of PNI on cancer specific survival
The impact of PNI on 5yCSS could be extracted from six studies with in total 3964 
patients.[11, 35, 37, 42, 47, 58] The presence of PNI is associated with worse 5yCSS (RR 3.61, 
95%CI 2.76-4.72, p<0.001)(Figure 3C). Significant heterogeneity was observed 
(χ2=21.39, df=5 (p<0.001); I2=77%). We investigated study size, time-frame, location 
of the primary tumor and TNM stage. These factors did not explain the heterogeneity. 
There was no indication of publication bias. With respect to the quality of the articles, 
the percentage of items reported ranged from 50% to 83.3%, and this did not correlate 
with the magnitude of RR (Spearman r=0.23, p=0.66). PNI was rescored in all studies 
with univariate data on 5yCSS.
 Multivariate analysis was performed in seven studies comprising 3160 patients, 
confirming a decreased 5yCSS in the presence of PNI (HR 1.91, 95%CI 1.50-2.42, 
p<0.001)(Figure 4B).[11, 25, 36-38, 42, 47] No heterogeneity was observed (χ2=10.59, df=6 
(p=0.10); I2=43%). There was no indication of publication bias. The percentage 
of items reported varied from 52.6% to 84.2% and this did not correlate with the 
magnitude of HR (Spearman r=0.14, p=0.78). Studies in which PNI was extracted from 
pathology reports showed similar HR compared to studies with specific review of PNI 
(1.85 vs. 2.34, p=0.41). 
 Other independent prognostic factors for 5yCSS in multivariate analysis were 
T-stage, N-stage, LVI and differentiation grade. The HR of these factors were 
comparable with that of PNI (T-stage: combined HR of 3.66 (95%CI 2.21-6.06)[11, 37, 38, 47], 
N-stage: combined HR of 2.59 (95%CI 1.59-4.21)[11, 37, 38], LVI: combined HR of 1.81 
(95%CI 1.44-2.27)[25, 37, 47], differentiation grade: combined HR of 1.51 (95%CI 1.08-
2.11)[25, 36, 37, 42, 47]).
Effect of PNI on overall survival
The impact of PNI on 5yOS was evaluated in 14 studies with in total 5116 patients.[15, 
22, 24, 26, 29, 30, 36, 40, 43, 45, 48, 49, 56, 57] The 5yOS decreased in the presence of PNI (RR 2.09, 95%CI 
1.68-2.61, p<0.001) (Figure 3D). Significant heterogeneity was observed (χ2=115.65, 
df=13 (p<0.001); I2=89%). We investigated the factors study size, time-frame, neo-
adjuvant therapy, location of the primary tumor and TNM stage. These factors did 
not explain the heterogeneity. There was no indication of publication bias. The 
percentage of items reported varied from 17.7% to 84.2%, and did not correlate with 
the magnitude of RR (Spearman r=-0.15, p=0.61). Studies in which PNI was extracted 
from pathology reports showed similar RR compared to studies with specific review 
of PNI (2.49 vs. 1.99, p=0.25).
 Multivariate analysis was performed in 14 studies comprising 7011 patients.[17, 25, 
26, 28, 30, 32, 34, 39-41, 45, 52, 56, 62] However, four studies did not provide separate data.[20, 46, 48, 
61] The presence of PNI is associated with decreased 5yOS, combined hazard ratio of 
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1.85 (95%CI 1.63-2.12, p<0.001)(Figure 4C). No heterogeneity was observed (χ2=8.16, 
df=13 (p=0.83); I2=0%). There was no indication of publication bias. The percentage 
of items reported ranged from 38.9% to 83.3% and this did not correlate with the 
magnitude of HR (Spearman r=-0.39, p=0.17). Studies in which PNI was extracted from 
pathology reports showed similar HR compared to studies with specific review of PNI 
(2.39 vs. 1.70, p=0.40). Other independent prognostic factors for 5yOS were T-stage, 
N-stage, LVI and differentiation grade. The HR of these factors were comparable with 
that of PNI (T-stage: HR of 2.08 (95%CI 1.46-2.95)[17, 26, 28], N-stage: combined HR of 1.97 
(95%CI 1.63-2.37)[26, 30, 34, 39, 41, 56, 62], LVI: combined HR of 1.76 (95%CI 1.52-2.03)[17, 25, 26, 28, 
32, 39, 41, 52, 56], differentiation grade: combined HR of 1.76 (95% CI 1.25-2.47)[25, 34, 56]). 
Discussion
The overall incidence of PNI found in this meta-analysis was 18.2%, which is lower than the 
33% found in a previous review.[1] That review included four studies (478 patients in total) 
that had PNI as their main focus, and in two of these studies immunohistochemistry was 
used to detect PNI.[8, 63] In our meta-analysis both studies which re-examined pathologic 
slides with a specific focus on PNI and studies that extracted PNI from pathology reports 
were included. Interestingly, the percentage of PNI was not significantly different 
between studies that re-examined pathologic slides and studies that extracted PNI from 
pathology reports, suggesting that this biomarker is well reported in daily practice. In 
studies that re-examined PNI, the method of scoring was often not clearly described. 
Definitions of PNI and the number of scorers were often lacking. However, it is clear that 
PNI is relatively uncommon in CRC compared to other cancer types. One explanation 
for this difference might be a lower neural density in colorectal tissue compared to 
other tissues. Likewise, differences in the expression of neurotrophins, chemokines, 
proteinases and their receptors may be involved.[1, 50, 64] 
 Our meta-analysis shows increased PNI rates in rectal cancer (20.6%) compared to 
colon cancer (14.1%),[36, 47, 65] which might be explained by the fact that the rectum is 
surrounded by many autonomic nerve plexuses. The colon is intraperitoneal and lacks 
an external plexus and thus has less innervation than the rectum. Moreover, more 
extensive examination of the mesorectal fat in rectal carcinoma for investigating CRM 
involvement may increase detection of PNI.
 In our meta-analysis we tried to evaluate the influence of neo-adjuvant treatment 
on PNI. Since not all studies reported data on neo-adjuvant treatment, the effect of 
radiotherapy on PNI was difficult to establish. It seems that tumors without neo-
adjuvant therapy have a higher incidence of PNI (24.9% versus 17.2%). However, in 
the current analyses different treatment schedules were compared. One randomized 
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controlled trial compared the effects of neo-adjuvant chemoradiation (45Gy/5-FU) 
directly.[11] They showed 19% PNI in tumors after chemoradiation compared to 32% in 
tumors without treatment (p=0.01). 
 Differences in reporting of published studies hampered our investigation. Some 
studies had to be excluded because they did not fulfil our criteria of outcome, for 
example they used 3 or 8 year survival or local and distant recurrence were grouped 
together. A more uniform reporting or adherence to the REMARK criteria would have 
given more comparable data. The overall quality of reporting was moderate, with 
a mean percentage of reported items of 61%. However, some studies did not give 
criteria for PNI positivity or the estimated effect of PNI in uni- or multivariate analysis 
was not given. Moreover, PNI was not re-examined in many studies and therefore 
the ‘real’ percentage of PNI could differ. However, this effect might be small, given 
the lack of difference in outcome between studies in which PNI was extracted from 
pathology reports compared to the studies with specific review of PNI.
 We confirmed and quantified the strong negative prognostic impact of PNI for 
recurrence and survival in CRC. The largest number of studies and patients could be 
included in the analyses for OS. Here the HR was 1.85 (95%CI 1.63-2.12, p<0.001), 
and most comparable to T-stage, N-stage, LVI and differentiation grade.  The biggest 
effect was observed for DFS. Here the HR was 2.35 (95%CI 1.79-3.08, p<0.001), an 
effect comparable to T-stage, N-stage and LVI. It should be noted that we observed 
significant heterogeneity in four out of seven pooled analyses, which we could not 
resolve by sub-analyses, but the direction of the effect was consistent over studies.
 In summary, our meta-analysis shows that PNI is a pathologic feature in CRC 
with a strong impact on prognosis. The impact of PNI on prognosis is similar to 
well established prognostic factors as depth of invasion, presence of lymph node 
metastases, lymphatic invasion, vascular invasion and differentiation grade. 
Therefore, PNI should be one of the factors in the standardised reporting of CRC and 
might be considered a high-risk feature.
137
7
References
1. Liebig, C., et al., Perineural invasion in cancer: a review of the literature. Cancer, 2009. 115(15): p. 3379-
91.
2. Sobin, L.H., et al., TNM classification of malignant tumours. 7th ed. 2010, Chichester, West Sussex, UK 
; Hoboken, NJ: Wiley-Blackwell. xx, 309 p.
3. Knijn, N., F. Simmer, and I.D. Nagtegaal, Recommendations for reporting histopathology studies: a 
proposal. Virchows Arch, 2015.
4. McShane, L.M., et al., Reporting recommendations for tumor marker prognostic studies. J Clin Oncol, 
2005. 23(36): p. 9067-72.
5. Allard, M.A., et al., Linear quantification of lymphoid infiltration of the tumor margin: a reproducible 
method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. 
Diagn Pathol, 2012. 7: p. 156.
6. Bamias, A., et al., Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy 
or chemoradiotherapy: a pooled analysis of two randomized studies. Int J Gastrointest Cancer, 2005. 
36(1): p. 29-38.
7. Barresi, V., et al., Histologic grading based on counting poorly differentiated clusters in preoperative 
biopsy predicts nodal involvement and pTNM stage in colorectal cancer patients. Hum Pathol, 2014. 
45(2): p. 268-75.
8. Bellis, D., V. Marci, and G. Monga, Light microscopic and immunohistochemical evaluation of vascular 
and neural invasion in colorectal cancer. Pathol Res Pract, 1993. 189(4): p. 443-7.
9. Bentzen, S.M., et al., A regression analysis of prognostic factors after resection of Dukes’ B and C 
carcinoma of the rectum and rectosigmoid. Does post-operative radiotherapy change the prognosis? 
Br J Cancer, 1988. 58(2): p. 195-201.
10. Bouassida, M., et al., Histopathologic characteristics and short-term outcomes of colorectal cancer in 
young Tunisian patients: one center’s experience. Pan Afr Med J, 2012. 12: p. 10.
11. Ceyhan, G.O., et al., The severity of neural invasion is a crucial prognostic factor in rectal cancer 
independent of neoadjuvant radiochemotherapy. Ann Surg, 2010. 252(5): p. 797-804.
12. Chandrasinghe, P.C., et al., Pre-operative hypoalbuminaemia predicts poor overall survival in rectal 
cancer: a retrospective cohort analysis. BMC Clin Pathol, 2013. 13: p. 12.
13. Chang, D.T., et al., Clinicopathologic and molecular features of sporadic early-onset colorectal 
adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid 
involvement, and adverse morphologic features. Mod Pathol, 2012. 25(8): p. 1128-39.
14. Choi, P.W., et al., Risk factors for lymph node metastasis in submucosal invasive colorectal cancer. World 
J Surg, 2008. 32(9): p. 2089-94.
15. Cohn, K.H., et al., The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of 
a 5-year follow-up study. Cancer, 1997. 79(2): p. 233-44.
16. da Fonseca, L.M., et al., Colorectal carcinoma in different age groups : a histopathological analysis. Int 
J Colorectal Dis, 2012. 27(2): p. 249-55.
17. Desolneux, G., et al., Prognostic factors in node-negative colorectal cancer: a retrospective study from 
a prospective database. Int J Colorectal Dis, 2010. 25(7): p. 829-34.
18. Dogan, L., et al., Characteristics and risk factors for colorectal cancer recurrence. J BUON, 2010. 15(1): 
p. 61-7.
19. Dresen, R.C., et al., Local recurrence in rectal cancer can be predicted by histopathological factors. Eur J 
Surg Oncol, 2009. 35(10): p. 1071-7.
20. Galindo Gallego, M., et al., Vascular enumeration as a prognosticator for colorectal carcinoma. Eur J 
Cancer, 2000. 36(1): p. 55-60.
21. Gray, K.D., et al., Do adverse histopathologic findings in colorectal cancer patients explain disparate 
outcomes? J Natl Med Assoc, 2006. 98(3): p. 348-51.
138
Chapter 7 – Perineural invasion is a strong prognostic factor
22. Guerra, A., et al., Multivariate analysis of prognostic factors in resected colorectal cancer: a new 
prognostic index. Eur J Gastroenterol Hepatol, 1998. 10(1): p. 51-8.
23. Guillem, J.G., et al., Long-term oncologic outcome following preoperative combined modality therapy 
and total mesorectal excision of locally advanced rectal cancer. Ann Surg, 2005. 241(5): p. 829-36; 
discussion 836-8.
24. Horn, A., O. Dahl, and I. Morild, Venous and neural invasion as predictors of recurrence in rectal 
adenocarcinoma. Dis Colon Rectum, 1991. 34(9): p. 798-804.
25. Huang, C.W., et al., The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese 
patients with colorectal cancer. World J Surg Oncol, 2012. 10: p. 76.
26. Huh, J.W., et al., Factors predicting long-term survival in colorectal cancer patients with a normal 
preoperative serum level of carcinoembryonic antigen. J Cancer Res Clin Oncol, 2013.
27. Ianosi, G., et al., Histopathological factors as predictors for survival in colon and rectal cancers. Rom J 
Morphol Embryol, 2008. 49(3): p. 365-9.
28. Jee, S.H., et al., Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II 
Colon Cancer. J Korean Soc Coloproctol, 2011. 27(6): p. 322-8.
29. Kang, H., et al., Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with 
stages II and III colorectal carcinoma. Ann Surg Oncol, 2011. 18(3): p. 711-9.
30. Kim, J.S., et al., Prognostic significance of distribution of lymph node metastasis in advanced mid or low 
rectal cancer. J Surg Oncol, 2011. 104(5): p. 486-92.
31. Kim, J.Y., et al., Prognostic significance of epidermal growth factor receptor and vascular endothelial 
growth factor receptor in colorectal adenocarcinoma. APMIS, 2011. 119(7): p. 449-59.
32. Knudsen, J.B., et al., Venous and nerve invasion as prognostic factors in postoperative survival of 
patients with resectable cancer of the rectum. Dis Colon Rectum, 1983. 26(9): p. 613-7.
33. Krebs, B., et al., Prognostic value of additional pathological variables for long-term survival after 
curative resection of rectal cancer. World J Gastroenterol, 2006. 12(28): p. 4565-8.
34. Law, W.L., et al., Comparison of outcome of open and laparoscopic resection for stage II and stage III 
rectal cancer. Ann Surg Oncol, 2009. 16(6): p. 1488-93.
35. Lennon, A.M., et al., Peritoneal involvement in stage II colon cancer. Am J Clin Pathol, 2003. 119(1): p. 
108-13.
36. Liebig, C., et al., Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin 
Oncol, 2009. 27(31): p. 5131-7.
37. Liebl, F., et al., The severity of neural invasion is associated with shortened survival in colon cancer. Clin 
Cancer Res, 2013. 19(1): p. 50-61.
38. Lim, J.W., et al., Close distal margins do not increase rectal cancer recurrence after sphincter-saving 
surgery without neoadjuvant therapy. Int J Colorectal Dis, 2012. 27(10): p. 1285-94.
39. Lin, M., et al., Elevated pre-treatment levels of high sensitivity C-reactive protein as a potential 
prognosticator in patients with colorectal cancer. Exp Ther Med, 2013. 6(6): p. 1369-1374.
40. Mulcahy, H.E., et al., Identifying stage B colorectal cancer patients at high risk of tumor recurrence and 
death. Dis Colon Rectum, 1997. 40(3): p. 326-31.
41. Oh, S.Y., et al., Contiguous invasion per se does not affect prognosis in colon cancer. J Surg Oncol, 2009. 
99(1): p. 71-4.
42. Onate-Ocana, L.F., et al., Identification of patients with high-risk lymph node-negative colorectal 
cancer and potential benefit from adjuvant chemotherapy. Jpn J Clin Oncol, 2004. 34(6): p. 323-8.
43. Pages, F., et al., Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J 
Med, 2005. 353(25): p. 2654-66.
44. Peng, J., et al., Oncological outcome of T1 rectal cancer undergoing standard resection and local 
excision. Colorectal Dis, 2011. 13(2): p. e14-9.
45. Peng, J., et al., Perineural invasion in pT3N0 rectal cancer: the incidence and its prognostic effect. 
Cancer, 2011. 117(7): p. 1415-21.
139
7
46. Peng, S.L., et al., Conventional adverse features do not predict response to adjuvant chemotherapy in 
stage II colon cancer. ANZ J Surg, 2013.
47. Poeschl, E.M., et al., Perineural invasion: correlation with aggressive phenotype and independent 
prognostic variable in both colon and rectum cancer. J Clin Oncol, 2010. 28(21): p. e358-60; author 
reply e361-2.
48. Rullier, A., et al., Impact of colloid response on survival after preoperative radiotherapy in locally 
advanced rectal carcinoma. Am J Surg Pathol, 2005. 29(5): p. 602-6.
49. Seefeld, P.H. and J.A. Bargen, The Spread of Carcinoma of the Rectum: Invasion of Lymphatics, Veins 
and Nerves. Ann Surg, 1943. 118(1): p. 76-90.
50. Shiozawa, J., et al., Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod 
Pathol, 2000. 13(9): p. 925-33.
51. Shirouzu, K., et al., Clinicopathologic study of perineural invasion in rectal cancer. Kurume Med J, 1992. 
39(1): p. 41-9.
52. Silberfein, E.J., et al., Long-term survival and recurrence outcomes following surgery for distal rectal 
cancer. Ann Surg Oncol, 2010. 17(11): p. 2863-9.
53. Sitzler, P.J., et al., Lymph node involvement and tumor depth in rectal cancers: an analysis of 805 
patients. Dis Colon Rectum, 1997. 40(12): p. 1472-6.
54. Stor, Z., et al., Prognostic value of clinical, pathological and immunohistochemical markers in stage II 
colon cancer patients. Acta Chir Iugosl, 2008. 55(3): p. 39-44.
55. Tanaka, M., et al., Tumor budding at the invasive margin can predict patients at high risk of recurrence 
after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum, 2003. 46(8): p. 1054-9.
56. Ting, W.C., et al., Common genetic variants in Wnt signaling pathway genes as potential prognostic 
biomarkers for colorectal cancer. PLoS One, 2013. 8(2): p. e56196.
57. Ueno, H., K. Hase, and H. Mochizuki, Criteria for extramural perineural invasion as a prognostic factor 
in rectal cancer. Br J Surg, 2001. 88(7): p. 994-1000.
58. Ueno, H., et al., Characterization of perineural invasion as a component of colorectal cancer staging. 
Am J Surg Pathol, 2013. 37(10): p. 1542-9.
59. Viana Lde, S., et al., Relationship between the expression of the extracellular matrix genes SPARC, SPP1, 
FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer 
dissemination. Oncology, 2013. 84(2): p. 81-91.
60. Weiser, M.R., et al., Individualized prediction of colon cancer recurrence using a nomogram. J Clin 
Oncol, 2008. 26(3): p. 380-5.
61. Wied, U., et al., Postoperative survival of patients with potentially curable cancer of the colon. Dis Colon 
Rectum, 1985. 28(5): p. 333-5.
62. Yun, H.R., et al., The prognostic factors of stage IV colorectal cancer and assessment of proper treatment 
according to the patient’s status. Int J Colorectal Dis, 2007. 22(11): p. 1301-10.
63. Matsushima, T., et al., Preoperative estimation of neural invasion in rectal carcinoma. Oncol Rep, 1998. 
5(1): p. 73-6.
64. Marchesi, F., et al., Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous 
system by cancer. J Neuroimmunol, 2010. 224(1-2): p. 39-44.
65. Fujita, S., et al., Cancer invasion to Auerbach’s plexus is an important prognostic factor in patients with 
pT3-pT4 colorectal cancer. Dis Colon Rectum, 2007. 50(11): p. 1860-6.
140
Chapter 7 – Perineural invasion is a strong prognostic factor
Supplementary table 1
Quality of Reporting yes(1)/no(0)/ 
not applicable (n.a.)
Specifies criteria for PNI positivity
Describes the number of slides examined for PNI
Describes the number of independent blinded scorers of PNI
Defines LR
Defines DFS
Defines OS
Defines CSS
Describes the end of follow-up period/date
Reports the median follow-up time
Mentions the hospital where the samples come from
Mentions the time frame of included samples
Describes sample selection (inclusion/exclusion criteria)
>90% of initial cases included in UV/MV analysis 
Mentions location (minimally rectum/colon)
Describes pre-operative treatment details
Lists freq of patients with T stage; N stage; M stage; perineural invasion
Reports the relation of PNI to standard prognostic variables
Reports the estimated effect for PNI on survival in UV analysis (RR, CI and p-value; freq in table)
Reports the estimated effect (HR, CI and p-value provided) for PNI on survival in MV analysis
Reports the estimated effects (HR, CI and p-values provided) of all other prognostic factors included in the 
MV analysis of point 19
Percentage of reported items total score/no. of 
applicable items*100
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Describes the number of slides examined for PNI 0 1 0 0 0 1 0 0 0 0 0 1 0 1 1 1 0 0 1 0 1 1 1 1 1 0 0 0 1 0 0
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Defines LR na 0 na na na 0 na 1 na na 1 na 1 na na 0 na 1 na na 0 0 1 na 1 1 1 na 1 na na
Defines DFS 1 na na na na na na 1 0 na na na na na 1 na na 1 na 1 na 1 1 0 0 na na 1 na 0 0
Defines OS na na 0 1 0 0 1 1 0 1 0 1 1 na 1 na 1 na 0 1 na 1 0 na 0 0 0 1 0 na 1
Defines CSS na 0 na na na na 1 na na na na 0 na 0 0 0 na 0 na na 1 na na 0 na na na na na 1 na
Describes the end of follow-up period/date 0 0 0 0 0 1 1 0 0 1 0 1 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 1 0 0 0
Reports the median follow-up time 1 1 1 1 0 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1
Mentions the hospital of included samples 1 1 1 0 0 0 1 0 1 1 1 1 1 0 1 1 1 0 1 1 1 1 1 1 0 1 1 1 1 1 0
Mentions the time frame of included samples 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1
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Mentions location (minimally rectum/colon) 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 0 1 1 1
Describes pre-operative treatment details 1 1 0 1 0 1 0 1 na 1 1 0 1 na 1 na 1 1 1 na 0 0 1 0 1 0 1 0 1 1 0
Lists freq of patients with T,N,M-stage and PNI 1 1 0 1 0 1 1 1 1 0 1 0 0 0 1 1 0 1 0 1 1 1 na 1 1 0 0 0 1 1 0
Reports relation of PNI to standard prognostic variables 1 1 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 1 0 1 0 0 1 1 0
Reports effect for PNI in UV analysis (RR/CI/p-value; freq in 
table)
0 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 0 0 1 0 1 1 1 1 1 1 1 1 1 1 1
Reports effect for PNI in MV analysis (HR/CI/p-value) 0 1 1 1 0 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 0 0 1 1 1 1 1
Reports effects for all other prognostic variables included in 
the MV analysis.
0 1 1 0 0 0 1 1 1 0 0 0 0 0 1 1 1 1 0 0 1 1 0 1 0 0 1 1 0 0 0
Percentage of reported items
(=total score/no of applicable items*100)
58.8 83.3 47.1 58.8 17.7 50.0 72.2 68.4 58.8 64.7 61.1 58.8 61.1 50.0 84.2 76.5 58.8 52.6 64.7 64.7 72.2 73.7 83.3 61.1 47.3 50.0 61.1 61.1 83.3 72.2 38.9
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Abstract 
Extramural venous invasion (EMVI) is a well-known prognostic factor in colorectal 
cancer (CRC). Vascular invasion within the bowel wall, intramural vascular invasion 
(IMVI), has received less attention and its incidence and prognostic importance in 
CRC is not completely known. 
A systematic literature search was performed focusing on the impact of IMVI in CRC. 
Data were analysed using Review Manager 5.3 on incidence and clinical endpoints 
local recurrence, five year cancer specific survival (CSS) and five year overall survival 
(OS). Meta-analysis was performed in terms of risk ratios (RR) and hazard ratios (HR) 
with 95% confidence interval (95%CI). 
Of the initial 1199 articles identified by our search strategy, 20 were included in this 
meta-analysis. Of the 8078 included patients, 1008 patients had IMVI (12.5%). Studies 
that re-examined histological slides showed a higher incidence of IMVI compared to 
studies extracting IMVI from pathology reports (17.6% vs. 7.7%, p<0.001). Detection 
of IMVI increased significantly with the use of additional staining (22.9% vs. 12.3%, 
p<0.001). IMVI was associated with a decreased CSS (HR 1.6, 95%CI 1.2-2.2 in 
multivariate analysis). A borderline significant effect was observed for IMVI on local 
recurrence (RR 1.5, 95%CI 0.98-2.3) and OS (RR 1.2, 95%CI 1.0-1.4).
In conclusion, despite the limited number of studies, there is a clear association with 
outcome in the presence of IMVI. This warrants more attention to this underreported 
prognostic factor. 
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Introduction
The presence of tumour cells in veins outside the bowel wall, extramural venous 
invasion (EMVI), is a well-known prognostic factor in colorectal cancer (CRC). In fact, 
in stage II patients, EMVI is one of the indications for adjuvant chemotherapy.1 Its 
strong association with the development of particularly liver metastases2 seems 
to justify this decision. EMVI is therefore a mandatory item in many guidelines and 
datasets for reporting CRC. The Royal College of Pathologists has set a standard 
detection rate for EMVI at 25% and a minimum of four tumour blocks per specimen 
is advised for optimal determination of its presence.3 Vascular invasion within the 
bowel wall, intramural vascular invasion (IMVI), has received less attention and its 
prognostic importance in CRC is not entirely clear. 
 There is a wide variation in reported frequencies of IMVI in CRC, ranging from 
8% to 39%.4, 5 Analogous to EMVI, this variation might be explained by differences 
in pathological assessment.6, 7 The incidence of vascular invasion increases with the 
number of tumour blocks analysed and with the use of additional elastic stains.8-10 
 Some studies demonstrated an association between IMVI and development of 
distant metastases,10, 11 suggesting that the presence of venous invasion may be more 
important than its location in the bowel wall. 
 To investigate the impact of IMVI in CRC, we systematically reviewed the frequency 
and impact of IMVI in CRC. The prognostic endpoints are local recurrence, five year 
overall survival (5yOS) and five year cancer specific survival (5yCSS).
Materials and methods
Search strategy and selection
A comprehensive literature search was performed using the PubMed database from 
inception to 1 January 2016, using the following keywords: “Colorectal Neoplasms”[Mesh] 
or “colorectal”[Title/Abstract] or “colon”[Title/Abstract] or “rectum”[Title/Abstract] or 
“rectal”[Title/Abstract] and “cancer”[Title/Abstract] or “carcinomas”[Title/Abstract] or 
“neoplasms”[Title/Abstract] or “tumors”[Title/Abstract] and “vascular”[Text Word] or 
“venous”[Text Word] or “veins”[Text Word] or “vessels”[Text Word] and “invasion”[Text 
Word] or “spread”[Text Word] and “prognosis”[Text Word] or “prognostic”[Text Word] or 
“survival”[Text Word] or “predict”[Text Word]. Additional searches were performed by 
manual cross-referencing.
 Two independent investigators (NK,UvE) reviewed each report for eligibility. Only 
articles that were published in English were selected. Studies with and without 
neoadjuvant treatment were included. In case of overlapping patient data, as a 
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consequence of subsequent publication of updated series, results of the largest 
study or the study with longest follow-up were included in this meta-analysis.
Data extraction
Data on tumour stage, histologic factors, method of IMVI detection, incidence of 
IMVI and EMVI were extracted. Data on prognostic factors, local recurrence, 5yOS 
and 5yCSS from univariate and multivariate analyses were collected and entered in 
Review Manager Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2012. Analyses were performed with a minimum of two studies for 
each endpoint. In case multiple studies used different point estimates (e.g. risk ratio 
(RR) or hazard ratio (HR)) on the same survival endpoint, the point estimate used in 
the largest number of articles was included in our meta-analysis.
Quality assessment and risk of bias
A scale to assess the quality of the reporting of the included articles was developed, 
based on the REMARK guidelines, specifically looking at reporting of IMVI.12, 13 Only 
studies with data on outcome were subjected to quality assessment. Scoring was 
performed by two independent investigators (NK,UvE). In case of disagreement, 
a consensus score was agreed after discussion. The association between quality 
of reporting and the RR/HR was analysed with scatter plots and non-parametric 
correlation testing. Publication bias was assessed through visual inspection of 
symmetry of funnel plots.
Statistical analysis
A meta-analysis was performed with all available studies on each endpoint, in terms 
of RR/HR with 95%CI. If no HR was reported, it was calculated from Kaplan-Meier 
curves.14 Univariate and multivariate analyses were subdivided. A random effects 
model with inverse variance weighting of studies was used. Heterogeneity was 
assessed using a χ2 test, with a p-value of <0.10 to show the presence of significant 
heterogeneity. In case of heterogeneity, sub-analyses were performed to identify the 
potential source of heterogeneity.
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Results 
Search results
A total of 1199 potentially relevant articles were retrieved by the database search. 1181 
articles were excluded because they did not meet inclusion criteria (Figure 1). Manual 
cross-referencing resulted in two additional articles. The remaining 20 articles, 
comprising 8078 patients, were included in the meta-analysis.4, 5, 8, 9, 11, 15-28
Figure 1: Flow chart of search strategy. Abbreviations: IMVI: intramural vascular invasion, CRC: 
colorectal carcinoma, *lymphatic and vascular invasion were grouped together or vascular invasion 
was not subdivided into intramural or extramural vascular invasion.
Seven studies investigated IMVI in rectal cancer (2342 patients), two in colon cancer 
(562 patients) and in 11 rectal and colon carcinomas were grouped together (5174 
patients). The main characteristics are shown in table 1. The mean number of patients 
per study included in our meta-analysis was 404 (range 34-3040).
Quality of reporting of the included articles
Studies with outcome data (n=9) were subjected to quality assessment, focused 
on the quality of reporting of IMVI.4, 11, 15, 17, 18, 24-27 The mean percentage of reported 
relevant parameters of the included studies was 63.5% (range 38.9-88.9%). Two 
studies reported less than 50% of required items, four studies reported 50-75% of 
required items and three studies reported >75% of items.
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Frequency of IMVI and association with other prognostic factors
The overall published incidence of IMVI was 12.5% (table 1). The percentage 
of IMVI was significantly higher in studies that re-examined pathologic slides 
(16 studies; 3899 patients) versus studies that extracted IMVI from pathology 
reports (4 studies; 4179 patients) (17.6% vs. 7.7%, p<0.001). In the studies that 
re-examined pathologic slides, the use of additional staining (9 studies; 1959 
patients) increased detection even more compared to routine Haematoxilyn 
and Eosin (HE) (7 studies; 1940 patients) (22.9% vs. 12.3%, p<0.001). Only one 
article15 directly compared HE- and Elastina von Gieson (EvG) staining: IMVI was 
detected in 3.2% of the HE stained slides and in 14.1% of the EvG stained slides. 
The frequency of IMVI also increased with TNM stage. A low incidence was 
detected in patients with stage I disease (6.0%, total 684 cases). Higher 
incidences were found in CRC stage II, III and IV (11.6%, total cases 2182, 
14.3%, total cases 1339 and 19.6%, total cases 689, respectively, (p<0.001)). 
19 studies (7653 patients) provided data on both IMVI and EMVI, the overall incidence 
of EMVI was 24.3% in those studies, compared to 11.7% of IMVI. Eight of these 
publications (4151 patients)4, 5, 8, 10, 11, 16, 21, 22 subdivided the incidence of vascular 
invasion in three groups; IMVI-only, EMVI-only, both IMVI and EMVI. IMVI-only was 
detected in 7.1%, EMVI-only in 15.3%, both IMVI and EMVI in 5.1% of patients. 
Effect of IMVI on local recurrence
Data on the impact of IMVI on local recurrence in univariable analysis could be 
extracted from two articles, which included 503 patients.17, 25 The presence of IMVI 
was not significantly associated with local recurrence (RR 1.5, 95%CI 0.98-2.3, p=0.06) 
(Figure 2A). No heterogeneity was observed (χ2=0.46, df=1 (p=0.50); I2=0%). Both 
studies showed comparable RR and no heterogeneity, therefore subgroup analysis 
was not performed. Dresen et al.17 provided data on multivariate analysis, confirming 
the lack of association between IMVI and local recurrence (OR 1.9, 95%CI 0.7-5.1).
Effect of IMVI on overall survival
Data on the impact of IMVI on 5yOS in univariable analysis could be extracted from five 
studies, which included 2117 patients.4, 15, 18, 25, 26 The 5yOS decreased in the presence 
of IMVI (RR 1.2, 95%CI 1.0-1.4, p=0.02) (Figure 2B). Some heterogeneity was observed 
(χ2=11.87, df=6 (p=0.07); I2=49%), which could not be explained by differences in 
sample size, timeframe and TNM stage. Despite the observed heterogeneity, the 
direction of the effect in the forest plots was rather consistent. There was no asymmetry 
in funnel plot. The percentage of items reported in the individual studies varied from 
38.9% to 84.2%, and did not correlate with the magnitude of RR (Spearman r=-0.60, 
p=0.35). The studies in which IMVI was extracted from pathology reports4, 18 showed 
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similar RR compared to those with specific review for IMVI15, 25, 26 (RR 1.3, 95%CI 0.98-
1.7 and RR 1.2, 95%CI 0.98-1.4, respectively).
Table 1: Main characteristics of 20 included studies with data on IMVI. 
Author Location Stage Method of 
IMVI 
detection 
Staining used No. obser-
vers 
Used for 
outcome 
No. pts % IMVI 
Baumhoer15 Colorectal I-II Revision HE, Elastic stain nm 5yOS UV 185 14.1% 
Betge11 Colorectal I-IV Revision HE 2 5yCSS UV+MV 381 8.7% 
Cavdar16 Rectum I-IV Extraction from 
PA reports
- - - 34 14.7% 
Dresen17 Rectum I-III Revision HE 2 LR UV+MV 277 10.1% 
Freedman18 Rectum I-III Extraction from 
PA reports
- - 5yOS UV 673 6.7% 
Gibson4 Colorectal I-IV Extraction from 
PA reports
- - 5yOS UV+MV, 
5yCSS UV+MV 
3040 7.5% 
Hayes19 Colorectal I-III Revision HE 1 - 179 14.0% 
Howlett8 Colorectal I-IV Revision HE, Elastic stain 3 - 92 27.2% 
Inoue9 Colorectal I-III Revision HE, Elastic stain 2 - 94 20.2% 
Krasna20 Colorectal I-III Revision HE 2 - 77 3.9% 
Minsky21 Colon I-III Revision HE, Elastic stain 1 - 294 32.3% 
Minsky5 Rectum I-III Revision HE, Elastic stain 1 - 168 38.7% 
Ouchi22 Colorectal III-IV Revision HE, Elastic stain nm - 61 29.5% 
Petersen28 Colon II Revision HE 1 - 268 9.0%
Prabhudesai23 Rectum I-IV Revision HE 2 - 55 25.5% 
Roxburgh24 Colorectal I-III Revision HE, Elastic stain 2 5yCSS UV 559 10.6% 
Shirouzu25 Colorectal II-III Revision HE, Elastic stain 1 5yOS UV, LR UV 425 25.9% 
Sternberg10 Colorectal IV Revision HE, Elastic stain 2 - 81 38.3% 
Talbot26 Rectum II Revision HE nm 5yOS UV 703 15.8% 
Tilney27 Rectum I-III Extraction from 
PA reports
- - 5yCSS UV+MV 432 10.0% 
Abbreviations: IMVI: intramural vascular invasion; no: number of; pts: patients; nm: not mentioned; 
HE: Haematoxylin and Eosin; LR: local recurrence; 5yCSS: 5 year cancer specific survival; 5yOS: 5 year 
overall survival; UV: univariate; MV: multivariate.
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Two articles analysed stage-dependent 5yOS.4, 25 Shirouzu et al.25 found no effect of 
IMVI in stage II, nor in stage III patients. In contrast, Gibson et al.4 found a significant 
effect of IMVI on 5yOS in stage III and IV patients, but not in stage II patients. 
 Gibson et al.4 provided data on multivariate analysis, showing IMVI to be an 
independent prognostic factor in stage III CRC (HR 1.5, 95%CI 1.1-2.2, p=0.02). Other 
independent prognostic factors reported in stage III CRC were EMVI (HR 1.5, 95%CI 
1.2-1.8), age≥75 (HR 2.0, 95%CI 1.6-2.4), male sex (HR 1.3, 95%CI 1.1-1.6), T3 tumours 
(HR 1.3, 95%CI 1.1-1.7), T4 tumours (combined HR 1.6, 95%CI 1.2-2.1), apical node 
involvement (HR 1.7, 95%CI 1.3-2.3), ≥30% of nodes involved (combined HR 1.5, 
95%CI 1.3-1.8), high grade (HR 1.3, 95%CI 1.1-1.6), postoperative chemotherapy (HR 
0.7, 95%CI 0.5-0.9) and year of resection (HR 0.98. 95%CI 0.96-0.99). In stage IV CRC, 
IMVI was not independently associated with OS (HR 1.4, 95%CI 0.9-2.3, p=0.14).
Effect of IMVI on cancer specific survival
The impact of IMVI on 5yCSS in univariate analysis could be extracted from four articles, 
which included 1620 patients.4, 11, 24, 27 The presence of IMVI is associated with worse 
5yCSS (HR 2.0, 95%CI 1.4-3.0, p<0.001) (Figure 2C). Some heterogeneity was observed 
(χ2=6.69, df=3 (p=0.08); I2=55%), which could not be explained by differences in sample 
size, timeframe and TNM stage. Despite the observed heterogeneity, the direction 
of the effect in the forest plots was rather consistent. There was no asymmetry in 
funnel plot. With respect to quality of the included publications, percentage of items 
reported ranged from 57.9% to 88.9%. This did not correlate with the magnitude of 
HR (Spearman r=-0.21, p=0.92). Articles in which IMVI was extracted from pathology 
reports4, 27 showed a lower HR compared to studies with specific review for IMVI11, 24 
(HR 1.6, 95%CI 1.2-2.0 and HR 3.3, 95%CI 2.0-5.5, respectively).
 Multivariate analysis was performed in three studies comprising 1283 patients, 
confirming a decreased 5yCSS in the presence of IMVI (HR 1.6, 95%CI 1.2-2.2, 
p<0.001) (Figure 2D).4, 11, 27 No heterogeneity was observed (χ2=0.16, df=2 (p=0.92); 
I2=0%), there was no asymmetry in funnel plot. The percentage of items reported 
varied from 57.9% to 88.9% and this did not correlate with the magnitude of HR 
(Spearman r=0.50, p=1.00). Articles in which IMVI was extracted from pathology 
reports4, 27 showed similar HR compared to the study with specific review for IMVI11 
(HR 1.6, 95%CI 1.1-2.3 and HR 1.8, 95%CI 0.7-4.2, respectively).
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Figure 2: The impact of IMVI on outcome in univariate and multivariate analysis. 
A) Impact of IMVI on LR, UV analysis. B) Impact of IMVI on 5yOS, UV analysis. C) Impact of IMVI 
on 5yCSS, UV analysis. D) Impact of IMVI on 5yCSS, MV analysis. Abbreviations: IMVI: intramural 
vascular invasion; IV: inverse variance; RR: risk ratio; HR: hazard ratio; CI: confidence interval; LR: local 
recurrence; 5yCSS: 5 year cancer specific survival; 5yOS: 5 year overall survival.
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Other independent prognostic factors for 5yCSS in multivariate analysis reported in 
all three studies  were T-stage and EMVI. T-stage T3/T4 showed a combined HR of 3.2 
(95%CI 1.4-7.3). EMVI showed a combined HR of 1.7 (95%CI 1.4-2.1). Tumour grade 
was reported in two studies and provided a combined HR of 1.5 (95%CI 1.2-1.8).4, 11
Comparison with EMVI
Six articles4, 11, 15, 24, 25, 27 included in our meta-analysis compared the effect of IMVI 
with EMVI on survival. Four studies4, 11, 24, 27 reported on the impact of EMVI on 
5yCSS in univariate analysis, showing worse survival in the presence of EMVI (HR 
3.6, 95%CI 2.4-5.5). Three studies4, 11, 27 provided data on the impact of EMVI on 
5yCSS in multivariate analysis, showing worse outcome (HR 1.7, 95%CI 1.4-2.1). 
These HR are not statistically different from the HR of IMVI in the same studies 
(univariate analysis HR 2.0, 95%CI 1.4-3.0, multivariate analysis HR 1.6, 95%CI 1.1-2.2). 
Baumhoer et al.15 also detected no significant differences in 5yOS of patients with 
IMVI or EMVI (62% vs. 74%, p=0.473). Shirouzu et al.25 analysed three different 
subcategories of vascular invasion; IMVI-only, IMVI more prominent than EMVI 
and EMVI more prominent than IMVI. In stage II CRC the survival rates were not 
significantly different for IMVI-only, IMVI more prominent than EMVI and EMVI more 
prominent than IMVI (85.8%, 87.3% and 82.9%, respectively). In stage III CRC survival 
of patients with EMVI more prominent than IMVI was significantly worse compared 
to patients with IMVI-only and IMVI more prominent than EMVI (45% vs. 84.9% and 
73.3%, p<0.005 and p<0.001, respectively).
Discussion
In the current meta-analysis we have shown that IMVI, with an overall published 
incidence of 12.5%, is a prognostic factor in CRC. Despite its prognostic importance, 
IMVI is currently underreported: specific revision aimed on the detection of IMVI 
showed an increase of 10% compared to standard diagnostic evaluation in published 
studies. 
 Ideally, potential new histological markers should be compared to established 
biomarkers to interpret their additional value. Unfortunately, in this meta-analysis it 
was not possible to compare IMVI to other risk factors in CRC. Each individual study 
included different prognostic factors, such as age, lymph node metastases, tumour 
location or circumferential resection margin in their multivariate analysis.4, 11, 27 Only 
EMVI and T-stage were included in multiple studies, showing similar HR for EMVI and a 
higher HR for T-stage, compared to IMVI. It would be interesting to compare potential 
histological risk factors to other well-known risk factors in CRC, but therefore uniform 
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definitions are needed. Furthermore, ideally all risk factors should be included in 
outcome analysis per study. 
 Differences in studies reporting oncologic outcomes hampered our investigation. 
In some studies local and distant recurrences were reported together, and different 
outcome measurements were used, decreasing the number of studies that could 
be analysed. Due to the limited number of studies included in this meta-analysis, 
interesting subgroup analyses could not be performed. For example, it would be 
good to know whether the increased detection of IMVI due to additional elastic 
staining also results in an improved prognostic power. In the literature, there are 
many studies that were potentially interesting, but did not report IMVI separately 
from either EMVI or lymphatic invasion. This was the main point of exclusion in our 
current study, accounting for 717 exclusions.
 The articles included in our meta-analysis showed a detection rate of EMVI of 
24.3%, nearly twice the detection rate of IMVI. A comparable percentage of EMVI 
prevalence was found in a recent meta-analysis (26%).29 Six articles in our meta-
analysis directly compared the impact of IMVI with EMVI and at least four studies 
showed no significant difference in prognostic impact. This supports the AJCC/UICC 
TNM classification and the current Japanese guidelines, where IMVI and EMVI are 
not separated.30, 31 However, a large study32 including 2405 patients, showed a HR of 
2.8, (95%CI 2.1-3.8) on overall survival in multivariate analysis, which seems higher 
than the HR of IMVI found in our meta-analysis. A recent meta-analysis29 also linked 
EMVI to worse oncological outcome in rectal cancer with a pooled overall survival of 
39.5% (95%CI 0.29-0.51). In that particular meta-analysis all studies were published 
between 1943 and 1988, which explains the poor survival outcome and limits its 
current relevance. 
 In conclusion, despite the limited number of studies, our meta-analysis clearly 
shows decreased outcomes in the presence of IMVI. A direct comparison of IMVI with 
EMVI showed no significant difference in prognostic impact, supporting the idea 
that the presence of vascular invasion is more important than its exact location. 
Since its relevance to better clinical outcome, more attention to this underreported 
prognostic factor seems justified. 
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Background
Most published histopathology studies (describing histological characteristics of 
existing or new entities, existing or new markers detected by immunohistochemistry, 
in situ hybridization or molecular methods in tumor material often in relation to patient 
outcome) are retrospective and use tissue samples from a single center only. This 
limits the quality of the evidence provided in such a paper. A higher level of evidence, 
such as would be required to justify implementation in daily clinical practice, can be 
reached for tissue-based biomarkers by systematic review of published studies and 
meta-analysis of the provided data.
 In such meta-analyses only research data of sufficient quality should be used. 
Universally accepted criteria for the assessment of data quality do not exist. However, 
an essential element would be reporting at a sufficient level of detail of the key 
components that make up the body of evidence presented in any particular paper. 
This would also facilitate repetition of the experiments performed and of the relevant 
observations, an essential step as reproducibility is an absolute prerequisite for 
validation of tissue biomarkers prior to their implementation in clinical practice.
 For in situ hybridization and immunohistochemistry biomarkers the Minimum 
Information Specification for in situ hybridization and immunohistochemistry 
experiments (MISFISHIE) guidelines have been developed to ensure that a report 
contains sufficient detail of the assay used.[1] MISFISHIE guidelines identify six 
types of information to be provided for each experiment: experimental design, 
biomaterials (biospecimens used) and treatments (preanalytical conditions such as 
fixation and embedding), reporters (antibodies and probes), staining (fluorescence or 
chromogenic), imaging data (how images were obtained) and image characterization 
(how information was extracted from the images, including quantification of relevant 
image elements). However, they do not focus on statistics (correlation of image 
derived information with clinical data) or interpretation of the results, which are 
essential elements of a scientific paper.
 To improve possibilities to compare results across studies involving molecular 
prognostic biomarkers, the Reporting Recommendations for Tumor Marker Prognostic 
Studies (REMARK) guidelines have been developed. These are intended to facilitate 
evaluation of the appropriateness and quality of study design, used methods, 
approaches applied to data analysis and presentation of the results.[2] The REMARK 
guidelines can also be used for reporting of biomarker studies that are not strictly 
molecular, such as those reporting retrospective histopathological observations, 
although some items on the checklist will then be less applicable. Notably, building 
of prognostic models, checking model assumptions, model validation and internal 
validation might not be feasible. 
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In view of a perceived need for better standardization of retrospective histopathology 
studies, we have used the REMARK guidelines as a blueprint for the development of 
basic rules for their reporting.[3] In analogy with REMARK guidelines, we propose a 
checklist of 20 items, grouped according to the generally used headings in a research 
paper: Introduction, Material and Methods, Results, and Discussion. We have put 
these together in a table and will discuss each of them briefly. The intention of our 
commentary is to increase awareness of the need for more standardization and to 
stimulate discussion, in order to get to a generally accepted approach to standardized 
reporting of histopathological studies (table 1).
Table: Proposed items for reporting histopathology studies 
 
Introduction
States the FOI, the study objectives and hypotheses
Material and Methods
Describes patient characteristics, inclusion and exclusion criteria
Describes (neoadjuvant) treatment details
Describes type of material used and number of slides examined
Specifies criteria for the FOI
Describes the number of independent (blinded) scorers
States the method of case selection, study design, hospital and time period
Describes the end of follow-up period and median follow up time
Defines all clinical end points examined
Specifies all statistical methods
Describes how associations with other clinical/pathological factors were analyzed
Results
Describes the number of patients included in the analysis and reason for drop-out
Reports patient/tumor characteristics (including FOI) with number of missing values
Describes the relation of the FOI to standard prognostic variables
>90% of initial cases included in UV/MV analysis
Reports the estimated effect (RR/OR, CI and p-value provided) in UV analysis
Reports the estimated effect (HR, CI and p-value provided) in MV analysis
Reports the estimated effects (HR, CI and p-values provided) of other prognostic factors included in MV analysis
Discussion
Interprets the results in context of the prespecified hypotheses and other relevant studies; include a discussion of limitations of the 
study. 
Discusses implications for future research and clinical value
Legend: FOI: factor of interest, RR: relative risk, OR: odds ratio, CI: confidence interval, HR: hazard ratio; 
UV: Univariate; MV: multivariate
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The checklist
1.  State the marker of interest, study objectives and working hypotheses. 
In order to understand the rationale (why this particular marker) and potential clinical 
applications (what is needed for this particular condition) a description of the marker 
of interest, study objectives and a working hypotheses are necessary. Describe what 
is known on the biology of the marker, methods to detect and quantify the marker 
and why the marker might be of clinical interest. A working hypothesis should be 
formulated as a rule in terms that can be tested statistically. 
2.  Describe patient characteristics, inclusion and exclusion criteria.
Describe the clinical context of the study. Describe why a particular cohort of patients 
was selected and the criteria used to define the cohort, which includes inclusion and 
exclusion criteria. Describe clinical details of the cohort in relation to potential use of 
the marker of interest. As an example, when the working hypothesis is that a marker 
might have a different prognostic value in different stages of disease, disease stage is 
an essential element in the description of patient data. 
3. Describe treatment details.
Treatment (neoadjuvant, adjuvant, first line, second line etc.) is intended to alter the 
disease course of a patient. Different treatment modalities might not be distributed 
equally between groups with or without the biomarker, and this will become an 
important confounding factor when correlation between outcome and marker 
expression is looked for. Moreover treatment might also have an influence on marker 
expression if the patient was treated prior to the moment the sample was taken, which 
will be a confounding factor in the analysis of the impact of the biomarker. When 
treatment information is missing this should be specifically stated and in studies on 
marker expression in relation to treatment response such patients should be excluded.
4. Describe type of material used.
Tissue samples used in retrospective studies are often convenience collections, 
which potentially run a serious risk of collection bias.[4] Authors should report 
why and how the specimens were collected and how the specimen was handled 
(primary tumor site or metastatic lesion, biopsy or resection formalin fixed paraffin-
embedded or frozen tumor tissue). Where possible, data on pre-analytical handling 
of specimens should also be given, in order to clarify potential confounding effects 
associated with sample condition.[5] When control samples are used, their origin 
should be stated as well as how they were selected. Control samples should fit into 
the experimental design based upon the working hypothesis, to avoid problems of 
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unexpected differences between control and patient samples. Authors should report 
methodological variables as much as possible according to MISFISHIE guidelines1). 
5. Specify how expression of the biomarker was assessed.
A detailed description of the criteria for assessment of the presence or absence of 
the biomarker at tissue level allows evaluation of potential shortcomings but also 
will enable future researchers to reproduce the study. Some retrospective studies on 
classical pathological markers tend to extract data from pathology reports, instead 
of rereading the slides or repeating marker expression analysis for the purpose of 
the investigation. This runs a risk of heterogeneity between method runs or methods 
applied and problems of lack of inter-individual reproducibility in reading the results. 
This can lead to over- or underestimation of the number of patients expressing a 
certain marker and might introduce selection bias.6 For purely morphological (gross or 
microscopical) markers details of specimen examination, number of slides investigated 
and criteria when a marker was called positive or negative should be provided. 
6.  Describe the number of independent (blinded) scorers and how they 
scored
Visual assessment of a biomarker is an important source of variance.[5] Interpretation 
varies between pathologists and biomarker data will be more robust if expression of 
a biomarker is scored by multiple independent observers unaware of (blinded to) the 
clinical parameter of interest (such as outcome). Justification of the chosen method 
of and criteria for (semi-) quantitative assessment should be provided in detail.
7.  State the method of case selection, study design, origin of the cases 
and time-frame.
Important determinants of the reliability of study results are study design and 
method of patient selection. Selection of cases according to clinical or pathological 
parameters (for example patients selected according to age, only T4 or N0 tumors) 
may introduce bias; therefore details of case selection should be reported. Stating 
where the patients came from might provide relevant information regarding the 
patient population (for example a patient population from a tertiary referral hospital 
might differ significantly from that of a primary care centre). The time-frame (when 
cases were recruited or diagnosis was made) should also be mentioned, because 
therapies change over time which might affect outcome. 
8. State the end of follow-up period and median follow up time.
In many studies outcome is the time to an event (e.g. recurrence, death), and follow-
up should be long enough to make sure that events can happen. If for example a 
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biomarker is associated with the risk of dissemination, follow-up should be long 
enough to allow this effect to be observed. Follow-up usually ends at a specific point 
in time (notably this date and the median follow-up time should be stated).   
9. Define all clinical endpoints examined.
In histopathology studies common endpoints include death and discovery of 
recurrence. Endpoints used in survival analysis are not always clearly defined. Analysis 
of time to death might include deaths from any cause or cancer specific deaths. A 
clear distinction should be made between overall survival, disease specific survival 
and recurrence free survival. Definition of parameters defining recurrence of disease 
should be clear. Recurrence might include local recurrence or distant metastasis or 
both. Local recurrence and distant metastases are two biologically different events 
and the effect of a biomarker on each of these might be different. Lack of clearly 
defined endpoints may lead to misinterpretation of its association with a biomarker 
and preclude inclusion of a publication in a meta-analysis.
10. Specify all applied statistical methods.
If the statistical methods used in a biomarker study are not clearly specified, it will 
be difficult or impossible for the reader to interpret the results or reproduce and 
validate the findings. Rather often the amount of detail provided in publications is 
marginal. Mathoulin-Pelissier et al. concluded that 68% of the articles published in 
major journals reported insufficient information regarding the survival analysis.7 
11.  Describe how interactions with other clinical/pathological variables 
were analyzed.
Any seemingly interesting biomarker might interact with established clinical or 
pathological factors. Methods used to assess potential interactions with other 
variables should be described. The interactions are essential to evaluate whether 
or not found associations have independent value. All included variables should be 
clearly defined and the choice of variables included in the study has to be justified 
(why variables included in the study were retained while others were left out).
12.  Describe the number of patients included in the analysis and reasons 
for drop-out.
In retrospective biomarker studies the number of cases included in analysis is often 
lower than the initial number of cases included in the study. This is mainly due to 
missing values, such as impossibility to (re-) evaluate staining results or missing 
outcome data. A solution often chosen is to restrict the analyses to samples with 
complete data. However, this may introduce selection bias when samples with 
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missing data are not typical for the whole study population. It is therefore necessary 
to state the number of patients and events included in each analysis. Only with this 
information it is possible to assess the reliability of reported findings. 
13.  Report patient/disease characteristics (including the biomarker of 
interest) with number of missing values.
A detailed description of patient characteristics and relevant histopathological 
parameters is needed to assess whether or not the patient cohort included in the study 
is representative for the condition under scrutiny. Obvious patient characteristics are 
age and gender but parameters such as ethnicity, performance status or medical 
history might be relevant. In case of cancer, characteristics of the lesion should 
include parameters defining TNM stage.
14.  Describe the interaction of the factor of interest with established 
prognostic variables
As stated in point 11, a new biomarker is only useful if its effect is maintained 
when interaction with other prognostic factors is ruled out, or if its assessment is 
(quantitatively or qualitatively) superior in comparison with established prognostic 
variables. For evaluation of clinical value, the potential interactions between a new 
biomarker and established prognostic variables should therefore be reported. 
15.  Included at least 90% of initial cases in univariate and multivariate 
analysis
As mentioned above, due to missing values the number of cases included in statistical 
analysis is often lower than the initial number of cases included in the study. The 
risk of attrition bias will increase along with the proportion of cases not included in 
statistical analysis[6] To minimize attrition bias, Smith et al. proposed that at least 90% 
of the selected cohort should be included in statistical analysis.[8] Sub-analyses should 
be avoided because of the high risk of false positive findings due to increasingly small 
patient numbers. 
16.  Report the estimated effect (relative risk/odds ratio, confidence 
interval and p-value provided) of the biomarker in univariate analysis
Establishing a biomarker’s potential association with clinical outcome is the key 
subject in biomarker research. In univariate analysis the relationship between the 
biomarker and outcome can be assessed without adjustment for additional variables. 
Relative risks or odds ratios with their associated confidence intervals and p-values 
should be given, regardless of statistical significance. Kaplan-Meier curves should be 
included when illustrative, but p-values from log rank tests should be given regardless 
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of statistical significance. Univariate analysis should also be performed for all other 
variables and presented in a summarizing table.
17.  Report the estimated effect (hazard ratio, confidence interval and 
p-value provided) of the biomarker in multivariate analysis.
In multivariate analysis the association between a biomarker and clinical outcome 
can be established, correcting for established prognostic variables. Authors should 
report which prognostic variables were included in multivariate analysis. As a rule, 
significant factors identified in univariate analysis should all be included. Hazard 
ratios with associated confidence intervals and p-values should be given, regardless 
of statistical significance.
18.  Report estimated effects (hazard ratio, confidence interval 
and p-values provided) of other prognostic factors included in 
multivariate analysis.
Within a study significant findings are more likely to be reported than non-significant 
findings. In order to prevent selective reporting bias, authors should report the 
effects of all prognostic factors included in the multivariable analysis; not only the 
marker of interest or the significant findings. 
19.  Interpret the results in the context of the working hypothesis 
elaborated in the introduction and other relevant studies; include a 
discussion of limitations of the study.
Authors should critically evaluate their findings, mentioning limitations of the study 
and possible biases. A good discussion will allow the reader to retain a balanced 
perception of the importance of the results of the study. 
20.  Discuss potential clinical applications and implications for future 
research.
The intention of biomarker studies is to develop new disease associated parameters 
of which the contribution to clinical decision making reaches beyond that of existing 
parameters included in standard of care. A statistically significant association between 
a marker and disease outcome might seem promising, but authors should mention in 
the discussion which steps will be taken in order to eventually reach implementation 
of the marker in patient care.
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Conclusion
Adherence to guidelines on reporting, whenever possible, should facilitate a clear 
perception by the reader of the inherent qualities of the reported study and we 
presume that it might also have a positive effect on study quality, for as much as 
the checkpoints we propose are already used when the study is planned. The 20 
checkpoints we propose speak for themselves. We paid no attention to sample size 
calculations, because most histopathological studies are retrospective and based 
upon convenience case collections that were not set up to answer specific questions 
well defined before the collection was started. Checking model assumptions, 
standardized model making and model validation is unusual in histopathology 
research but might become more main-stream when this is more often performed 
in the context of clinical trials. For a biomarker identified in a retrospective study 
we consider external validation by independent groups on separate patient cohorts 
of much greater value than internal validation. Our checkpoints might be of help 
for investigators who study tissue-based biomarkers, reviewers of manuscripts 
and researchers performing meta-analyses. They should ultimately support quality 
improvement of histopathological studies and implementation of new findings into 
daily practice. We welcome feedback from the scientific community to improve on 
and facilitate implementation of our list of checkpoints.
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Introduction
There have been major efforts to apply our ever expanding knowledge of molecular 
and cellular processes in colorectal cancer to gain insights into the metastatic 
process, however predicting which patient will develop metastases remains difficult. 
Thus, treatment decisions in colorectal cancer are generally based on TNM staging. 
With the increased resolution of imaging techniques in combination with high 
quality pathology, we can try to take the next step in colorectal cancer staging 
and appreciate the anatomical “highways” resulting in more accurate prediction of 
patient outcome, and critically re-appraise the traditional “lymph node–oriented” 
way of treatment decision making.
 Although the TNM system[1] is currently the best tool for predicting prognosis, some 
issues need to be addressed.[2, 3] The main driver for prognosis is the presence/absence 
of regional lymph node metastases (LNM), but overlap between stage II and stage III 
patients (i.e. stage IIb patients perform worse than stage IIIa patients)[4] suggests that the 
importance of LNM is limited. Moreover, the presence of venous and lymphatic invasion 
(LI), perineural invasion (PNI) and extranodal tumor deposits (TD) are not separately 
classified in the TNM system, which inevitably results in a loss of the prognostic power. 
Growing evidence now indicates that for an adequate staging system these morphologic 
features should be appropriately weighed to improve prognostic accuracy.
 This review aims to critically synthesise the evidence for each mode of tumor 
spread in order to improve the prognostic value of staging and resulting treatment 
decisions.
Routes of spread
Direct invasion
Depth of spread into and beyond the bowel wall is directly linked to prognosis and 
forms an important feature in staging systems.[5-7] I believe that depth of invasion 
is important in the pathogenesis of metastatic disease for two reasons: firstly, with 
increasing depth of invasion, the likelihood of the tumor encountering and invading 
an anatomical highway also increases, leading to systemic spread. Secondly, locally 
advanced tumors can threaten the circumferential resection margin (CRM) in rectal 
cancer, or can directly invade adjacent organs or can spread within the peritoneal 
cavity. The depth of invasion can be seen on pathology and – in case of rectal cancer 
- on staging MRI with a high level of prognostic accuracy.[8] This information is used 
to plan the sequence and contents of treatment and indicates whether neoadjuvant 
therapy is necessary for tumor downstaging in rectal cancer[8] or whether local 
excision[9] is sufficient in case of early rectal cancer.
173
D
Lymphatic invasion and lymph node metastases
Tumor infiltration into the local lymphatics (lymphatic invasion (LI)) may be associated 
with a poor prognosis (Figure 1) but its individual contribution is unclear because 
many studies have grouped lymphatic and venous invasion as a single entity 
“lymphovascular spread”. However, we consider this incorrect since studies in which 
lymphatic spread is described separately its prognostic relevance is much less 
important than venous invasion.[10, 11] Lymphatic spread is closely linked to lymph 
node metastasis, as one would expect.[12-14] Lymphatic and venous channels are 
completely different pathways of spread and should therefore always be reported as 
distinct entities.
Figure 1. LNM : lymph node metastases; EN: extra nodal growth; LVI: lymphovascular invasion; 
IMVI: intramural vascular invasion; PNI: perineural invasion; TD: tumor deposits; CI: confidence 
interval; OS: overall survival.
 Lymph node involvement is traditionally considered as the most important feature 
of a high-risk tumor and is one of the most common indications for neo-adjuvant and 
adjuvant therapy. Lymph node metastases can be detected on MRI (indication for 
neo-adjuvant therapy) or, most reliably, during pathology investigation (indication 
for adjuvant chemotherapy) (Figure 2). 
 Two histological features have additional value at the histological evaluation of 
lymph node metastases: micrometastases and extranodal growth. Small clusters of 
tumor cells, detected within a lymph node, using molecular detection techniques or 
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immunohistochemistry are – depending on their size – classified as micrometastases 
(between 0.02 and 0.2 cm in diameter) or isolated tumor cells (single or small nest of 
distinct tumor cells smaller than 0.02 cm, only detectable with IHC or molecular biology).
[1, 15] Their presence is associated with worse outcome in meta-analyses compared to 
negative lymph nodes (Figure 1).[16, 17] If the metastatic tumor cells extend through the 
nodal capsule into the perinodal fat (extranodal growth), this is associated with a worse 
prognosis compared to positive lymph nodes without extranodal growth.[18]
Figure 2. EMVI: Extramural vascular invasion
 Much attention is focused on lymph node yield, since increasing numbers of 
examined lymph nodes are associated with improved outcome.[19, 20] This could be due 
to a more radical surgical technique with removal of sufficient mesorectal and mesocolic 
fat associated with subsequent improved oncological outcome and/or to the effect of 
upstaging patients who subsequently benefit from additional adjuvant treatment.[21, 22] 
However a high number of lymph nodes could also be the result of an ongoing immune 
response, which in itself confers a survival advantage.[22-24] Some studies have shown 
that the use of positive: negative lymph node ratio rather than total number of involved 
lymph nodes is a better predictor of prognosis than traditional N stage,[25-27] since this 
might indeed reflect the power of the immune response.
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 A mechanistic view of the TNM system has often been taken in that the tumor first seeds 
to lymph nodes, which in turn cause distant metastases. This does not make anatomical 
sense, as there is no direct access from the lymphatic system to the portal circulation, 
as one would expect given that the liver is the most common site of metastases. 
Furthermore we found no association with lymph node status in patients with liver and 
lung metastases, providing indirect evidence for an alternative metastatic pathway, most 
likely vascular.[28] A recent study by Naxerova et al supports this hypothesis, by showing 
65% discordance in the subclonal origin of lymph node and distant metastases.[29] 
 With the widespread adoption of high quality TME surgery, it has been suggested 
that lymph nodes are no longer an important cause of local recurrence unless they 
are outside the TME plane.[30] Some studies have gone further and shown that there 
is no strong link between lymph node involvement and distant metastases.[28, 31] This 
may account for the lack of significant improvements in survival as observed with the 
use of adjuvant chemotherapy in lymph node positive patients.[32]
Venous invasion, both intramural and extramural
Venous invasion has consistently been shown to be associated with poor prognosis, 
both when detected by pathology[33-35] and MRI.[35-39] It has a particularly strong 
association with synchronous metastases, which is stronger than that of nodal 
disease.[38] The direct access to the portal circulation in tumors drained by the 
inferior mesenteric vein supports this association since direct venous dissemination 
to the liver may be more successful than indirect dissemination via the lymphatic 
system. One could hypothesise that low rectal tumors drained by the inferior rectal 
veins, and therefore the systemic rather than portal circulation, may be more closely 
associated with lung rather than liver metastases, but conclusive evidence to support 
this hypothesis is lacking. Distinction has been made between large vein and small 
vein EMVI and also between intramural and extramural venous spread. Extramural 
spread appears to be more strongly associated with a poor prognosis, as is the invasion 
of larger veins.[10, 11] Nevertheless, intramural invasion is a poor prognostic marker 
(Figure 1).[40]
 Several authors have highlighted the problems with underreporting of EMVI on 
pathology, which makes it more difficult to assess its prognostic effect.[10, 11, 41, 42] The 
use of elastin staining greatly improves EMVI detection but this is not commonly 
used in practice.[42-45] The Royal College of Pathologists states that EMVI detection rate 
should be greater than 30% as this is a useful quality marker. In our experience, the 
reported prevalence is often lower and this might be improved by using MRI scans to 
alert the pathologist to the presence of EMVI. EMVI is seen more readily on MRI than 
on pathology (Figure 2) and the use of MRI detected EMVI as a prognostic marker has 
previously been validated.[37, 39]
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Tumor Deposits; Origin and Impact
Tumor deposits (TD) are defined as “separate nodules or deposits of malignant cells 
in the perirectal or pericolic fat without evidence of residual lymph node tissue” 
(Figure 2).[1] They have only recently been recognised as a prognostically distinct entity 
in TNM 7 and 8. In previous versions these were classified as either lymph nodes or as 
part of the T stage according to inconsistent criteria which has resulted in controversy 
within the pathology community. In the current TNM edition these are classified as 
“N1c”, the implication being that their prognostic effect is somewhere between having 
involvement of 3 and 4 lymph nodes. This is, however, not evidence based as two recent 
meta-analyses[46, 47] have shown that the presence of TD is actually worse (i.e. more in 
line with N2 or even M1 disease). 
 There are problems with the consistent pathological reporting of TD, partly due 
to lack of clarity in diagnostic criteria and a great degree of inter-observer variability, 
and partly due to differences in TNM staging systems. This is shown by the large 
variation in prevalence (10%-40%) reported in meta-analyses (Figure 1).[46, 47] In 
TNM 5 TD should be reported as lymph node metastases or as part of the T stage 
depending on their size. Even in TNM 7 and 8 there is no requirement to report TD 
in patients who also have lymph node metastases as this latter is considered to be 
of more importance (an assumption we strongly question given recent data).[47] We 
conclude that it is impossible to individually evaluate the prognostic effect of lymph 
node metastases versus TD, as long as TD are not separately classified. 
Perineural invasion
PNI is defined as neoplastic invasion of nervous structures with spread along nerve 
sheaths (Figure 2). The presence of PNI has been consistently shown to be a poor 
prognostic marker (Figure 1).[48, 49] There is a great variation in reported prevalence, 
ranging from 2% to over 50%.[48, 49] S100 staining has been shown to significantly 
increase detection but is not used as standard. Some studies have shown that the 
severity of PNI gives further prognostic information[50] although this is not commonly 
reported. Although tumor growing along nerves would logically provide a route to 
local spread, threatening the CRM and contributing to the risk of local recurrence, 
the route to causing distant metastatic disease is unclear. We would hypothesise that 
PNI is more likely an indicator of an aggressive tumor with metastatic potential and 
a possible cause of local recurrence, rather than a direct cause of distant metastases. 
There is evidence to support this hypothesis.[51] 
Combination of spread: limited evidence
Given that many of these pathways of spread are present simultaneously, it is 
impossible on the basis of current evidence to separate out the prognostic effect of 
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each parameter individually. Meta-analyses have shown that each feature confers a 
survival disadvantage but this is generally on univariate analysis and does not tell 
us whether a radiological or pathological feature is a bystander or the true cause 
of spread. Patients with lymph node metastases have a worse prognosis than those 
without, but most patients with lymph node metastases also have EMVI, so was EMVI 
or lymph node metastases the cause of distant metastases? 
Conclusions
Assessment of individual prognostic features is currently made difficult by variations in 
the quality of pathological assessment and interobserver variation, as demonstrated 
by the significant differences in the reported prevalence of these features between 
studies.[10, 41, 46, 47] Multiple authors have shown that additional techniques such as 
elastin staining and immunohistochemistry can greatly increase the detection rate 
of features such as EMVI and PNI.[2, 10, 41] Further prospective work is needed with 
meticulous pathological assessment and reporting to ensure adequate detection 
rates of features such as EMVI and PNI, separate out venous from lymphatic invasion 
and TD from lymph node metastases. Problems such as under-detection of EMVI and 
misclassification of TD implies that retrospective data may be flawed, and that any 
conclusions need to be reconsidered. 
 It is of paramount importance that a distinction is made between two categories 
of radiological and pathological tumor spread: tumor that has spread locally but does 
not have the ability to cause distant metastases versus tumor that has the ability 
of dissemination irrespectively of local extent. The first category includes lymph 
node metastases, LI and PNI which are biomarkers of an aggressive tumor with the 
ability to spread but, as long as they can be removed with adequate surgery, do 
not have access to the anatomical “highways” which lead to metastases. The second 
category predominantly centres on venous invasion, as this is how tumor accesses 
the circulation. Probably TD should be included in this category as well, since MRI 
imaging suggests they are closely related to veins and are, in many cases, likely to be 
a result of discontinuous EMVI with formation of nodules along the course of a vein. 
This hypothesis requires validation which is planned in a prospective trial.[52] 
 The widespread availability of technology today means that it would be incredibly 
easy for clinicians to access a multivariable algorithm via PCs, tablets or smartphones. 
This is quite common in other situations in medicine such as calculating POSSUM 
scores to assess pre-operative risk. However, we have still not seized the opportunity 
that technology gives us to develop more prognostically accurate staging algorithms. 
In our opinion this is a missed opportunity to deliver personalised cancer care. It 
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is possible that molecular and genetic factors could also be taken into account 
and may add additional prognostic information.[53-55] Novel techniques such as the 
measurement of circulating tumor DNA or other biomarkers may also be useful in the 
future but are still at an early stage of investigation.[56] We suggest that the TNM system 
needs further improvement, as it does not accurately predict prognosis. TNM 7 and 
8 have increased in complexity with multiple sub-classifications, but remain over-
simplistic in ignoring important routes of local spread other than crudely assessed 
tumor depth and LN metastases. We recommend that the following factors are taken 
into account in any future staging system: depth of invasion, LN status, EMVI, TD, 
lymphatic invasion, perineural invasion, CRM involvement and tumor height. There is 
an urgent need to improve the pathological and radiological documentation of these 
features in routine practice, given their potential prognostic effect and the ability to 
personalise outcome. Greater precision in documentation of these features will, in 
the future, yield a better understanding of the real drivers of metastatic spread. 
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Dissemination of colorectal cancer 
Despite intensive follow-up and increasing therapeutic options for colorectal cancer 
(CRC), metastatic disease is the leading factor in CRC mortality. Tumor cells from 
CRC can disseminate to other parts of the body through different pathways. They 
can invade blood vessels, lymphatic vessels and lymph nodes, grow along nerves 
(perineural invasion) or directly grow through the bowel wall and reach the peritoneal 
cavity. Perineural invasion might be important in local spread, vascular and lymphatic 
invasion might be more important in dissemination towards distant organs. Direct 
growth of the tumor through the bowel wall is considered the key element for 
dissemination within the peritoneal cavity. Insight in the role of histological and 
molecular factors in the dissemination of CRC is lacking.
 In chapter 1 we reviewed the literature regarding prognostic histological features 
in colorectal liver metastases. As increasing numbers of patients are selected for 
resection of colorectal liver metastases, it is crucial to identify factors that may predict 
outcome after resection. This review shows that invasion of tumor cells in the portal 
vein and in lymphatic vessels are related to prognosis. Moreover a fibrous capsule 
around the metastases appears to be correlated with prognosis. The involvement 
of resection margins is a strong prognostic factor, although the significance of the 
width of negative margins remains controversial. Various studies have evaluated 
tumor response to neo-adjuvant chemotherapy, but different grading systems were 
used, and definite recommendations cannot be made. Research of colorectal liver 
metastases is still in its infancy, and well-defined factors, studied in homogenous 
patient populations are needed to improve patient care. That is the reason why we 
addressed some of the suggested prognostic factors from literature in a homogenous 
patient population in chapter 2. We investigated possible prognostic histologic 
factors in 124 patients who underwent a complete resection of solitary colorectal liver 
metastases without neo-adjuvant treatment. We evaluated tumor thickness at the 
tumor-normal interface, the  presence of a fibrotic capsule, intrahepatic vascular 
invasion, lymphatic invasion, or bile duct invasion and perineural invasion, using 
immunohistochemistry. All variables that were associated with survival in univariate 
analysis were included in multivariate analysis. There was no association between 
histologic factors and disease-free survival in multivariate analysis. Intrahepatic 
lymphatic invasion was associated with a decreased overall survival in multivariate 
analysis, especially in combination with vascular invasion. Size of the metastases 
over 50 mm and an interval of  less than 12 months between resection of the 
primary tumor and diagnosis of liver metastasis were other independent adverse 
prognostic factors. We concluded that only intrahepatic lymphatic invasion, especially 
in combination with vascular invasion, is an important adverse prognostic factor for 
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overall survival in patients with resected colorectal liver metastases. Therefore, 
we recommend to evaluate the presence or absence of intrahepatic lymphatic and 
vascular invasion in the histological assessment of colorectal liver metastases. Future 
research is needed to determine whether adjuvant treatment strategies should be 
based on these adverse prognostic histologic factors.
 Identification of mutations in the proto-oncogenes KRAS and NRAS as predictive 
markers for response to anti-EGFR therapy has improved patient selection, however 
even in RAS wild type patients response to anti-EGFR therapy is limited. KRAS mutation 
analysis is usually performed on primary tumor tissue, because metastatic tissue is 
not always available. A possible discordance of test results between primary tumors 
and metastases has been suggested as an explanation for the failure rate of anti-
EGFR therapy in patients without mutations in KRAS. In chapter 3 we evaluated the 
concordance of the KRAS mutation status in 305 primary colorectal tumors and their 
corresponding liver metastases. KRAS mutations were detected in 35.4% of primary 
tumors. In 11 cases (3.6%) we observed a discordance between primary tumors 
and metastases: 5 primary tumors had a KRAS mutation which was not found in the 
metastases, 1 primary tumor was wild type with a mutation in the metastases, and 
in 5 cases the primary tumor and metastases had a different type of KRAS mutation. 
In only 6 patients the discordance was clinically relevant (2.0%). In this large and 
homogeneous study, we observed a high concordance of KRAS mutation status of 
96.4% (95%CI 93.6-98.2%) between primary colorectal tumors and corresponding 
liver metastases. Therefore, both primary tumors and liver metastases can be used 
for KRAS mutation analysis. 
 In chapter 4 we have expanded our research on the concordance in mutational 
status between primary tumors and corresponding liver metastases to lung 
metastases. Next to KRAS mutation status, mutation status of the proto-oncogenes 
BRAF, HRAS, NRAS and PIK3CA were investigated using next-generation sequencing 
including single molecule tags. The obtained number of unique reads was not 
always sufficient to confidentially call the absence or presence of mutations for 
all regions of interest. Paired sequencing results on all five genes were reached in 
249 of the 402 cases (62%). With this unique sequencing technique, we observed a 
high concordance in RAS/RAF mutation status between tumors and corresponding 
metastases, which implies that both primary tumors and their distant metastases can 
be used to determine the mutational status for targeted therapy. Lung metastases 
had a higher percentage of RAS mutations compared to liver metastases (71% vs. 
48%). We showed that next-generation sequencing including a single molecule tags 
is feasible, however in combination with archival formalin-fixed paraffin embedded 
material is limited by coverage depth.
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Nodules or foci of cancer cells can be found in the pericolic or perirectal fat, without 
evidence of residual lymph node tissue. Those nodules are called tumor deposits. 
The etiology of tumor deposits is unclear, and they are currently included in staging 
as a separate lymph node category (N1c). If tumor deposits are equal to lymph node 
metastases, both in prognostic and biological sense, this would simplify staging. 
However, if tumor deposits add information to staging, we should apply specific 
sub-staging. In chapter 5 we investigated the prognostic value of tumor deposits in 
comparison to lymph node metastases. We assessed the prognostic value of tumor 
deposits in CRC by systematically reviewing the literature and performing a meta-
analysis. Seventeen articles with a total of 10106 CRC patients were identified, and 
tumor deposits were observed in 22% of patients. Tumor deposits occurred more 
often in tumors with lymph node metastases and with extramural vascular invasion 
(EMVI). Tumor deposits showed a strong effect on disease-free, cancer specific and 
overall survival with a hazard ratio of 2. We used four large cohorts, comprising 4914 
patients, to investigate the impact of tumor deposits on metastatic pattern and 
compared it with the impact of lymph node metastases and EMVI. Logistic regression 
revealed that both tumor deposits and lymph node metastases increases the risk 
on liver metastases, lung metastases and peritoneal metastases. However the risk 
on liver metastases is significantly higher in patients with both tumor deposits and 
lymph node metastases, compared to lymph node metastases alone. Moreover, EMVI 
is associated with an increased risk on liver and lung metastases, but seems not to be 
involved in peritoneal metastases. Our study shows that tumor deposits are not equal 
to lymph node metastases or EMVI with respect to biology and outcome. Separate 
scoring of tumor deposits provides additional information about prognosis and is 
important in metastatic patterns. We conclude that valuable prognostic information 
is lost when tumor deposits are allocated to nodal category .
 In chapter 6 we report on the effect of regional lymph node metastases on 
metastatic patterns in CRC. We compared lymph node negative CRC (N-) with 
lymph node positive CRC (N+) in a large autopsy study comprising 1393 patients 
with metastatic CRC. Incidences of peritoneal metastases and distant lymph node 
metastases were higher in the N+ group (28% vs. 21% and 25% vs. 15%). The 
incidence of liver and lung metastases was comparable in both groups. We validated 
our findings in a population-based study of 2382 patients of the Eindhoven Cancer 
Registry. Peritoneal metastases occurred in 22% of the N+ patients, compared 
to 17% of the N- patients. The incidence of distant lymph node metastases was 
16% in the N+ group, compared to 10% in the N- group. The higher incidence of 
peritoneal and distant lymph node metastases, but comparable incidences of liver 
and lung metastases shows that lymph node metastases have a limited influence 
on metastatic patterns. We conclude that dissemination to distant organs, like the 
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liver and lung, occurs independently of lymphatic spread. Moreover, we assume that 
lymph node metastases function as a sign of advanced disease and are not involved 
in the metastatic process.
 Tumor growth along nerves, perineural invasion (PNI), is described in many 
cancers. Its prognostic value in CRC is not established. In chapter 7 we systematically 
reviewed the impact of PNI in CRC. We included 58 studies, comprising 22.900 
patients, revealing an incidence of 18%. PNI is more often found in rectal tumors 
compared to colon tumors (22% vs. 16%) and is associated with tumor stage. Our 
meta-analysis confirms the strong impact of PNI on local recurrence, but also shows a 
strong prognostic impact on disease free survival, cancer specific and overall survival. 
The effect of PNI is comparable to that of established prognostic factors. Thus, PNI 
has a strong impact on local recurrence and survival, with a prognostic value similar 
to that of well-established prognostic factors. Therefore we recommend PNI to be 
included in the standardized reporting of CRC and might be considered a high-risk 
feature.  
 Vascular invasion is the presence of tumor cells within blood vessels. It can be 
subdivided into intramural vascular invasion (IMVI) and extramural vascular invasion 
(EMVI), according to the location of the vessels towards the muscle wall. EMVI is a 
well-established independent prognostic indicator, the prognostic importance of 
IMVI is less clear. In chapter 8 we report the impact of IMVI in CRC. Our literature 
search revealed 20 articles, comprising 8078 patients. The overall reported incidence 
of IMVI is 12.5% and IMVI is associated with a decreased cancer specific survival. We 
conclude that, despite the limited number of studies, there is a clear association with 
outcome in the presence of IMVI. This warrants more attention to this underreported 
prognostic factor. 
 Most published histopathology studies are retrospective and this limits the quality 
of the evidence provided in those papers. A higher level of evidence, such as would 
be required to justify implementation in daily clinical practice, can be reached by 
systematic review of published studies and meta-analysis of the provided data. 
However, those meta-analyses are based on individual studies of which the quality of 
reporting varies. In the appendix we proposed a guideline to improve the reporting 
of retrospective histopathology studies. The intention of our proposal was to increase 
the awareness of the need for more standardization. Adherence to guidelines on 
reporting will support quality improvement of histopathological studies, facilitate 
comparison of results across different studies and ultimately help implementing new 
biomarkers into daily practice.
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General conclusion
In this thesis we investigated the role of different histological and molecular features 
in the dissemination of colorectal cancer. We showed in colorectal liver metastases 
that invasion of tumor cells in lymphatic vessels within the liver is associated with a 
poorer survival. Reporting of this factor and other potentially prognostic factors in 
pathology reports of resected colorectal liver metastases may help to individualize 
patient care. We also analyzed factors in the primary tumor that might be associated 
with survival. Our meta-analyses provided evidence to incorporate perineural 
invasion and intramural vascular invasion as prognostic factors in the TNM staging 
system. Regional lymph node metastases play a crucial role in TNM staging and 
adjuvant treatment is based on the presence of lymph node metastases. However, 
we have challenged the role of lymph node metastases by demonstrating that other 
factors are more important in metastatic spread. We demonstrated the importance 
of tumor deposits and extramural vascular invasion in comparison to lymph node 
metastases. We advocate separate scoring of tumor deposits, as it provides additional 
information about prognosis and is important in metastatic patterns. Moreover, we 
showed that lymph node metastases have a limited influence on metastatic patterns. 
Lymph node metastases may herald more advanced disease, but are not involved in 
the metastatic process itself.
 Next to prognostic factors, predictive factors are important to individualize patient 
care. In colorectal cancer the most important predictive marker is RAS mutation 
status for response to anti-EGFR therapy and therefore molecular testing is required 
to determine RAS/RAF mutation status prior to initiation of anti-EGFR therapy. The 
high concordance rate of RAS mutation status that we established between primary 
tumor and metastatic tissue justifies testing the primary tumor for anti-EGFR therapy. 
We excluded discordance in test results as explanation for the failure rate of anti-
EGFR therapy in patients with tumors without mutations in RAS.  
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Metastasering van darmkanker
Ondanks vroege opsporing, verbeterde diagnostiek en toegenomen behandelopties 
voor darmkanker blijft gemetastaseerde ziekte een probleem. Er zijn verschillende 
routes van metastasering herkenbaar onder de microscoop: via bloedvaten, 
lymfevaten en lymfklieren, via zenuwen (perineurale invasie) of via directe groei 
door de darmwand. Het was onduidelijk welke rol de verschillende histologische en 
moleculaire factoren spelen bij de metastasering van darmkanker. 
 De histologische factoren zijn niet alleen herkenbaar in de primaire tumor, maar 
ook in de metastasen. In hoofdstuk 1 beschrijf ik het literatuuronderzoek naar 
histologische factoren in colorectale lever metastasen. Verschillende factoren blijken 
geassocieerd met een slechte uitkomst: lymfvat- en bloedvatinvasie, de aanwezigheid 
van een fibreus kapsel en het hebben van positieve resectiemarges. Uit onze studie 
bleek ook dat het histologisch onderzoek van colorectale levermetastasen nog in 
de kinderschoenen staat: goed gedefinieerde factoren, onderzocht in homogene 
patiëntpopulaties zijn nodig. Daarom hebben wij in hoofdstuk 2 enkele mogelijk 
prognostische factoren onderzocht in een homogene populatie van 124 patiënten 
met een solitaire colorectale levermetastase. In de multivariabele analyse bleek 
intrahepatische lymfvatinvasie geassocieerd met een slechte overleving, vooral in 
combinatie met bloedvatinvasie. De grootte van de metastase en een interval van 
minder dan 12 maanden tussen resectie van de primaire tumor en de diagnose van 
levermetastase waren andere onafhankelijk prognostische factoren. De aanwezigheid 
van intrahepatische lymfvat- en bloedvatinvasie zou daarom benoemd moeten 
worden in pathologie verslagen van colorectale levermetastasen. Meer onderzoek is 
nodig om te beoordelen of adjuvante behandeling zinvol is bij patiënten met deze 
slechte prognostische histologische factoren.
 Identificatie van mutaties in proto-oncogenen KRAS en NRAS als predictieve 
markers voor respons op anti-EGFR therapie heeft de patiëntselectie verbeterd. 
Echter, de respons op anti-EGFR therapie is ook beperkt in een groot aantal patiënten 
zonder mutaties in RAS. RAS mutatie analyse wordt meestal uitgevoerd op de primaire 
tumor omdat weefsel van de metastase niet altijd beschikbaar is. Een verschil in 
mutatie status tussen de primaire tumor en metastase zou een verklaring kunnen 
vormen voor het lage succes percentage van anti-EGFR therapie in tumoren zonder 
RAS mutatie. In hoofdstuk 3 hebben we de concordantie van de KRAS mutatie 
status in 305 primaire colorectale tumoren en hun bijbehorende lever metastasen 
onderzocht. KRAS mutaties waren aanwezig in 35.4% van primaire tumoren. In 11 
gevallen (3.6%) constateerden wij een verschil tussen primaire tumor en metastase: 5 
primaire tumoren hadden een KRAS mutatie die werd niet gevonden in de metastase, 
1 primaire tumor had geen mutatie in KRAS maar wel een KRAS mutatie in de 
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metastase, en in 5 gevallen hadden de primaire tumor en metastase een andere KRAS 
mutatie. De discordantie was derhalve klinisch relevant in slechts 6 patiënten (2.0%). 
Daarom concluderen wij dat zowel de primaire tumor als de levermetastase gebruikt 
kan worden voor KRAS mutatie analyse. 
 In hoofdstuk 4 hebben we het moleculair onderzoek uitgebreid. Naast primaire 
tumoren met levermetastasen, hebben we ook primaire tumoren met bijbehorende 
longmetastasen geanalyseerd, om tevens inzicht te krijgen in de relatie tussen 
mutatie status en metastaseringspatroon. Naast een uitgebreider onderzoek van 
KRAS, is ook de mutatie status van de proto-oncogenen BRAF, HRAS, NRAS en PIK3CA 
onderzocht met behulp van next-generation sequencing met specifieke probes. Het 
aantal verkregen unieke ‘reads’ was niet altijd voldoende om betrouwbaar de aan- 
of afwezigheid van mutaties te detecteren in alle regio’s van interesse. Gepaarde 
resultaten van alle vijf genen werden verkregen in 249 van de 402 gevallen (62%). 
Met deze unieke next-generation sequencing techniek, vonden wij een hoge 
concordantie in RAS/RAF mutatie status tussen tumoren en bijbehorende metastasen, 
wat inhoudt dat zowel primaire tumoren als metastasen gebruikt kunnen worden 
om de mutatie status te bepalen voor anti-EGFR therapie. Long metastasen hadden 
een hoger percentage RAS mutaties ten opzichte van lever metastasen (71% versus 
48%). In dit onderzoek hebben we aangetoond dat next-generation sequencing met 
specifieke probes mogelijk is, maar op paraffine materiaal wat vaker onvoldoende 
resultaat geeft. 
 Foci van tumorcellen kunnen worden gevonden in het pericolische of perirectale 
vetweefsel, zonder dat er lymfklier weefsel aanwezig is. Deze foci worden tumor 
deposities genoemd. De etiologie van tumor deposities is onduidelijk, ze zijn momenteel 
in stadiering opgenomen als een afzonderlijke lymfeklier categorie (N1c). Echter, als 
tumor deposities een prognostisch andere waarde hebben dan lymfkliermetastasen, dan 
zou een specifieke sub-stadiering beter zijn. In hoofdstuk 5 hebben we onderzocht of 
tumor deposities gelijk zijn aan lymfkliermetastasen met betrekking tot prognose. 
Wij hebben een systematisch literatuuronderzoek en meta-analyse uitgevoerd 
naar de prognostische waarde van tumor deposities in darmkanker. 17 artikelen 
met 10106 patiënten werden geïncludeerd en de incidentie van tumor deposities 
was 22%. Tumor deposities komen vaker voor in tumoren met lymfkliermetastasen 
en vaatinvasie. Tumor deposities zijn geassocieerd met een slechte ziektevrije 
overleving, kanker specifieke overleving en totale overleving met een hazard ratio 
van 2. Daarnaast hebben we in vier grote cohorten, met in totaal 4914 patiënten, 
het effect van tumor deposities, lymfkliermetastasen en vaatinvasie op het 
metastaseringspatroon onderzocht. Logistische regressie toonde dat zowel tumor 
deposities als lymfkliermetastasen het risico op lever, long en peritoneale metastasen 
verhoogt. Het risico op lever metastasen is significant verhoogd in patiënten met 
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zowel tumor deposities als lymfkliermetastasen vergeleken bij patiënten met alleen 
lymfkliermetastasen. Extramurale vaatinvasie is geassocieerd met een verhoogd 
risico op lever- en long metastasen, maar niet met peritoneale metastasering. Onze 
studie toont aan dat tumor deposities biologisch en prognostisch niet hetzelfde 
zijn als lymfkliermetastasen of extramurale vaatinvasie. Door tumor deposities in de 
N1c categorie te stoppen, gaat er waardevolle prognostische informatie verloren. 
Daarom zouden tumor deposities apart moeten worden opgenomen in de stadiering 
van darmkanker. 
 Om meer inzicht te krijgen in de rol van lymfklieren in metastasering op 
afstand hebben we in hoofdstuk 6 het metastaseringspatroon onderzocht in 
een obductiestudie met 1393 patiënten met metastasen op afstand, in relatie tot 
de aanwezigheid van regionale lymfkliermetastasen. Peritoneale metastasering 
en metastasen in lymfklieren op afstand kwamen vaker voor in de groep met 
regionale lymfkliermetastasen (28% versus 21% en 25% versus 15%). De incidentie 
van lever- en longmetastasen is vergelijkbaar in beide groepen. We hebben onze 
bevindingen gevalideerd in een grote cohort studie op basis van 2382 patiënten 
van de Eindhovense kanker registratie en vonden hier vergelijkbare resultaten. De 
hogere incidentie van peritoneale metastasen en lymfkliermetastasen op afstand, 
maar de vergelijkbare incidentie van lever- en long metastasen, suggereert dat 
regionale lymfkliermetastasen een beperkte invloed op het metastaseringspatroon 
hebben. Lymfkliermetastasen moeten gezien worden als teken van een 
agressieve tumor, maar lijken zelf niet betrokken in het metastaseringsproces. 
Tumorgroei langs zenuwen, perineurale invasie (PNI), is beschreven in vele vormen 
van kanker. De prognostische waarde van PNI voor darmkanker is onduidelijk. In 
hoofdstuk 7 onderzoeken we het effect van PNI door middel van een literatuur 
studie. In totaal hebben we 58 studies geïncludeerd, bestaande uit 22900 patiënten, 
met een incidentie van 18%. PNI komt vaker voor in rectale tumoren vergeleken 
met colon tumoren (22% vs. 16%) en is geassocieerd met TNM stadiering. Onze 
meta-analyse toont een sterke invloed van de PNI op lokaal recidief, maar ook een 
sterk prognostisch effect op ziektevrije overleving, kanker specifieke overleving 
en totale overleving. Het effect van PNI was vergelijkbaar met dat van bekende/
gevestigde prognostische factoren. Daarom adviseren wij om PNI op te nemen in de 
gestandaardiseerde rapportage van tumoren.
 Vaatinvasie is de aanwezigheid van tumorcellen in bloedvaten. Het kan worden 
onderverdeeld in intramurale vaatinvasie (IMVI) en extramurale vaatinvasie (EMVI), 
afhankelijk van de locatie van de vaten ten opzichte van de spierwand. EMVI is een 
bekende onafhankelijke prognostische factor, de prognostische betekenis van IMVI is 
minder duidelijk. In hoofdstuk 8 rapporteren we de impact van IMVI in darmkanker. 
In totaal omvat de meta-analyse 20 artikelen, bestaande uit 8078 patiënten. De 
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incidentie van IMVI is 12.5% en IMVI is geassocieerd met een slechtere kanker 
specifieke overleving. We concluderen dat, ondanks het beperkte aantal studies, er 
een duidelijk verband is tussen IMVI en een slechtere overleving. Er zou daarom meer 
aandacht voor IMVI moeten komen en een betere rapportage hiervan in pathologie 
verslagen.
 Veel gepubliceerde histopathologische artikelen zijn retrospectief van aard en dit 
beperkt de kwaliteit van bewijs van deze studies. Een hoger niveau van bewijs, welke 
noodzakelijk is om implementatie van een factor in de dagelijkse klinische praktijk 
te rechtvaardigen, kan worden bereikt door systematische reviews en meta-analyses 
van gepubliceerde studies. Deze meta-analyse zijn echter gebaseerd op individuele 
studies welke sterk verschillen in kwaliteit. In de appendix doen wij een voorstel ter 
verbetering van de rapportage van retrospectieve histopathologische studies. Naleving 
van richtlijnen met betrekking tot rapportage zal leiden tot een kwaliteitsverbetering 
van histopathologische studies. Daarnaast zal het de vergelijking van resultaten tussen 
verschillende studies vergemakkelijken en uiteindelijk helpen bij het implementeren 
van nieuwe biomarkers in de dagelijkse praktijk.
 
196
Samenvatting
Algemene conclusie
Dit proefschrift richt zich op de verschillende histologische en moleculaire factoren 
die mogelijk van invloed zijn op de prognose en verspreiding van darmkanker. Wij 
hebben aangetoond dat in colorectale levermetastasen de invasie van tumorcellen in 
lymfvaten geassocieerd is met een slechte overleving. Rapportage van deze factor en 
andere potentieel prognostische factoren in de pathologie verslagen van colorectale 
lever metastasen, kan leiden tot een meer geïndividualiseerde patiëntenzorg. We 
hebben ook gekeken naar factoren in de primaire tumor die mogelijk van invloed 
zijn op overleving. Onze meta-analyses hebben bewijs geleverd om perineurale 
invasie en intramurale vaatinvasie op te nemen in de TNM stadiering. In de TNM 
stadiering nemen regionale lymfklieren een centrale rol in en adjuvante behandeling 
is grotendeels gebaseerd op de aanwezigheid van lymfkliermetastasen. Wij twijfelen 
aan de rol van deze lymfkliermetastasen in metastasering van darmkanker, onder 
meer omdat we hebben aangetoond dat andere factoren, zoals tumor deposities en 
vaatinvasie, belangrijker zijn in de metastasering van darmkanker. We adviseren om 
tumor deposities apart te scoren, aangezien ze extra informatie geven over prognose 
en invloed hebben op het metastaseringspatroon. Lymfkliermetastasen moeten 
worden gezien als teken van gevorderde ziekte, maar zijn zelf niet betrokken bij 
metastasering van darmkanker. 
 Naast prognostische factoren zijn ook predictieve factoren belangrijk om de 
behandeling van patiënten met darmkanker te kunnen individualiseren. De meest 
bekende predictieve marker in darmkanker is de RAS mutatie status, waarbij 
voorafgaand aan anti-EGFR therapie altijd moleculaire analyse wordt verricht. Wij 
hebben aangetoond dat er een hoge concordantie van RAS mutatie status is tussen 
primaire tumor en metastasen. Hierdoor kan de primaire tumor gebruikt worden 
voor analyse van de RAS mutatie status. Discordantie in testresultaten vormt derhalve 
geen verklaring voor het falen van anti-EGFR therapie in patiënten met tumoren 
zonder RAS mutatie.
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En dan ben je nu aangekomen bij het dankwoord. Misschien ben je hier als eerste 
naar toe gebladerd en heb je het voorgaande niet gelezen. Dit is ook een belangrijk 
(en misschien wel het meest gelezen) stuk van het proefschrift. Onderzoek doen kan 
alleen met hulp van anderen, die ik hieronder zal noemen. 
Allereerst mijn promotoren.
Prof. dr. Nagtegaal, beste Iris, door jou ben ik in dit onderzoek en op de afdeling 
pathologie beland. Dus eigenlijk dank ik mijn carrière in de pathologie aan jou ;-). 
Jouw fijne en intensieve begeleiding in het onderzoek, is een luxe die maar weinig 
promovendi hebben. Door alle wekelijkse gesprekken, kwam er al snel een goede 
structuur en lijn in het onderzoek. Jouw enthousiasme en ideeën werken aanstekelijk 
en hebben ervoor gezorgd dat ik de vele projecten tot het eind toe met veel plezier 
en vol motivatie kon afronden. 
 Prof. dr. Punt, beste Kees, dankzij jou ben ik in aanraking gekomen met onderzoek. 
Ik heb een geweldige onderzoekstijd gehad samen met het CAIRO-team. Door jouw 
vertrek naar Amsterdam werd ons contact minder. Maar zodra ik je expertise nodig 
had voor een artikel, kon ik op je bouwen. Jouw wetenschappelijke kennis en kritische 
input heeft dit proefschrift naar een hoger niveau getild. Dank voor je vertrouwen en 
steun.
 Dank aan de leden van de manuscriptcommissie voor het lezen en beoordelen van 
mijn manuscript: Prof. dr. Camiel Rosman, Prof. dr. Jolanda de Vries en Prof. dr. Johan 
Offerhaus. Dank aan alle leden van de promotiecommissie voor hun bereidheid om 
zitting te nemen in de corona. 
 Dear Prof. Matt Seymour, Prof. Phil Quirke and dr. Susan Richman, thanks for all the 
wonderful times I had in Leeds and during several conferences. You made me fond of 
research. Phil, thanks for introducing the amazing field of pathology to me. You are 
right, it is the best specialty one can choose. Dear Susan, you were a great supervisor, 
but more importantly.... you became a great friend. I am happy and proud that you 
are part of my corona.  
 De pathologen van het Radboudumc wil ik graag bedanken voor de waardevolle 
bijdrage aan mijn opleiding, de flexibiliteit die jullie mij hebben gegeven om 
onderzoek te kunnen combineren met de opleiding en de vele fijne gesprekken. 
Speciaal bedank ik mijn opleiders (Prof. dr. Piet Slootweg, dr. Willeke Blokx). Ook dank 
aan Patricia Groenen voor haar onuitputtende enthousiasme voor onderwijs en de 
mogelijkheden die zij aan mij heeft gegeven om zelf onderwijs te ontwikkelen. 
207
Dw
 Afdeling pathologie in het Canisius Ziekenhuis in Nijmegen en in het Rijnstate 
Ziekenhuis in Arnhem. Hartelijk dank voor de leerzame en vooral ook gezellige tijd 
die ik bij jullie heb doorgebracht en op dit moment doorbreng. 
 Beste AIOS, veel dank voor de gezellige momenten, lunches, borrels, diners en 
AIOS weekenden.  
 Mijn collega-onderzoekers en kamergenootjes wil ik bedanken voor de leuke tijd die 
we samen hebben gehad. Het was fijn om met jullie te kunnen overleggen, advies te 
vragen of soms frustraties te delen over tegenvallend onderzoek. Jolien, Miriam, Lieke, 
Leonie, Sabine, Steven, Annemarie, Femke, Michiel, Marianne, Yasmijn, Loes, Lauranne, 
Guus, Niek, Jannemarie. Jannemarie bedankt voor de prettige samenwerking bij het 
onderzoek over levermetastasen en Niek voor de fijne samenwerking bij de obductie 
studie. Jullie zijn/worden top chirurgen! Femke, bedankt voor je kritische blik en je 
vermogen om tot de kern van een probleem te komen. Het heeft erg geholpen bij de 
vele artikelen waar we samen aan hebben gewerkt.
 Beste Jeroen, Elisa, Marjolein, Shannon en Carlijn, “mijn’” hardwerkende analisten. 
Ik wil jullie bedanken voor al jullie hulp bij mijn onderzoek. De talloze DNA isolaties, 
PCRs en interpretaties van sequencing resultaten had ik niet zonder jullie kunnen en 
willen doen. Wat ben ik vaak op jullie analistenkamer geweest voor een vraag, maar 
vooral ook voor een gezellig gesprek. Het was misschien niet altijd efficiënt, maar wel 
super gezellig. Bedankt voor de geweldige tijd die ik met jullie heb gehad.
 Steven Teerenstra en Ton de Haan, dank voor het helpen bij de statistische analyses. 
Dank aan alle studenten waarmee ik onderzoek heb gedaan. Speciale dank voor 
Stephanie en Ursula, voor jullie inzet en de mooie publicaties.
 Dit proefschrift was niet mogelijk geweest zonder het gebruik van gearchiveerd 
materiaal. Daarom dank aan de medewerkers van de afdeling pathologie van het 
Radboudumc (Nijmegen), het pathologie laboratorium van het Rijnstate ziekenhuis 
(Arnhem) en het laboratorium Pathologie Oost Nederland (Enschede) waar ik 
meerdere keren hartelijk ontvangen ben.
 Sybilla, Anne, Brechtje, Loes en Sanneke, vriendinnen van de geneeskunde 
opleiding. Dank voor jullie interesse in mijn onderzoek, maar vooral bedankt voor de 
gezellige momenten samen. Fijn om altijd bij elkaar terecht te kunnen.
 Floor en Anne, mijn musketiers. Bedankt dat jullie al zo lang mijn vriendinnen zijn. 
Ondanks onze drukke leventjes en de reisafstand, ben ik er trots op dat we tijd vrij 
blijven maken voor onze vriendschap. Het voelt altijd als vanouds.
 Monica en Chella, eerst mijn twee favoriete AIOS en onderzoekscollega’s, nu mijn 
twee favoriete stafleden ;-). Wat is het fijn om hoogtepunten, maar ook frustraties 
met elkaar te kunnen delen. Heerlijk om vriendinnen zoals jullie te hebben, even 
samen een theetje te doen terwijl de kinderen spelen, of lekker ‘s avonds afspreken 
en echt te kunnen praten. Superfijn dat jullie mijn paranimfen zijn. 
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 Tom en Krista, Jan en Barbara, Jop, Rens en Finn, Jan, Leni en Tim. Bedankt voor 
jullie interesse. Het is fijn om jullie als familie te hebben.
 Astrid en Eric, wat fijn dat jullie deze verdediging nog samen kunnen bijwonen. Na 
al die jaren voel ik me nog steeds kind aan huis bij jullie. Ook alle andere familieleden, 
vrienden en kennissen bedankt dat jullie hier nu aanwezig zijn. Top dat jullie altijd 
geïnteresseerd waren en vroegen hoe het met het onderzoek stond!
 Lieve papa en mama, dank voor al jullie steun. Ik kan niet beschrijven hoeveel 
het voor mij betekent dat ik altijd op jullie terug kan vallen. Jullie hebben zo vaak 
bijgesprongen en geholpen met de kinderen, zodat ik aan het onderzoek kon werken. 
Mede dankzij jullie ben ik zover gekomen. 
 Ezra, Senn en Liz: wat ben ik blij met jullie. Jullie lieve en vooral ook eigenwijze 
karakters zou ik niet meer kunnen missen. Zonder jullie was ik veel sneller 
gepromoveerd maar was mijn leven een stuk minder leuk geweest.
 Jean, mijn alles. Al zoveel jaar samen, zo vertrouwd. Dank voor je eindeloze steun. 
Wat is het fijn om te weten dat je altijd met me meegaat en we daardoor overal heen 
kunnen. Wat zou ik toch zonder jou moeten? Ik hoop dat we altijd ‘vriendtjes’ blijven.
